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The review of the literature indicated that although
there have been several recent studies into the aetiology
and pathology of equine chronic obstructive pulmonary
disease (CORD) as well as into the functional disturbances
occurring in this disease, very few objective studies
have been carried out into the management and therapy of
affected horses. The effects of environmental control
and several therapeutic agents in COPD affected horses
are therefore investigated in this thesis.
The use of a controlled environment, i.e.
minimising exposure to the aetiological antigens which
are contained in hay and straw, by bedding horses on
peat or shredded paper and feeding a complete cubed diet,
allowed symptomatic COPD affected horses to become
asymptomatic within 4 to 32 days (mean (- S.D.) 9.0 -
4.8 days). When asymptomatic, their respiratory function
values did not differ significantly from those of
normal horses. This indicates that the pathophysiol¬
ogical changes occurring in equine COPD are reversible
and that most COPD affected horses are capable of re¬
gaining normal pulmonary function when contact with
the aetiological antigens is minimised.
Symptomatic COPD affected horses are those showing
clinical signs of COPD with abnormal pulmonary function
values, as described by McPherson e_t al_. , 1978 , i.e.
maximum change in intrathoracic pressure (max.APpl) >
(x)
6 mm Hg and partial pressure of arterial oxygen (PaC^^
82 mm Hg. Asymptomatic COPD affected horses are
those previously shown to be affected with COPD by
the above-mentioned criteria which, at the time of the
present examination, are clinically normal and their
pulmonary function values within normal ranges, i.e.
max.APpl <6 mm Hg and Pa02 > 82 mm Hg.
Inhalation or intravenous administration of
bronchodilator drugs (atropine, isoprenaline, terbutaline,
clenbuterol and etamiphylline camsylate) to symptomatic
COPD affected horses brought about a temporary, marked
improvement in clinical signs, accompanied by significant
decreases in max.APpl and significant increases in PaO^.
These findings show that airway spasm is involved in the
pathogenesis of equine COPD. Although the therapeutic
use of parenterally administered bronchodilator drugs
in this disease is subject to many limitations including
partial effectiveness, short duration of action and side
effects, this form of therapy could be of value as a
temporary measure in the treatment of acute or severe
attacks .
Studies into the efficacy of orally administered
bronchodilator drugs for equine COPD proved disappointing.
When horses were housed in the natural antigen challenge
environment, i.e. exposed to poor quality hay and straw
bedding which was dusty and visibly contaminated with
moulds, and treated with oral clenbuterol or
(xi)
etamiphylline camsylate, they remained symptomatic.
Apart from the significant decreases in respiratory
rate and max.APpl recorded on 2 days during the clen-
buterol trials, there were no significant changes in
their pulmonary function values from those recorded
when horses were untreated and housed in similar
conditions. In addition, neither drug significantly
hastened the remission of clinical signs which normally
occurred when symptomatic COPD affected horses were
housed in the controlled environment.
In contrast to the results of oral bronchodilator
treatment, studies on the prophylactic treatment of
asymptomatic COPD affected horses with inhaled sodium
cromoglycate proved hopeful. In preliminary studies,
prophylactic sodium cromoglycate inhalation in 2
affected horses prevented the exacerbation of respiratory
disease, normally observed in COPD affected horses 4 to
8 hours after experimental Micropolyspora faeni inhal¬
ation challenge. These studies were followed by a
clinical trial with 56 COPD affected horses in which it
was shown that a linear response existed between the
number of successive days treatment with this drug and
the duration of remission of COPD, while horses, were
exposed to natural challenge. The protective period
was 3.6 - 1.1 days (mean - 5.D.) after a single sodium
cromoglycate treatment, 8.0 - 3.4 days after 2 days
treatment, 11.9 - 2.9 days after 3 days treatment and
(xii)
24.3 - 13.4 days after 4 days treatment.
In a 28 day trial, two successive days sodium
cromoglycate treatment administered at weekly intervals
was effective in preventing the onset of CDPD in 6 out
of 8 affected horses housed in the natural challenge
environment. These experiments show that prophylactic
treatment of asymptomatic COPD affected horses with
inhaled sodium cromoglycate is an effective method of
controlling this disease. As sodium cromoglycate is
believed to act by stabilising mast cell membranes,
these results suggest that pulmonary mast cell degran-
ulation is involved in the pathogenesis of equine COPD.
Sodium cromoglycate treatment would be useful
when unavoidable exposure to the aetiological antigens
is anticipated, for instance, during transportation or
when horses are moved temporarily away from the home
environment. Long term intermittent sodium cromo¬
glycate treatment could facilitate the management of
a horse kept at livery or in large stables where the
provision of special environmental control measures to
individual animals may prove difficult to institute.
COPD.
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Chronic obstructive pulmonary disease (COPD)
formerly known as heaves, broken wind or alveolar
emphysema is probably the commonest chronic equine re¬
spiratory disease occurring in the United Kingdom and
Western Europe. The disease was recognised as early as
333 B.C. by Aristotle who described the characteristic
"drawing in of the flank" or "heave". Although the
prevalence of the disease appears to fluctuate from year
to year, COPD was regarded by Gerber (1973) as the most
common cause of premature retirement in horses through
disease.
COPD which affects horses 2 years old and over has
been shown to be a respiratory hypersensitivity to
thermophyllic actinomycetes and fungal organisms (here¬
after loosely termed "moulds") occurring in hay, straw
and organic dust and/or to pollens. Although the
aetiological antigens may vary with geographical
location Micropolyspora faeni (M_. faeni) and Aspergillus
fumiqatus (A. fumiqatus) have been identified as common
causes of the disease in Northern Britain (McPherson
et al., 1979b). Very large numbers of these moulds
occur in hay and straw which has been baled with a high
moisture content and subsequently become heated giving
rise to ideal conditions for growth of these thermophyllic
actinomycetes (Lacey, 1974).
The pathogenesis of COPD is poorly understood.
Upon exposure to the aetiological antigens, affected
horses may show signs of disease within 30 minutes to
3.
1 hour, however, the response is more frequently observed
4 to 8 hours thereafter. The major pathological
anatomical changes occurring in equine COPD are a diffuse
exudative bronchiolitis and alveolar overinflation
(Nicholls, 1978). Despite the disease's previous nomen¬
clature i.e.: alveolar emphysema and despite the long
standing but unproven analogy between this syndrome and
human pulmonary emphysema, in which the pulmonary changes
are largely irreversible, structural emphysema is not a
major feature of equine COPD and when it does occur, is
limited to small areas of the lungs (Nicholls, 1978).
Although equine COPD has been recognised for many
centuries, few definitive studies have been carried out
on the treatment of the disease. Early authors
advocated good nutrition, good ventilation, clean stables
and rest combined with the empirical systemic admini¬
stration of agents such as arsenic or strychnine (Huytra
and Marek, 1926) and later, the parasympatholytic drug
atropine or the feeding of atropine-containing plants
(Alegren and Carlstrom, 1940) despite the attendant side
effects which were frequently quite severe.
Management of the disease by means of environmental
control has been favoured by more recent authors (Cook,
1965; Eyre, 1972) who reported clinical improvement in
horses turned out to grass or housed on peat moss or
wood shavings instead of straw and fed a pelleted diet
or dampened hay. Chemotherapeutic agents which have
been used for the treatment of COPD include
4.
corticosteroids, bronchodilators, bromhexine hydrochloride
and antihistamines.
The corticosteroids act by suppressing the allergic
response and will partially alleviate clinical dyspnoea
in affected horses (Gerber, 1973; Beech, 1979b).
However, the resulting improvement only lasts for the
duration of the corticosteroid therapy and due to their
side effects, the corticosteroids are not favoured for
long term therapy of this condition.
Bronchodilator drugs including atropine and the
sympathomimetic drugs, adrenaline and noradrenaline have
been reported to bring about a very rapid and marked
clinical improvement in affected horses (Obel and
If
Schmiterlow, 1948; Schatzmann,Straub and Gerber, 1972)
but they have not been widely used due to their very
short duration of action (less than 2 hours) and their
untoward cardiac stimulating effects. More recently, a
longer acting beta 2 sympathomimetic bronchodilator,
clenbuterol, has been used with more success in a
limited number of horses (Sasse and Hajer, 1977).
Neither the antihistamines nor bromhexine hydro¬
chloride have been found to have any lasting beneficial
effects in COPD affected horses (Beech, 1979a).
As yet, none of the above measures have been shown
to adequately control the disease. More work is therefore
required on the therapy of equine COPD, regarding both




REVIEW OF THE LITERATURE
6.
HISTORICAL REVIEW OF THE LITERATURE
COPD was recognised as early as 333 B.C. when
Aristotle, in "The History of Animals" described a
disease of horses characterised by "drawing in of the
flank" (Smith, 1919). In the 13th Century, a German,
Conrad Heresbach reported that under the existing laws,
any horse which developed "broken wind" subsequent to
purchase could be returned to the original owner. The
disease was thought to be chronic, incurable and of un¬
known aetiology (Smith, 1919).
In 1323, Fitzherbert considered "broken wind" to
be a possible sequel to fast work especially after re¬
cently drinking water (Smith, 1919). Fitzherbert
observed that the condition was least likely to occur
in horses kept at grass. Clifford, in 1585, is
believed to be the first author to advocate good
ventilation for the prevention of "broken wind" (Smith,
1919) .
In 1664, Solleysel associated "broken wind" with
the feeding of hay, particularly to older animals. Many
later authors ascribed the disease to poor quality feed
(Gibson, 1751; Law, 1896; Baker, 1900; Malkmus, 1912).
Solleysel considered the disease to be hereditary
(Smith, 1919), as did Gibson (1751) and Axe (1906), the
latter author observing the disease more frequently in
coarse-bred horses and ponies than in thoroughbreds.
Floyer (1698) was the first to record the
7.
pathological changes in the lungs of a horse with
"broken wind". He described "....rupture or dilation
of the bladders of the lungs". Gibson (1751) con¬
sidered the lungs to have lost their elasticity. In
1837, Bracy Clark performed postmortem examinations
on a few affected horses and found pulmonary emphysema
which he thought resulted from "rupture of the air cells"
(Smith, 1924). Delafond (1844) found emphysema in 45
out of 54 horses with "broken wind", however Percivall
(1853) reported that emphysema was not necessarily
present in all cases, an opinion shared by Law (1896).
The importance of "good stable ventilation and
hygiene" in the prevention of respiratory disorders,
and in particular "broken wind" was stressed by Clark
(1788), by Coleman and by many other early authors
(Smith, 1905; Fitzwygram, 1911).
Malkmus (1912) was the first to perform pulmonary
function studies in horses and use such tests .to
quantify equine pulmonary dysfunction. By means of
a kymograph, he recorded the intrapleural pressure
during the respiratory cycle of a horse with "heaves"
and compared it with that of a n.ormal horse. He was
thus able to demonstrate an increased expiratory
effort in the affected horse.
DISEASE DEFINITION
The problem of disease definition and in particular
that of defining the equine syndrome known as "heaves",
8 .
"broken wind", chronic alveolar emphysema, chronic
pulmonary disease, pulmonary emphysema, chronic
obstructive pulmonary disease (COPD), "dampfigkeit"
in the German literature and "pousse" in the French
literature has been reviewed by Breeze (1979). This
author outlined the main features upon which disease
definitions are usually based, namely; clinical-
descriptive, morbid-anatomical, functional or
aetiological. A term such as "heaves" is clinical -
descriptive but unfortunately, there is incomplete
agreement on what is understood by this term (Sasse,
1971 ) .
Although there is unanimous agreement over the
respiratory involvement in this syndrome, there has
been a tendency particularly in the German literature
to also include certain cardiac conditions under the
term "heaves" (Malkmus and Oppermann, 1935; Bolz
and Bieniek, 1961; Gerber, 1969). Neither "heaves"
nor "broken wind" give any exact indication as to the
underlying pathology. This was demonstrated by Breeze
(1979) who classified 9 pathological conditions all of
which he claimed could give the clinical signs of
"heaves".
Gn the basis of lung function tests, Sasse (1971)
introduced COPD into the veterinary literature and this
functional-descriptive term has been adopted by most
subsequent authors. Littlejohn (1978) and Breeze
(1979) felt a need for further clarification of the
9.
term CQPD, as they claimed there were a number of
different pathological entities potentially capable
of being classed as COPD. However, rigidly sub-
classifying COPD on a pathological basis could re¬
introduce confusion as detailed pathological
sub-divisions may be impossible to differentiate
clinically. Furthermore, it is possible that
differing pathological changes may be manifestations
of the same disease process depending on the degree and
duration of the illness.
On the basis of post-mortem examinations on 25
COPD affected horses, in the only thorough pathological
study of this syndrome to date, Nicholls (1978)
suggested that the term COPD should be replaced by
chronic bronchiolitis as this was the major pathological
feature present in all the horses.
Currently, COPD appears to be the most appropriate
term available for this syndrome and it is probable that
a more definitive term will only arise when there is
universal agreement on the aetiology, pathogenesis and
pathology of this disease.
EPIDEMIOLOGY
OCCURRENCE AND PREVALENCE.
The occurrence of equine COPD appears to be world¬
wide. There are many reports in the literature from
European countries (Sasse, 1971), Great Britain
(McPherson e_t al_. , 1978), U.S.A. (Halliwell et_ al. ,
1979), Canada (Eyre, 1972) and Southern Africa
(Littlejohn, 1978). COPD is reported to occur very
10.
rarely in Australia and New Zealand (Rose, R.J.,
1981; Goulden, B.E., 1981, both personal communications).
The current prevalence of COPD in Great Britain
is unknown, but Cook (1976) considered it to be the
most common chronic equine pulmonary disease. A
survey carried out by the British Equine Veterinary
Association in 1962-63 (BEVA, 1965) indicated that
0.3% of horses examined by veterinary surgeons in
Great Britain suffered from this disease. In
Sweden, more accurate statistics of its incidence are
available owing to the practice of insuring against
this disease. Over a 10 year period from 1968-
1977, COPD accounted for 428 claims out of 509,400
horses insured with a company which insures over half
of the horses in Sweden (Bergsten, G., 1979,
personal communication). This gives a mean incidence
of 0.08?o in that country.
In general, COPD is a disease of individual
animals (Eyre, 1972), but there have been reports where
a large proportion of horses in a stable were affected
(Morgan, 1940; McPherson e_t al_. , 1979a).
AGE DISTRIBUTION
Up to the 1960's COPD was generally regarded to
affect horses 8 years old and above (Udall, 1954;
Alexander, 1959). However, Bolz and Bienick (1961)
recorded the disease in horses 3 and 4 years of age, as
11.
did Gerber (1973) who noted the disease in horses from
3 to 19 years of age. Sasse (1971) found a mean (-
S.D.) age of 8.5 i 4.1 years in 38 COPD affected animals
and this group included 2 foals, 1 two-year-old, 1 three-
year-old and 5 four-year-old horses. Littlejohn's
(1978) series of 20 COPD affected horses ranged in age
from 3 to 19 years old, mean (- S.D.) 9.9 - 4.5 years.
A group of 37 affected horses examined by McPherson
et al. , (1979a) included horses from 2 years old upwards,
the prevalence of the disease increasing with age.
Most horses were in the 6 to 10 year old age group, but
the authors suggested that this may have been a reflection
of the age grouping of the horse population as a whole.
BREED TYPE AND WORK PERFORMED.
There does not appear to be any recorded breed
predisposition for COPD. Udall (1954) and Alegren and
Carlstrom (1940) observed the disease more commonly in
heavier breeds and draught horses, than in thoroughbreds.
The disease was frequently seen in ponies and hunters
but was rare in the British racehorse (Cook and Rossdale,
1963; Cook, 1965). A wide representation of different
breeds was recorded by Bolz and Bieniek (1961) Sasse
(1971) and Eyre (1972). McPherson et_ al_. , (1 979a)
detected COPD most commonly in showjumping and hacking
horses. Of the horses in their non-random sample of
the population, thoroughbred horses were affected least
and ponies most often.
12.
SEX.
Alexander (1959) considered COPD to affect both
sexes equally and Sasse (1971) and McPherson e_t al . ,
(1979a) found no significant difference in the sex
«
distribution between affected and non-affected
horses .
ENVIRONMENTAL CONDITIONS AND SEASONAL FACTORS.
Many authors have associated COPD with the stabling
of horses and with the feeding of hay, particularly poor
quality hay (Alexander, 1959; Cook and Rossdale, 1963;
Eyre, 1972; Gerber, 1 973; McPherson £t_ al_. , 1979a).
However, there are a few reports of the disease
commencing or being exacerbated in horses at pasture,
in the absence of hay feeding (Foley & Lowell, 1966;
Halliwell, R. 1979, personal communication).
McPherson et_ al_. , (1979a) found that stabling
horses did not, in itself, significantly influence the
incidence of COPD (P>0.05) but poor stable ventilation
did (P <0.05). Contact with 'poor quality1 hay or
straw (visibly heavily contaminated by moulds, very
dusty or showing marked evidence of dampness or over¬
heating) was significantly greater in their affected
animals (P <0.05). The authors concluded, "Thus the
more frequent the exposure to moulds in the fodder and
bedding, especially if combined with inadequate ventil¬
ation of the stables, the more likely a horse is to
develop COPD. The increase in the disease prevalence as
horses age may be related to the summation of exposure to
13.
these factors".
Whereas Gerber (1973) believed a seasonal incidence
existed depending on seasonal differences in feeding
practices, neither Gillespie and Tyler (1969) nor
Littlejohn, Schlegemilch and Le Roux (1977) or
McPherson e_t al_. , (1979a) were able to record any
significant seasonal distribution of COPD.
AETIOLOGY
THE ROLE OF ALLERGY
As large numbers of horses subjected to poor en¬
vironmental conditions do not contract COPD, McPherson
et al_.,N (1979a) postulated that intrinsic factors,
possibly related to the immunological reactivity of
individuals, play a role in the pathogenesis of
equine COPD. Many earlier authors considered the
ff
disease to be allergic in nature (Alstrom and
Lauritzson, 1933; Cook and Rossdale, 1963; Lowell,
1964; Eyre, 1972; Gerber, 1973; McPherson and Lawson,
1974; Cook, 1976). Furthermore, some authors likened
the disease to allergic respiratory disease in man and
in particular, to bronchial asthma (Alexander, 1959;
Hoyt, 1963; Thurlbeck and Lowell, 1964; Cook, 1963;
Gerber, 1973).
Lowell (1964) hypothesised that the disease was
induced by contact with one or more of the components
of hay. Cook (1965) and Eyre (1972) believed that
moulds and dust from hay and straw constituted the
aetiological allergens, whilst Cook (1976) also in—
crimated fungal spores.
14.
In studies on the pathogenesis of CQPD and on the
possible antigenic agents involved, researchers carried
out intradermal, inhalation and serum precipitin tests,
the results of which are discussed on pages 15, 16, and
17 respectively. To the same ends, Eyre (1972),
using isolated pulmonary venous strips from 3 affected
horses, demonstrated positive Shultz-Dale reactions to
specific fungal antigens in 2 animals which had
previously elicited positive intradermal reactions to
these same antigens in vivo. The contraction of the
pulmonary venous strips in the presence of antigen was
taken to indicate pulmonary vascular hypersensitivity
in the donor animal.
Antigen Intradermal Tests
Larsson (1936) appears to have been the first to
perform equine antigen intradermal tests and he found
cutaneous hypersensitivity in COPD affected horses,
to extracts of mouldy hay as also did SerticT (1968 ).
However, Lowell (1964) reported that hay dust, house
dust and mould extracts elicited similar intradermal
reactions in 6 affected and 6 normal horses. He,
therefore, thought it possible that many hay-fed
horses develop skin hypersensitivity to allergenic
components in hay without developing pulmonary hyper¬
sensitivity, i.e. COPD. Eyre (1972) recorded marked in¬
tradermal reactions in 10 out of 15 COPD affected horses
against moulds commonly found in Canadian stables, whilst
6 out of 10 clinically normal horses showed relatively weak
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skin reactions to the same antigens. A_. fumiqatus
was found to elicit the most positive reactions in
affected horses. Eyre (1972) also demonstrated the
presence of reagin-like skin-sensitising antibodies
in the sera of 8 affected horses by means of the
If
Prausnitz-Kustner passive cutaneous anaphylactic test.
Schatzmann and Gerber (1972) performed intradermal
tests on horses in Switzerland using a wide range of
commercially available allergy testing solutions, but
were unable to demonstrate any allergen causing signi¬
ficantly more positive reactions in affected horses as
compared with the controls. McPherson et_ al_. , (1979b)
recorded positive intradermal reactions in 25 out of
35 affected horses to M_. faeni and in 17 out of 34
affected horses to _A. fumiqatus. Significantly
more COPD affected horses showed skin sensitivity to
these agents than did those in the control group (P<0.001).
Many of their horses responded positively to mixed
moulds, actinomycetes and fewer to pollens, but there
was no significant difference in the incidence of
positive responses to these antigens between the affected
and non-affected horses.
Using a wide range of allergens including moulds,
Halliwell e_t al_. , (1979 ) carried out intradermal tests
on 25 COPD affected and 25 normal horses. Positive
reactions were seen more frequently and the mean
reaction size was greater in diseased horses than in
normal horses (both P< 0.001). M. faeni elicited the
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greatest number of positive reactions.
From the literature, it is apparent that COPD
affected horses show cutaneous hypersensitivity to
certain environmental antigens more frequently than do
normal horses. Moulds appear to be involved most
frequently and although the most prevalent antigens
may differ from one country to another, M_. faeni and
_A. fumiqatus have each been implicated by two groups
of workers on different continents.
To evaluate the accuracy of intradermal tests in
the diagnosis of respiratory hypersensitivity as
assessed by antigen inhalation tests, McPherson e_t al. ,
(1979b) compared the results of these tests in 35 COPD
affected horses. Using M_. faeni antigen, the agreement
between the tests was 92%, so the M_. faeni intradermal
test could therefore be used as an indicator of the
cause of respiratory hypersensitivity in CQPD affected
animals. The agreement between the two tests using
A_. fumiqatus was low, possibly resulting from the two
antigens being prepared differently from different
strains.
Antigen Inhalation Tests
Alstrom and Lauritzson (1953), Lowell (1964),
Sertic (1968), Eyre (1972) and Nicholls (1978) performed
crude antigen inhalation tests on COPD affected horses
by exposing them to dusty hay and provoked signs of
COPD in this way. All these authors thus concluded
that the disease was allergic in nature and that the
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causal allergic agents were airborne.
McPherson e_t al_. , (1979b) performed antigen in¬
halation tests on normal and affected horses. Maximum
intrapleural pressure changes and arterial oxygen
partial pressures were used in addition to clinical
examinations, to assess the response to inhalation
challenge. 25 out of 32 COPD affected horses
responded positively to M_. faeni, 12 out of 29 to
A_. fumigatus, 6 out of 8 to mouldy hay and 5 out of 12
to Rye grass pollen. 2 COPD affected horses failed
to respond to inhalation challenge with available
antigens. Multiple hypersensitivity was not uncommon.
6 and 4 normal horses were challenged with M. faeni
and A_. fumiqatus respectively. None of these horses
gave a positive response to inhalation challenge.
Antigen inhalation tests using specific antigens
confirmed the hypothesis that respiratory hyper¬
sensitivity exists in COPD affected horses and studies
by McPherson £t_ al_. , (1979b) identified M_. faeni and
A_. fumiqatus as common allergens involved in COPD in
Northern Britain.
Serological Tests
Serum precipitating antibodies to the aetiological
antigens are found in humans and cattle suffering from
certain allergic pulmonary diseases (Pepys e_t al_. , 1963 ;
Longbottom and Pepys, 1964; Wiseman £t al_. , 1973;
Hollingdale, 1974) and they are thought to indicate
previous exposure to the relevant antigen.
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Serum precipitating antibodies to _M. faeni and
A_. fumiqatus were isolated in COPD affected horses by
Schatzmann and Gerber (1972), Nicholls (1978 ) and
Lawson _et_ al_. , (1979). Lawson et_ al_. , (1979) re¬
ported that whilst precipitins to both antigens were
shown in normal horses, they occurred more frequently
in affected animals and their findings indicate that
_M. faeni is a major allergen involved in equine COPD in
Great Britain. It is, however, interesting to note
that the serum precipitating antibody responses in
COPD affected horses following M. faeni and A_. fumiqatus
inhalation challenge are quite different (Lawson £t_ al. ,
1979). It seems likely that the varying responses
reflect differences in the nature of the antigens and
the behaviour of these micro-organisms following
inhalation.
THE ROLE OF INFECTIOUS AGENTS.
A number of authors considered infectious agents
to be a primary cause of COPD (Huytra and Marek, 1926;
Wester, 1935; Cook and Rossdale, 1963; Lowell, 1964;
Gerber, 1973; Fischer, 1980). Gerber (1973) re¬
corded acute influenza prior to developing the syndrome
in 25 out of 33 affected horses whilst Streptococcal
infections were believed to be secondary or aggravating
factors in COPD by Erasmus (1965) and Gerber (1973).
McPherson and Lawson (1974) reported that many affected
19 .
horses had a history of continuing coughing for many
months following bacterial e.g.: Streptococcus
zooepidemicus or viral e.g.: Influenza A/equi type 1
infections. The precise role of infectious agents
in the aetiology of equine COPD is unclear. McPherson
and Lawson (1974) postulated that damage to the
respiratory mucous membrane resulting from such in¬
fections may allow antigens to make contact with
immunologically active tissues resulting in the
development of respiratory allergy in susceptible
horses.
In man, stressful conditions or viral or bacterial
infections have been shown to be predisposing factors
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in the development of hypersensitivity (Szentivanyi,
1968). Following many viral respiratory infections in
man, Picken, Niewohner and Chester (1972) found that
there could be prolonged changes in the small airway
dynamics which were not clinically apparent and
Laitinen e_t aJL_. , (1976) found decreases, possibly
permanent, in the respiratory irritant receptor thres¬
hold. Similarly, Empey and co-workers (1976) reported
that viral upper respiratory infections in otherwise
healthy human subjects cause a transient but sometimes
striking increase in the bronchial response to
chemical and pharmacological stimuli. This bronchial
hyperreactivity persists for 4 to 6 weeks after
symptomatic recovery and is thought to be caused by
damage to the airway epithelium.
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THE ROLE OF IRRITANT MATERIALS.
There was a view held among Dutch and German
authors that stable dust could initiate COPD in horses
by direct irritation of respiratory mucous membranes
(Hajer, 1979; Fischer, 1980). There were, however,
no studies to substantiate this hypothesis. To
establish the effects of inhalation of non-allergic
foreign material by affected horses, McPherson, E.A.
(1980, personal communication) challenged horses with
kaolin dust. He was unable to elicit any response
in any of the horses as a result of dust inhalation.
Bannerman and Nicolet (1976), investigating the
components of the ML faeni antigen, discovered a
chymotrypsin-like enzyme produced by ML faeni as a
metabolic by-product of its growth process and postulated
that this enzyme, through its irritant nature, may be
responsible for respiratory diseases in man and animals
associated with M_. faeni. Thomson, J.R. (personal
observations) measured the chymotrypsin content of
different batches of ML faeni antigen used for inhalation
challenge of affected horses. There was no significant
correlation between the antigen's chymotrypsin content
and the degree of response to challenge in COPD affected
horses and the author deduced therefore, that this




Neither Gillespie and Tyler (1969) nor Sasse
(1971) found any evidence of a hereditary predisposition
to COPD in horses. However, Littlejohn, Schlegemilch
and Le Roux (1977), surveying a horse population of about
14,000 in Southern Africa found that the onset of
COPD in some cases may be associated with genetic
factors also linked to the coat colour. All reported
COPD cases were chestnut in colour and the probability
of such a colour linkage was highly significant
(P < 0 .001 ) .
In man, some cases of chronic alveolar emphysema
have been shown to be associated with a hereditary
alpha-1-antitrypsin deficiency caused by a single
autosomal recessive gene (Eriksson, 1965). Breeze
et al., (1977) investigated the role of antitrypsin
deficiency in the aetiology of equine COPD by studying
the serum trypsin inhibitory capacity in 19 affected
horses and ponies. These authors found no significant
diminution of this factor in COPD cases. Matthews
(1979) identified and characterised 2 major antiprotease
components in equine serum and investigated their role
in the onset of COPD. The author found no definite
association of reduced levels of the Pr antiprotease,
the homologue of human alpha-1-antitrypsin, with COPD
in the horse. Furthermore, Ek and Braend (1980) have
shown that no known allele product of the Pr locus in
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the horse is associated with significantly low serum
antiprotease protein levels. Thus, it is apparent
that a hereditary antiprotease deficiency does not
play a role in the aetiology of equine COPD.
OTHER FACTORS.
Gillespie and Tyler (1967a and b) postulated that
loss of pulmonary elastic tissue plus an increase in the
amount of surfactant was responsible for the emphysema
described in their cases of COPD. These authors
found type II epithelial cells, which are believed to
produce surfactant, to be present more frequently in
the alveoli and to be larger in size in horses with
COPD than in normal horses.
Emphysema and other structural pulmonary changes
have been artificially induced in normal horses through
administration of substances by routes other than in¬
halation. McLaughlin and Edwards (1966) injected
chlorpromazine into the proximal bronchial artery of
normal horses and this resulted in an obliterative
pulmonary endarteritis and emphysema in those animals.
Pathologically, the induced changes did not resemble
the major lesions occurring in equine COPD, as described
by Nicholls (1978). Breeze (1979) reported that oral
administration of 3-methylindole (an end-product in the
metabolism of L-tryptophan by Lactobacillus skatoli) to
normal horses consistently produced severe obstructive
pulmonary disease with similar pathological changes to
COPD. He, therefore, postulated that exposure routes
23.
other than inhalation may be involved in the pathogenesis
of equine COPD.
McPherson, E.A. and Thomson, J.R. (personal
observations) have recorded two cases of COPD in which
clinical signs on some occasions were excitement-induced.
Two horses in which signs of COPD appeared to be exercise-
induced have been reported (Robinson and Sorenson, 1978 ;
Hillidge, C.J., 1979, personal communication).
Thus the question as to why some horses develop
COPD whereas others, ostensibly exposed to similar
environmental conditions do not, still remains. Although
the aetiology may be complex with factors such as a
previous bacterial or viral infection predisposing to
the onset of the disease, most workers appear to agree
that COPD is primarily allergic in origin. The
aetiological allergens may vary in different parts of
the world but thermophyllic actinomycetes have been
widely implicated and in Northern Britain, M_. faeni
and /\. fumigatus have been identified as playing a
major aetiological role.
CLINICAL SIGNS
Horses affected with COPD were frequently presented
with a history of poor work performance (Gillespie and
Tyler, 1969; McPherson e_t a_l. , 1978 ; Littlejohn, 1978 ).
The disease was found to be non-febrile (Mahaffey,
24.
1962; Cook, 1965; Sasse, 1971) and the heart rate in
affected horses was reported to be slightly but not
significantly increased (Gillespie and Tyler, 1969;
Sasse, 1971; Littlejohn, 1978). Gillespie, Tyler
and Eberly (1966), Gillespie and Tyler (1969) and Sasse
(1971) found no significant increase in resting re¬
spiratory rates of affected horses, however, Eyre (1972),
Gerber (1973) and Littlejohn (1978) all recorded in¬
creased respiratory rates in affected animals.
Most authors agreed that the disease is invariably
associated with coughing of more than 3 months duration
(Sasse, 1971; Cook, 1976 ; McPherson ejt a_l_. , 1978;
Littlejohn, 1978). The nature of the cough was
frequently described as dry or non-productive (Gerber,
1973), but a nasal discharge has been reported in many
affected horses. This is usually slight and watery
(Boddie, 1962; McPherson ert a_l. , 1978; Littlejohn,
1978) but may occasionally be mucoid or mucopurulent
(Hoyt, 1963; Eyre, 1972; McPherson _et_ al_. , 1978).
Dyspnoea was reported to be present in some CQPD
affected horses (Gillespie and Tyler, 1969; Sasse,
1971; McPherson e_t a_l_. , 1978 ) but there was universal
agreement that a forced expiratory effort is present in
the vast majority of cases. The normal abdominal
phase of expiration is followed by a very marked
secondary contraction of the abdominal muscles variously
described as a "double expiratory effort", "abdominal
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lift" or "heave" (Figure 2.1) (Hoyt, 1963; Sasse, 1971;
Cook, 1976; McPherson et_ al_. , 1978). Littlejohn
(1969) and Robinson and Sorenson (1978) pointed out
that, as normal resting horses show an abdominal phase
of expiration, the clinical significance of the double
expiratory effort is one of degree. McPherson e_t al. ,
(1978) also recorded a double inspiratory effort in
some cases.
On chest auscultation the respiratory sounds,
particularly inspiratory, are increased in volume and
are harsh (Boddie, 1962; Hoyt, 1963; Gillespie
and Tyler, 1969 ; McPherson _et_ al_. , 1978 ). In more
advanced cases, crepitant and/or wheezing sounds occur
(Cook, 1965; Gillespie and Tyler, 1969; Eyre, 1972;
McPherson £t_ al_. , 1978 ).
Many authors described an enlarged area of
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resonance on chest percussion (Alegren and Carlstrom,
1940; Hoyt, 1963), but Sasse (1971) considered the results
of this technique to be too unreliable to be of
diagnostic value.
Additional signs described in advanced COPD cases
include elbow abduction, extension and lowering of the
head, an anxious expression, nostrils continually
dilated (Figure 2.2), wheezing audible at the nostril
and protrusion of the rectum during expiration (Hoyt,
1963; Cook, 1965; Gillespie and Tyler, 1969).
The clinical signs vary considerably according to
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Figure 2.1. The chest and abdomen of a
COPD affected horse showing
the characteristic "heave line".
Figure 2.2. A COPD affected horse showing
flaring of the nostrils.
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the severity of the disease. While most or all of the
signs could be present in severely affected horses,
few of these signs may be evident in early cases.
This can make the clinical diagnosis in early cases
difficult, as similar clinical signs may be observed
in horses with other equine pulmonary diseases.
PATHOLOGY
Although several authors have reported on the
pathology of equine COPD, many of these studies were
performed on small numbers of cases or gave very
limited descriptions of the pathological changes.
Many authors reported emphysema to be the major
pathological lesion in equine COPD, possibly due to
the long standing but unproven analogy between equine
COPD and human pulmonary emphysema (Alexander,
1959; Cook and Rossdale, 1963; Gillespie and Tyler,
1969; Jubb and Kennedy, 1970). However, more
objective studies by Thurlbeck and Lowell (1964),
Sasse (1971) and Nicholls (1978) have shown that
diffuse bronchiolitis and alveolar overinflation (or
alveolar emphysema) are the main lesions in this
disease. Breeze (1979) found that the term "alveolar
emphysema" had led fn confusion in the veterinary
literature, as some authors understood it to mean
alveolar overinflation whilst others considered it to
indicate destruction of alveolar walls. He suggested
that the definition for "emphysema", provided by the
World Health Organisation (1963) which includes"...
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destructive alterations of the alveolar walls" should be
adopted into the veterinary literature, whilst alveolar
overinflation should indicate "...an increase beyond
normal in the size of the airspaces distal to the
terminal bronchiole without destructive changes in the
interalveolar septa". The terminology recommended by
Breeze (1979) will be used in this work.
Other pathological changes described in equine
COPD are:- excess mucus in the airways (Figure 2.3)
(Hug, 1937; Roost, 1950; Hoyt, 1963; Thurlbeck and
Lowell, 1964; Nicholls, 1978), pulmonary eosinophilia
(Thurlbeck and Lowell, 1964; Gerber, 1973; Nicholls,
1978), bronchiolar smooth muscle hyperplasia (Wester,
1935; Gillespie and Tyler, 1969; Gerber, 1973;
Nicholls, 1978) and pulmonary vasculitis (Gillespie
and Tyler, 1969; Gerber, 1973).
Nicholls (1973) performed the most extensive and
objective pathological study of equine COPD using 25
affected horses, which included cases confirmed by
pulmonary function studies at the Royal 'Dick' School
Of Veterinary Studies, Edinburgh. The main lesions
found in diseased horses were:-
(1) alveolar ovcrinflotion
(2) bronchiolitis (a lesion affecting all
the small airways less than 2 mm in
diameter), characterised by epithelial
hyperplasia, epithelial metaplasia with
appearance of goblet cells in the
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Figure 2.3. Endoscopic view of the
tracheal lumen of a COPD
affected horse (at the level
of the thoracic inlet)
showing a large volume of
pooled mucus.
Figure 2.4. Lungs from a COPD affected
horse showing overinf1ation
of the diaphragmatic lobes
and small areas of emphy¬
sema in the apical lobes.
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bronchiolar epithelium and by peri¬
bronchiolar cellular infiltration.
(3) mucous and cellular exudation in the
bronchiolar lumina.
Emphysema occurred infrequently and was confined
to small areas in the apical lobe and periphery of the
diaphragmatic lobes. Several horses with a long
standing history of COPD but asymptomatic at the time
of death as a result of environmental control, showed
little or no pathological changes confirming therefore,
that the major pathological lesions are reversible.
Lungs from a COPD affected horse which was
symptomatic at the time of death are shown in Figure 2.4.
PATHOGENESIS.
As the majority of early authors believed emphysema
to occur in COPD affected horses, most of the hypotheses
on the pathogenesis of equine COPD were concerned with
the development of structural emphysema. Many authors
favoured the theory introduced by Laennec (1819) that
partial bronchial obstruction, possibly due to chronic
bronchitis, led to overinflation and to increased
intra-alveolar pressure distal to the obstructed
airways resulting in eventual destruction of the
alveolar walls (Wester, 1935; Hoyt, 1963; Cook and
Rossdale, 1963; Lowell, 1964; Cook, 1965; Gerber,
1973). However, Alexander (1959) and McLaughlin
and Edwards (1966) postulated that primary intra-
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pulmonary vascular lesions could give rise to regional
hypoxia in the lung resulting in emphysema in those
areas.
Cook and Rossdale (1963) clinically recognised
two forms of the disease, firstly, a so-called
"functional emphysema" which occurred in the initial
stages of the disease and was believed to be
reversible and secondly, emphysema with progressive,
structural lung damage. Other authors who believed
the disease to be progressive were Alexander (1959),
Foley and Lowell (1966), Gerber (1969), Gillespie
and Tyler (1969).
Lowell (1964) and Gerber (1973) considered that
emphysema might be the end result of recurrent or
protracted attacks of allergic respiratory disease.
Cook (1976) supporting an allergic pathogenesis of the
disease, suggested two means whereby the airways
might react to the allergens: (1) a simple inflam¬
matory response and (2) an allergic response producing
bronchospasm. He suggested that both mechanisms
operated together to produce "distal air trapping".
Other authors who believed bronchospasm to occur as
a result of an allergic reaction were Lowell (1964)
and McPherson and Lawson (1974).
Several authors described signs of COPD in horses
developing within one hour of exposure to certain
materials and postulated that this reaction was
analogous to the immediate allergic reaction (Type I
reaction) which occurs in human bronchial asthma
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(Alstrom and Lauritzson, 1953; Cook and Rossdale,
1963; Eyre, 1972). However, McPherson et al.,
(1979b) described the response to inhalatiqn challenge
as culminating at 4 to 8 hours after challenge and
believed the reaction was essentially Arthus-like
(Type III allergic reaction). The authors postulated
that both Type I and Type III reactions may be involved
in the pathogenesis of equine COPD.
Andberg, Boyd and Code (1941) and Qbel and
Schmiterlow (1948) believed that the pathogenesis con¬
sisted of an allergic reaction in the lungs involving
histamine and reproduced clinical signs of the disease
in normal horses by injecting histamine intravenously.
Obel and Schmiterlow (1948) reported that COPD affected
horses were more susceptible to histamine than normal
horses. Eyre (1972), however, measuring blood
histamine concentrations in eleven affected horses,
could only demonstrate elevated levels in one animal.
This author recorded increased plasma 5-hydroxytryptamine
concentrations in affected horses and postulated that
this mediator may play a role in the pathogenesis of
the disease. As yet, little is known about the role
of chemical mediators in equine pulmonary hypersen¬
sitivity.
Hajer (1979) and Fischer (1980) postulated that
bronchoconstriction in horses could be vagally-induced
due to stimulation of the airway irritant receptors
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by dust or mucus. This phenomenon is recognised in
man (Nadel, 1968 ; Boushey e_t al_. , 1980). Hajer (1979)
and Fischer (1980) also postulated that changes in the
chemical composition and increased viscosity of the
sputum leads to direct chemical or mechanical airway
irritation which, in turn, initiates the formation of
more abnormal sputum resulting in a vicious circle,
giving rise to COPD.
In conclusion, it appears that, although the
pathogenesis of COPD is unclear, the reaction gives
rise to airway obstruction, both mechanical (e.g.
bronchiolitis and mucus in the airways) and possibly
functional (e.g. airway spasm).
PULMONARY FUNCTION TESTS.
In view of the variability in the clinical signs
of equine COPD and the consequent difficulty in
establishing a diagnosis in early cases, equine pulmonary
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function testing was introduced by Sporri and Leeman
(1964) and Sporri and Zerobin (1964) to physiologically
classify and to aid in the diagnosis of equine respir¬
atory disorders. In the past, many reports differed
regarding, for instance, the clinical signs and
pathology of COPD, and this may have resulted from
authors describing different disease entities. However,
the use of pulmonary function tests provides a more
objective assessment of equine respiratory function and
allows a more accurate comparison of results between
authors. Pulmonary function tests are now widely used
in COPD cases both for diagnostic and research
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purposes. However, as patient co-operation is required
for many of these tests, only a restricted range of
those used in human medicine can be used in veterinary
medicine. Summaries of some respiratory function
values obtained from normal and COPD affected horses
by previous authors are shown in Tables 2.1 and 2.2
resp ectiv ely .
INTRATHORACIC PRESSURE CHANGES
Intrathoracic (intrapleural) pressures in horses
have been measured by two methods i.e. intrapleural
cannulation and by the intraoesophageal balloon. The
latter method is described on page 49. The intra¬
pleural cannulation technique gives a more accurate
intrapleural pressure reading as the intraoesophageal
balloon method measures not only intrathoracic pressure
but also pressures exerted by oesophageal wall con¬
tractions. The properties of the balloon itself and
its position in the oesophagus also affect readings
(Banchero, Rutishauser, Tsakiris and Wood, 1967; Dixon,
1979; Derksen and Robinson, 1980). The intraoeso¬
phageal balloon technique is, however, non-invasive and
is therefore more suitable for routine diagnostic use and
for repeated measurements on the same subject.
Fry e_t al_^, (1952) and Mead and Gaensler (1959)
recorded intrathoracic pressures in man using both
methods simultaneously and found a close correlation
between the values obtained by the two techniques.
Similar findings have been shown in the dog (Banchero,
TABLE2.1.
Summaryofrespirato yfunctionmeasurementsobt inedfrn r alhorsbyp evio sa th r . Intrapleuralpressure Measurements(mHg)Minute Volume (litres/ min.)
Insp. Plow Rate (litres/ min.)
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Schwartz, Tsakaris and Wood, 1967). Gillespie, Tyler
and Eberly (1966) recorded intrapleural pressures in
horses using both techniques simultaneously and found
that the shape of the recorded curves were very
similar and the pressure changes measured by the two
methods did not vary by more than 0.4 mm Hg when the
maximum change in intrathoracic pressure (max.APpl)
was 7.4 mm Hg or less. McPherson and Lawson (1974),
McPherson et_ al_. , (1973) and Willoughby and McDonell
(1979) also demonstrated a good correlation between
the two methods in horses. More recently, detailed
studies have confirmed that intrathoracic pressure
measurement using a balloon in the middle or caudal
thoracic oesophagus accurately reflects the local
changes in intrapleural pressure, in the standing horse
(Derksen and Robinson, 1980).
Several authors have demonstrated significantly
raised max.A Ppl levels in COPD affected horses and
concluded that max.APpl determination is a very
important diagnostic aid (Sasse, 1971; McPherson et al.,
1978; Littlejohn, 1978 ). The increased max.APpl in
COPD affected horses results from the pulmonary patho¬
physiological changes occurring in this disease, i.e.
diffuse bronchiolitis, excess mucus secretion, and
possibly airway spasm.
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VISCOUS (PULMONARY)RESISTANCE, VISCOUS WORK OF BREATHING
AND DYNAMIC COMPLIANCE.
II
The viscous resistance (Rossier, Buhlmann and
Wiesinger (1958 )), also termed pulmonary resistance
(Comroe £t_ al_. , 1962) designates the sum of; the airway
resistance (the resistance which must be overcome by the
air flowing in the bronchi and bronchioli), the deform¬
ation resistance, the frictional resistance and the
resistance due to inertness of the lung. Narrowing
of the airways can lead to increased viscous resistance
(Lambertsen, 1961) as recorded in COPD affected horses
If II
by Sporri and Leeman, (1964), Sporri and Zerobin (1964),
Gillespie, Tyler and Eberly (1966), Sporri and Denac
(1967) and Gillespie and Tyler (1969).
Sasse (1971) and Muylle and Oyaert (1973) calculated
the viscous work of breathing by constructing pressure-
volume diagrams and found that viscous work was
significantly greater (P< 0.01) in COPD affected horses
than in normal horses. Great importance was attached
by Sasse (1971) to the minute viscous work of breathing
(work = A pressure x A volume/minute) . However,
because minute volume did not differ significantly
between his normal and affected horses, it seems likely
that the increased max.A Ppl accounted for the
significantly greater minute viscous work of breathing
in the affected horses. Marschall, Stone and
Christie (1954) and Gilbert and Auchincloss (1969) both
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demonstrated a good correlation between max. A. Ppl and
viscous work of breathing in human patients.
Dynamic compliance is calculated from the ratio of
the tidal volume to the difference in intrathoracic
pressure between the points of zero airflow corres¬
ponding to the beginning of inspiration and expiration.
Gillespie, Tyler and Eberly (1966) and Muylle and
Oyaert (1973) recorded a significantly lower mean
dynamic compliance in COPD affected horses than in
normal horses.
TIDAL VOLUME AND AIR FLOW RATES.
Gillespie, Tyler and Eberly (1966) and Gillespie
and Tyler (1969) recorded significantly lower (P<0.05)
inspiratory tidal volumes in COPD affected horses than
in normal horses. This was in contrast to the findings
of Muylle and Oyaert (1973) who were unable to demon¬
strate any significant difference in inspiratory tidal
volume between normal and affected horses and Sasse
(1971) who found inspiratory tidal volumes to be
significantly greater (P< 0.01) in COPD affected horses
than in the control group. Muylle and Oyaert (1973)
believed that temperament, excitement and respiratory
rate could greatly influence the tidal volume and
considered this parameter too inconsistent to be of
diagnostic use. None of the above authors recorded
any significant difference in the minute volume between
normal and affected horses.
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A significant increase (P< 0.01) in mean inspir¬
atory flow rate in COPD affected horses above that of
normal horses has been reported by Gillespie, Tyler
and Eberly (1966), Gillespie and Tyler (1969), Sasse
(1971) and Muylle and Oyaert (1973). Sasse (1971)
believed that the increased inspiratory tidal volume
in his affected group accounted for the increased
inspiratory flow rate.
Neither Gillespie, Tyler and Eberly (1966) nor
Sasse (1971) recorded any significant difference in
mean expiratory flow rate between normal and COPD
affected horses. However, Muylle and Qyaert (1973)
found the mean expiratory flow rate in their group of
15 COPD affected horses to be significantly higher
(P< 0.05) than that in normal horses.
ARTERIAL BLOOD GAS AND pH ANALYSES
Arterial blood gas (i.e. partial pressure of
arterial oxygen (PaO^)* partial pressure of arterial
carbon dioxide (PaC02)) and arterial pH analyses are
frequently used as diagnostic aids in respiratory
diseases in man and animals as they reflect the degree
of respiratory dysfunction present in the patient.
They are consequently also used to assess the response
to therapy and for prognosis (Palmer and Flenley,
1976; Cumming and Semple, 1980).
A number of authors have recorded Pa02, PaC02 and
arterial pH values in normal and CQPD affected horses,
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shown in Tables 2.1 and 2.2 respectively.
When comparing the results of blood gas analyses
by various authors, it is important that the altitude
of the laboratory be taken into consideration. For
instance, Littlejohn (1978), at 1,300 metres above
sea level recorded far lower PaO^ levels in normal and
affected horses than did other authors, which would
appear to be an altitude-related hypoxaemia. It is
also important that normal values for blood gas
analyses are established for each laboratory as
variations in technique and equipment can account for
major differences in results (Barnett, 1971 ) . The
blood gases should preferably be measured at normal
equine body temperature i.e. 37.7°C. However, this
is not always possible as many blood gas analysers
operate at human body temperature only, i.e. 37.0°C.
There is a 5?o difference in values obtained from blood
analysed at these two temperatures, so the blood gas
analysing temperature should, therefore, always be noted.
In comparison with normal horses, COPD affected
horses are hypoxaemic (Tables 2.1 and 2.2) but there
appears to be no evidence of hypercapnia nor respiratory
acidosis. This suggests that the pulmonary dysfunction
in equine COPD is a perfusion:ventilation disorder rather
than a generalised alveolar hypoventilation, where the
hypoxaemia would be accompanied by hypercapnia and
possibly by respiratory acidosis (World Health
Organisation, 1963).
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Although several sites have been described for
collection of arterial blood samples from horses (Rose
and Rossdale, 1981), the two most commonly used are
the common carotid artery (Littlejohn and Mitchell,
1969; McPherson and Lawson, 1974; McPherson et_ al. ,
1978; Littlejohn, 1978; Dixon,1978) and the brachial
artery (Fisher, 1959; Sasse, 1971).
CONCLUSIONS OF THE USE OF PULMONARY FUNCTION TESTS IN
COPD AFFECTED HORSES.
There is universal agreement between authors that
COPD affected horses have a significantly higher max.A
Ppl, viscous resistance, viscous work of breathing,
mean inspiratory flow rate and a significantly lower
dynamic compliance and Pa02 than normal horses. There
is, however, no overall agreement as to whether the
tidal volume or mean expiratory flow rate differ between
normal and CQPD affected horses.
Sasse (1971) regarded the minute viscous work
of breathing and Pa02 to be the most useful tests for
diagnosing COPD. However, as previously noted,Sasse
(1971) failed to record any significant difference- in
minute volume between normal and COPD affected horses
and it is therefore likely that the increased max.APpl
gave rise to the increased minute viscous work of
breathing in his affected horses. For this reason,
and because of the good correlation between the viscous
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work of breathing and max.APpl recorded in man, the
main ancillary tests currently used by the Edinburgh
workers are max. A Ppl and PaC)2 measurements. Taking
the mean - 2 standard deviations of max.APpl and PaC^
for 11 normal horses, McPherson e_t £l_. , (1978 )
suggested that values for max.APpl greater than or
equal to 6 mm Hg and PaC^ less than or equal to 82
mm Hg were abnormal (for their laboratory and apparatus)
and used these parameters in their COPD diagnostic
criteria.
REVERSIBILITY OF RESPIRATORY FUNCTION DISTURBANCES.
The respiratory function disturbances in COPD,
being erroneously likened to human emphysema, were
formerly believed to be irreversible. However,
following atropine administration to affected horses
it
Obel and Schmiterlow (1948) recorded a temporary
decrease in max.APpl whilst Sporri and Leeman (1964)
and Muylle and Oyaert (1973) reported a temporary
decrease in the work of breathing which indicates
that the airway obstruction in COPD can be partially
reversed by parasympatholytic agents.
Using environmental control, i.e. removing hay
and straw from the stable and surrounding area, Meister,
Gerber and Tschudi (1976) recorded a marked clinical
improvement and a highly significant (P< 0.001) increase
in Pa02 from 65.8 - 11.1 mm Hg to 86.0 - 5.4 mm Hg in
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17 affected horses after 11 days. Similarly Dixon
(1978) rendered 10 COPD affected horses asymptomatic
and recorded a mean Pa02 value of 86.5 - 6.4 mm Hg in
asymptomatic horses which is significantly higher
(P <0.001) than that for his affected horses (66.1 -
6.4 mm Hg). This shows that COPD affected horses,
under certain conditions, are capable of improving
their ventilation.
MANAGEMENT AND TREATMENT.
Although equine COPD has been recognised for
many centuries, few definitive studies have been carried
out on the treatment of the disease. Early authors
advocated good nutrition, good ventilation, clean
stables and rest combined with the empirical systemic
administration of agents such as arsenic, strychnine,
vergotinin, fibrolysin, calcium chloride (Huytra and
Marek, 1926). However, as expected, none of these
agents were found to have a lasting beneficial effect.
The feeding of atropine-containing plants (Atropa
belladonna, Datura stramonium, Hyoscyamus niqer) or
twice daily subcutaneous atropine sulphate injections
temporarily reduced the dyspnoea and respiratory rate,
the latter method proving more successful (Raitsits,
1923; Burger, 1926; Alegren and Carlstrom, 1940).
Despite the untoward effects of systemic parasympatholytic
agents, especially on the gastro-intestinal system,
frequently resulting in severe colic, this form of
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treatment was advocated for many years.
Management of the disease by means of environ¬
mental control has been favoured by more recent authors.
Cook and Rossdale (1963), Lowell (1964), Cook (1965)
and Eyre (1972) reported an improvement in horses
turned out to grass, or housed on peat moss or wood
shavings instead of straw, and fed a pelleted diet or
dampened hay. None of these authors quantitatively
recorded the improvement which occurred in affected
horses through use of these measures.
Gerber (1973) injecting 25 mg dexamethasone intra¬
muscularly every second day, reported that "coughing
may stop, dyspnoea may be reduced or disappear as do
the enlargement of the lung percussion field and
abnormal auscultatory sounds in a number of cases". However,
horses have been found to revert to their dyspnoeic state on
cessation of corticosteroid treatment (Gregg, 1969; Gerber, 1973).
Due to the side effects of corticosteroids, these drugs
are not generally favoured for long-term therapy of
this condition.
The use of a bronchial/bronchiolar secretolytic
drug, bromhexine hydrochloride for the treatment of
equine COPD has been reported by Schatzmann, Bergi and
Straub (1973), Cook (1976), and Nicholls (1978), but
none of these authors found any lasting beneficial
effects as a result of treatment.
Calverley (1977) administered levamisole hydro¬
chloride, an anthelmintic, to 40 COPD affected horses.
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He claimed that one-third of the horses showed little or
no improvement, whilst the remaining two-thirds were
said to be cured after treatment although there was no
objective evidence to support the claim. This author
postulated that this drug's property of stimulating
the immunity was responsible for the alleged success in
treating COPD. However, in human medicine, levamisole
hydrochloride has only proved beneficial in patients
who have a primary immunodeficiency and it does not
stimulate immunity beyond the normal level in patients
who are immunocompetent (Symoens and Rosenthal, 1977).
Since immunodeficiency has not been demonstrated in
horses with COPD, the alleged mechanisms of action of
levamisole hydrochloride in COPD affected horses is
unci ear.
Sympathomimetic agents which are frequently used
for the treatment of human bronchial asthma have also
been used for the treatment of equine COPD. Sasse
and Hajer (1977) injected NAB 365CL (clenbuterol) a
beta 2 sympathomimetic bronchodilator intravenously
into 3 affected horses. They reported a marked decrease
in the viscous work of breathing similar to that obtained
after intravenous atropine administration and clinical
improvement lasting 5 to 8 hours. Additionally, 14
COPD affected horses were treated with clenbuterol
orally twice daily for 14 days and the response
assessed by the owners. The horses were all thought
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to improve as a result of treatment (Sasse and Hajer,
1977) .
From the literature review, it appears that more
information is required on the management and treatment
of equine COPD. Several questions remain unanswered,
in particular, on the degree of reversibility obtainable
through environmental control and on the time required
to obtain this improvement. Pertaining to chemo¬
therapy, more information is required on the effects of
bronchodilator drugs, particularly on the longer acting
oral bronchodilators. Additionally, the possible use
of the newer prophylactic anti-allergy compounds for
the therapy of equine COPD needs to be investigated.
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CHAPTER 3
GENERAL MATERIALS AND METHODS
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HORSES.
The control horses (Appendix 3.1) were mostly adult
hunters and thoroughbreds. They had no history of
recent respiratory illness and their respiratory
systems were normal on clinical and pulmonary function
examinations.
The COPD affected horses (Appendix 3.2) were of
similar age and breed-type. They coughed inter¬
mittently, were dyspnoeic, manifested a double
expiratory effort and had harsh inspiratory chest
sounds, including wheezing and crepitation in some
cases. Additionally, all horses showed a max. A Ppl
of greater than or equal to 6 mm Hg and a resting Pa02
of less than or equal to 82 mm Hg (McPherson ejt al. ,
1978 ) .
MONITORING TECHNIQUES.
During all recordings, the animals were standing,
untranquilised, loosely restrained by a halter only and
were handled quietly to prevent any excitement - induced
respiratory or cardiac changes.
INTRATHORACIC PRESSURE MEASUREMENTS.
Intrathoracic pressures including maximum expiratory
pressure, minimum inspiratory pressure and max.APpl
were measured using the intraoesophageal balloon
technique (McPherson _et_ al_. , 1 978 ). A medium-sized
plastic horse stomach tube with an internal diameter
of 13 mm (Portex, London) had 4 lateral openings cut
in the distal tip and a 2.5 cm length of rubber
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tubing slipped over and securely stitched to the
plastic tube 12 cm from the distal end. This end
including the lateral eyes was covered with a condom
(Durex Gossamer, LR Industries Ltd., London) which was
bound to the rubber tubing with linen thread (Figure
3.1 ) .
The tube was passed down the oesophagus in the
conventional manner, until the balloon was in the mid-
thoracic position opposite the 9th and 10th ribs
(Figure 3.2), as adjudged by the length of stomach
tube passed. The proximal end of the stomach tube
was connected by a rigid-walled plastic tube 260 cm
long, of internal diameter 3 mm, to a strain guage
pressure transducer (L22, Devices Ltd., London), an
amplifier and a heated pen recorder (M19, Devices Ltd.,
London). The intrathoracic pressure changes were
recorded in mm Hg. The recording equipment, was
allowed to heat up for 30 minutes before use and prior
to each recording was electronically calibrated with
a 10 mm Hg signal. Atmospheric pressure was used as
zero baseline. The position of the balloon within
the thoracic oesophagus was adjusted until maximal
intrathoracic pressure fluctuations were recorded. The
max. A Ppl was calculated from the mean of ten
consecutive and representative respiratory tracings.
TIDAL VOLUME AND AIR FLOW RATES.
The tidal volume, minute volume, mean inspiratory
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Figure 3.1» The intraoesophageal tube and
balloon used for intrathoracic
pressure measurement in horses.
Figure 3.2. Radiograph showing the
position of the intraoeso¬
phageal balloon in the
horse's chest during intra¬
pleural pressure recording.
The balloon has been filled




flow rate and mean expiratory flow rates were measured
using a face mask, a pneumotachograph (F3000L Flowhead,
Mercury Electronics (Scotland) Ltd., Glasgow) and an
electronic spirometer (CS9 Electrospirometer, Mercury
*
Electronics (Scotland) Ltd., Glasgow) (Figure 3.3).
The face mask which covered the horse's mouth
and nose was constructed from a rigid polythene con¬
tainer (length 20 cm,top diameter 20 cm, bottom
diameter 12 cm) with a 15 cm wide flexible plastic
sleeve attached to its proximal end by two 15 cm
diameter, 1.25 cm wide rubber bands. A circular
hole 5 cm diameter was cut in the centre of the base
of the mask into which a rigid plastic cuff was fitted
and fully sealed in place with perspex cement. This
cuff protruded 3 cm from the base of the mask. The
tapering entrance to the flowhead was fitted securely
into the cuff and the connection sealed by 7.5 cm
wide adhesive bandage (Elastoplast, T.J. Smith and
Nephew Ltd., Hull).
The mask was held in position on the horse's head
by a nylon strap from both sides of the mask over the
poll region. The proximal end of the mask was sealed
with a double rubber strap 66 cm long, 3 cm wide. A
foam pad 3 x 6 x 2 cm attached to the rubber strap was
positioned in the intermandibular space, the rubber
strap was tightened and secured with self-adhesive
nylon strip. Care was taken to ensure that the
strap provided an airtight closure. The pneumotacho¬
graph was connected by twin tubing 2.5 m long, inner
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Figure 3.3. The face mask, pneumotacho¬
graph and electronic spiro¬
meter used for measuring
tidal volume and air flow
rates in horses.
Figure 3.4. Anaerobic collection of
arterial blood from the




diameter 3 mm to the spirometer.
The spirometer was allowed to heat up for 30
minutes prior to recording and was calibrated using a
Rotameter Float Guage (G.E.C. - Elliott, Process
Instruments Ltd., Croydon). A vacuum pump
(Electrolux Ltd., Luton) provided a positive air¬
flow through the pneumotachograph and the float guage
and a valve between the pump and the pneumotachograph
allowed the flow level to be adjusted manually. The
tidal volume was calibrated by passing 3 litres of air
through the pneumotachograph from a measured 3 litre
syringe.
The tidal volume, expiratory and inspiratory flow
rates were calculated from a mean of ten consecutive
and representative respiratory tracings. The cumulative
volume was measured over 1 minute, i.e. the minute
volume.
ARTERIAL BLOOD GAS AND pH MEASUREMENTG.
Arterial blood samples for Pa0o, PaC02 and pH
analyses were obtained by percutaneous carotid puncture
in the lower neck region using a 21 guage, 4 cm
hypodermic needle, after swabbing the site with ~]%
chlorohexidine BP solution. The blood was collected
anaerobically into a 10 ml glass syringe (Rocket Ltd.,
London) which contained a brass washer to facilitate
mixing (Figure 3.4). The solid barrel was coated in
vaseline to prevent leakage of air into the syringe
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during sampling. The syringe was flushed with sterile
heparin 25,00U I.U/L (Pularin Heparin, Evan's Medical
Ltd., Liverpool), both to act as an anticoagulant and
to eliminate airspace within the syringe. Approximately
10 ml of blood was collected over a 30 to 60 second
period to ensure several respiratory cycles during
collection. The syringe was sealed with a plastic
cap and shaken to mix the blood with the heparin.
After withdrawing the needle, digital pressure
was applied to the puncture site for approximately two
minutes to reduce haematoma formation.
Samples were stored in iced water until analysed,
which was always within 1 hour of collection. Blood
gas estimations were carried out using a Corning pH/
blood gas 161 analyser (Corning Medical Ltd., Halstead,
Essex) by the technical staff of the Department of
Veterinary Medicine. All blood gas estimations were
measured and reported at 37°C. The equipment was
calibrated as instructed by the makers. The altitude
of the laboratory is 200 metres.
ANTIGEN INHALATION CHALLENGE.
NATURAL ANTIGEN INHALATION CHALLENGE.
Horses were housed in wel1-ventilated loose boxes
measuring 5 x 4 x 3 m and bedded on wheat straw which
was dusty and visibly contaminated with mould (Figure
3.5). The diet consisted of poor quality hay ad
libitum and oats (appropriate to the needs of the animal).
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Figure 3.5. A sample of mould-contaminated
straw used for natural
antigen inhalation challenge




Although the straw quality varied considerably,
every attempt was made to provide similar challenge
conditions with high mould levels for all horses.
ARTIFICIAL ANTIGEN INHALATION CHALLENGE.
M_. faeni and A_. fumiqatus antigens were prepared
by the Department of Veterinary Pathology as described
by Lawson e_t a_l_. , (1979). The challenge dose of each
antigen was approximately 12 mg of antigen extract
(estimated as dry matter) suspended in 5 ml normal
saline.
The antigens were nebulised over a period of 20
minutes using a Wright's nebuliser (Aerosol Products,
London) connected by a polythene tube, 2.5 m long, 10 mm
internal diameter to a face mask similar to that
described for tidal volume measurement (Figure 3.6).
The tube from the nebuliser passed through the face
seal into the mask. The attendant wore a nontoxic
particle face mask (No. 8800, Minnesota Mining and
Manufacturing Co., St. Paul, Minnesota) and the
administration was carried out in a well-ventilated
room. The Wright's nebuliser produces a droplet size
of less than 3 microns.
THE CONTROLLED ENVIRONMENT.
Exposure to the aetiological agents was minimised
using a controlled environment. The loose boxes
were bedded with shredded paper (Shredabed Ltd., Exeter)
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Figure 3.6. Method of artificial antigen
inhalation challenge using a
Wright's nebuliser, delivery
tube and face mask.
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and the horses were fed a complete cubed diet (Spillers
Agriculture Ltd., London). The loose boxes which
were washed regularly to minimise dust levels were
upwind from and 40 m away from the hay store. Care
was taken to ensure that stables in the immediate
vicinity were not bedded with straw and the hay
barrows and hay nets did not pass in front of the
horses.
DRUGS AND ADMINISTRATION METHODS.
As different drugs and different routes and methods
of administration were used in each trial, they will be
described in the materials and methods of the appropriate
chapters.
THE CROMOVET INHALATION SYSTEM.
The Cromovet inhalation system (Figure 3.7)
comprises a Pulmo-Aide series 561 Portable Compressor
(Devilbiss, Pennsylvania) a Cromovet nebuliser and face
mask and a delivery tube (Fisons Ltd., Loughborough).
The Cromovet face mask, the dimensions of which are
shown in Figure 3.8, is constructed from a rigid
polythene inhalation chamber and a flexible PVC/nylon
sleeve which fits over the horse's mouth and nose. The
face mask is attached to the poll piece of the headstall
by velcro strip and is sealed around the nose at the
proximal end by a draw string. The face mask is
connected to the Cromovet nebuliser by a polythene de¬
livery tube, 1.5 m in length and of 2.5 cm internal
diameter. The droplet size produced by the Cromovet
inhalation system is less than 8 microns.
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Figure 3.7. The Cromovet inhalation
system comprising a Pulmo-
Aide portable compressor,
a Cromovet nebuliser, face





Strap with velcro strip,




Top diameter = 19 cm.
Bottom diameter =
9.5 cm.
Height = 12.0 cm.
Tube leading to Cromovet
Nebuliser.




top diameter = 21.0
height = 22.0 cm.




EFFECTS OF ENVIRONMENTAL CONTROL ON
HORSES AFFECTED WITH COPD.
63.
INTRODUCTION
Several authors have noted clinical improvement
in COPD affected horses as a result of environmental
control and thus advocated minimal dust regimes for the
management of this disease (Thurlbeck and Lowell,
1964; Eyre, 1972; Cook, 1976). Such measures aim
to prevent exposure to the aetiological agents which
are usually moulds e.g. M_. faeni found in hay and straw.
Minimal dust regimes include, for example, keeping
horses permanently outdoors with no supplementary hay
feeding; stabling horses on peat moss, wood shavings
or shredded paper and feeding a complete cubed diet
along with stabling horses upwind and as far away as
possible from the hay store and other horses bedded
on straw and fed hay.
Although clinical improvement has been noted by
several authors as a result of environmental control,
there have been very few studies into the effects of
such measures on the respiratory function of COPD
affected horses. In this respect, arterial blood
gases appear to be the only parameters previously re¬
ported. Meister, Gerber and Tschudi (1976) and
Dixon (1979) recorded significant PaO^ increases in
COPD affected horses which had shown marked clinical
improvement following removal of hay and straw from
their environment. Further studies are, therefore,
required on the reversibility of the COPD pulmonary
function disturbances through the use of environmental
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control measures.
In this section, respiratory function measurements
are obtained from affected horses in the symptomatic
and asymptomatic phases of COPD along with values
from normal horses. The time taken for horses to
become asymptomatic and some factors playing a role
therein are also investigated.
MATERIALS AND METHODS.
92 COPD affected horses (horses Nos. B1-20, B93-
164; Appendix 3.2) (Group A) exposed to the natural
challenge environment (page 53) were examined
clinically and their max. A. Ppl? PaC^' PaC02 and
arterial blood pH values recorded. Additionally,
tidal volume, minute volume, maximum inspiratory
and expiratory flow rates were measured in 20 of
these horses (horses Nos. B1-20; Appendix 3.2).
These horses were then moved to the controlled en¬
vironment (page 57) and given daily clinical examin¬
ations. When clinically asymptomatic, the above-
named parameters were re-measured in the same horses
i.e. max. A.Ppl> Pa^' PaC^ and arterial pH in all
animals (horses Nos. B1-20, B93-164; Appendix 4.1)
(Group B); tidal volume, minute volume, maximum
inspiratory and expiratory flow rates (horses Nos.
B1-20; Appendix 4.1).
Max. A Ppl, Pa02? PaC02 and carotid, blood pH
values were recorded in 68 normal horses also housed
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in the natural challenge environment (horses Nos. A1-
68; Appendix 3.1) (Group C) 20 of which also had
tidal volume, minute volume, maximum inspiratory and
expiratory flow rates measured (horses Nos. A1-20;
Appendix 3.1).
The results from the asymptomatic COPD affected
horses were statistically compared with values for
symptomatic and normal horses by analysis of variance
(Downie and Heath, 1974) and the Duncan multiple-
range test (Bliss, 1967, 1970). The Students' t-test
was used to compare results between symptomatically
affected COPD horses and normal horses. The paired
t-test was used to compare findings between sympto¬
matic and asymptomatic COPD affected horses. The
significance of the correlation between the time taken
for horses to become asymptomatic and age, bodyweight,
duration of illness, symptomatic max.APpl, Pa02>
PaC02j arterial pH, tidal volume, minute volume, maximum
inspiratory and expiratory flow rates, was tested by
linear regression (Snedecor and Cochran, 1967).
RESULTS
Individual respiratory function measurements
(max.APpl, tidal volume, minute volume, maximum in¬
spiratory and expiratory flow rates, Pa02> PaC02> and
arterial pH values) for normal horses, symptomatic
COPD affected horses and asymptomatic COPD affected
horses are shown in Appendices 3.1, 3.2 and 4.1
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respectively. The mean (- S.D.) value for each para¬
meter in each group and the statistical differences
between groups are presented in Table 4.1.
Compared to normal horses, symptomatic COPD
affected horses (whilst in the natural challenge en¬
vironment) had significantly increased max. A. Ppl
(P <0.001), respiratory rate (P <0.001), minute volume
(P< 0.05), maximum inspiratory flow rate (P <0.05) and
PaC02 (P <0.001) and significant decreases in Pa02
(P< 0.001) and pH (P< 0.001) but no significant differ¬
ences (P >0.05) in tidal volume or maximum expiratory
flow rate.
When housed in the controlled environment, the
affected horses became clinically asymptomatic in 4 to
32 days, mean (- S.D.): 9.0 (- 4.8) days. When this
occurred, there were significant decreases in max.A Ppl
(P <0.001), respiratory rate (P <0.001), maximum in¬
spiratory flow rate (P< 0.05) and PaC02 (P< 0.001),
significant increases in Pa02 (P< 0.001) and arterial
pH (P <0.001) but no significant changes (P>0.05)
in tidal volume, minute volume or maximum expiratory
flow rate.
On testing the results by analysis of variance,
the 3 groups (i.e. Group A = symptomatic COPD horses,
Group B = asymptomatic COPD horses, Group C = normal
horses) fell into two subsets ( \A/\BC/ ) for all para¬
meters except minute volume (\A \B/ C/ ) , tidal volume
TABLE4.1.
Respiratoryfunct onvalues(m an±5.D.)fosymptomaticCOPDaffectedhor ,asymptomaticCQ affectedhorsesndnormalhors s. HorsesNumber of horsesRespiratory rate (breaths/ minute)Max.A Ppl (mmHg)0 Tidal volume (litres)0 Minute volume (litres/ minute)0 Maximum inspir¬ atory flow rate (litres/ minute)


































































0=Parameterrecord din20hors sgr upsA,BnC.
NS=notsignificant * =P<0.05 **=P<0.01
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and maximum expiratory flow rate. (In the latter two
parameters there were no significant differences
between groups, as shown in Table 4.1). This indicates
that there were no significant differences in respir¬
atory rate, max.APpl, tidal volume, minute volume,
maximum inspiratory and expiratory flow rates, PaC^j
PaCO^ or carotid arterial pH between normal and
asymptomatic COPD affected horses.
The individual times taken for horses to become
asymptomatic are shown in Appendix 4.1. Significant
linear and positive correlations existed between this
time and four parameters, namely age, symptomatic
max.APpl, respiratory rate and duration of illness.
Significant linear and negative correlations occurred
with symptomatic PaC^ and arterial pH (Table 4.2).
There were no significant correlations with bodyweight,
symptomatic tidal volume, minute volume, maximum in¬
spiratory and expiratory flow rates or PaCO^. Signifi¬
cant, linear and positive correlations existed between
duration of illness and age = +0-79, P< 0.01)
and symptomatic max.APpl (r(9Q) = +0-50, P< 0.01).
A significant linear and negative correlation existed
between duration of illness and symptomatic Pa02 (r(9Q)
= -0.23, P< 0.05).
DISCUSSION
The mean values of the recorded parameters for
symptomatic COPD affected horses and normal horses are
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TABLE 4.2.
Statistical correlation of the time taken for C0PD
affected horses to become asymptomatic in the controlled
environment with their aqe, bodyweiqht, duration of





Age r(90) = 0.458 P< 0.01**
Bodyweight r(90) =-0.119 P>0.05NS
Respiratory rate r(90) = 0.214 P< 0.05*
Max. APpl r(90) = 0.648 P< 0.01**
Tidal volume r(18) = 0.135 P > 0.05NS
Minute volume r(18) = -0.082
MS
P > 0.05
Inspiratory flow rate r(18) = 0.155
NS
P > 0.05
Expiratory flow rate r(18) = 0.129
NS
P > 0.05
Pa02 r(90) = -0.466 P< 0.01** •
PaC02 r(90) = 0.165
NS
P > 0.05
Arterial pH r(90) = -0.217 P< 0.05*
Duration of illness r(90) = 0.398 P< 0.01**
NS = not significant
* = P < 0 .05
** = P < 0.01
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similar to those recorded by previous authors (Tables
2.1. and 2.2). The great differences in max.A,Ppl
and Pa02 between normal and symptomatically affected
horses are in accordance with the findings of
Gillespie and Tyler (1969), Sasse (1971), Bergsten
(1974), Meister, Gerber and Tschudi (1976), Littlejohn
(1978), McPherson e_t al_. , (1978 ) and Dixon (1979).
The mean Pa0£ values reported by Littlejohn (1978) are
lower than those determined in this study (and by other
authors) probably owing to the higher altitude (1300m)
at which Littlejohn's work was performed.
There appears to be little agreement in the liter¬
ature as to whether tidal volume changes occur in COPD
affected horses. Gillespie, Tyler and Eberly (1966)
and Gillespie and Tyler (1969) reported significantly
lower mean tidal volumes in affected horses than in
normal horses whereas Sasse (1971) found the mean tidal
volume in affected horses to be significantly higher.
Like Muylle and Oyaert (1973), the present author
failed to record any significant difference in mean
tidal volume between normal and symptomatically affected
horses. The reason for the variation between authors
is unknown but it may have resulted from the COPD
syndrome differing with geographical location or
different horse populations. It is also possible that
some animals examined by other authors were suffering
from different forms of chronic pulmonary disease as
not all authors used the same identification criteria.
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As no significant change in tidal volume was
observed in affected horses, the increased minute
volume in this group is due to the elevated respiratory
rate, which possibly also gave rise to the increased
maximum inspiratory flow rate. Gillespie, Tyler and
Eberly (1966), Gillespie and Tyler (1969), Sasse
(1971) and Littlejohn (1978) all recorded higher
respiratory rates in affected horses, however, only
Littlejohn (1978) found this increase to be significant.
When studying the interactions of PaO^ and PaCO^ on
the ventilatory response in normal horses, Muir, Moore
and Hamlin (1975) found that the respiratory rate
increased with lowering of the PaC^. The increased
respiratory rate in the affected horses in this study
might therefore be related to the hypoxaemia.
Minimising exposure of COPD affected horses to
moulds in hay and straw enabled them to become
clinically asymptomatic, with mean values for the
respiratory function measurements not significantly
differing from normal horses.
There was a significant (P< 0.001) increase in
PaO^ (mean - S.D.) from 70.9 - 6.6 mm Hg (symptomatic
value) to 88.0 - 2.9 mm Hg when horses were asymptom¬
atic. This is similar to the findings of Meister,
Gerber and Tschudi (1976) who reported a significant
(P< 0.001) increase in (mean - S.D.) Pa02 from 65.8
- 11.1 mm Hg to 86.0 - 5.4 mm Hg in 17 COPD affected
horses after withdrawal of hay and straw for 11 days.
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However, the mean PaC^ tension remained significantly
lower than their values for normal horses (95.5 -
4.3 mm Hg). Similarly, Dixon (1979) recorded a
PaO^ (mean - S.D.) value of 87.2 - 5.1 mm Hg in 10
asymptomatic COPD affected horses which is signific¬
antly higher (P< 0.001) than that for this author's
symptomatically affected group (70.0 - 7.4 mm Hg)
but significantly lower (P<0.001) than that for his
normal horses (92.0 - 5.1 mm Hg) .
In human asthma, several studies have demonstrated
that complete reversal of all respiratory functional
abnormalities will occur (McFadden and Lyons, 1969;
Tooley, Demuth and Nadel, 1965) but hypoxaemia may
persist for long periods of time following the re¬
covery from an acute attack (Rees, Millar and Donald,
1968). The mechanism that most commonly produces
hypoxaemia in asthma is poor distribution of inspired
air leading to mismatched ventilation - perfusion
ratios (Heckscher e_t al_. , 1968 ; Levine _et al_. , 196.7;
McFadden and Lyons, 1968). A degree of mismatching
is thought to persist in patients for some time after
apparent full clinical recovery. Although ventil¬
ation - perfusion studies have not been performed on
COPD affected horses, it is probable that a similar
mechanism occurs as symptomatically affected horses
suffer a normocapnoeic hypoxaemia which indicates a
perfusion - ventilation imbalance. This could explain
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the recorded PaC^ differences between normal and
asymptomatic CQPD affected horses recently recovered
from the disease (Meister, Gerber and Tscudi, 1976;
Dixon, 1979) and it is possible that further increases
in Pa02 may occur with prolonged environmental control.
The time taken for horses to show remission of
CQPD signs varied greatly and correlated most signifi¬
cantly with the severity of the condition (as adjudged
by the symptomatic max. .A. Ppl and Pa02 values) and the
duration of illness. It seems likely that the
degree of pathological change in the lungs would increase
with increasing severity of disease and duration of
illness. However, there have been no studies
correlating the severity of equine CQPD pathology with
these two factors. In human asthma, it has been found
that the more prolonged the attack is, the longer it
takes to reverse the respiratory impairment (McFadden,
1976). This is thought to result in part from
mucous plugging of the bronchi and the formation of
mucous casts which tend to remain in the airways for
prolonged periods of time (Dunnill, 1963). Although,
as explained in chapter 2, equine COPD and human
asthma differ functionally and anatomically, hyper¬
secretion of mucus and mucous plugging of the bronchi
and bronchioles are also commonly found in equine CQPD
and this, as well as bronchiolar cellular infiltration
and fibrotic changes described by Nicholls (1978) could
all prolong the resolution of clinical signs.
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CONCLUSIONS
From this study, it is apparent that the patho¬
physiological changes occurring in equine COPD are
largely reversible and that many affeeted horses are
«
capable of regaining normal pulmonary functions




EFFECTS OF BRQNCHODILATOR DRUGS IN NORMAL
AND COPD AFFECTED HORSES.
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INTRODUCTION
Although the pathogenesis of equine COPD is not
fully understood, many authors have postulated that it
is allergic in nature. Additionally, McPherson
et al., (1979b)have demonstrated respiratory hyper¬
sensitivity in COPD affected horses to a number of
allergens, predominantly M_. f a eni . Equine COPD has
been likened to human bronchial asthma on account of
the predictable onset, clinical appearance and
spontaneous remission with environmental control. Air¬
way spasm is a major functional change in bronchial
asthma and it has, therefore, been postulated that
airway spasm also plays a role in the pathogenesis of
!»
equine COPD (Alegren and Carlstrom, 1940; Obel and
I!
Schmiterlow, 1948; Cook and Rossdale, 1963; Lowell,
1964; Eyre, 1972; Gerber, 1973; McPherson and Lawson,
1974; Cook, 1976) in addition to the well recognised
exudative bronchiolitis occurring in this disease.
A further reason for the hypothesis that airway
spasm is involved in the pathogenesis of equine COPD
is derived from results of ijn vitro studies on isolated
pulmonary tissues from COPD affected horses. Eyre
(1972), using pulmonary venous strips from 3 COPD
affected horses which had previously elicited positive
intradermal reactions to _A. fumiqatus, demonstrated
Schultz-Dale reactions in two of the horses, which in¬
dicated pulmonary vascular hypersensitivity in these
animals. In a pilot experiment, it was found that
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isolated airway tissues (bronchial strips and lung
parenchymal strips) from eight out of ten COPD affected
horses which showed i_n vivo respiratory hypersen¬
sitivity to M^. faeni, contracted i_n vitro when exposed
to M_. faeni antigen. Similar tissues from nine out
of eleven clinically normal horses failed to respond
to M. faeni antigen. (Details of this pilot study
are presented in Appendix 5.1). This confirms that
airway tissue in COPD affected horses is hypersensitive
in vitro to the causal antigens and suggests that
airway spasm occurs when horses are exposed to these
antigens i_n vivo. It was, therefore, decided to study
the effects of bronchodilator drugs on clinically
affected COPD horses i_n vivo.
There are 3 main classes of bronchodilator drugs;
sympathomimetic amines, parasympatholytic agents and
xanthine derivatives.
SYMPATHOMIMETIC AMINES
The sympathomimetic bronchodilators have been
widely used in the treatment of human bronchial asthma
over the past 30 years and extensive research into
these agents has resulted in their actions becoming in¬
creasingly more selective for bronchial asthma therapy.
The concept of selective adrenergic receptors, alpha
and beta, was introduced by Ahlquist (1948) to account
for the different responses to sympathomimetic agents
at various sites. In general the effects of alpha
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receptors in smooth muscle are mainly excitatory, in¬
cluding vasoconstriction and constriction of the
sphincters of the gastro-intestinal tract and those of
beta receptors at such sites are mainly inhibitory
causing airway dilation, vasodilation and cardiac
stimulation. The beta receptors were further sub¬
divided by Lands e_t al_. ,(1967) into beta 1 receptors which
are situated predominantly in the heart and small in¬
testine and beta 2 receptors found mainly in the airways,
vascular beds and uterus. The primary cardiopulmonary
response to beta 2 receptor stimulation is broncho-
dilation whilst tachycardia, increased cardiac output
and a slight rise in blood pressure occurs with beta 1
receptor stimulation (Gaddie e_t a_l. , 1972 ). Thus, the
specific beta 2 stimulants e.g. terbutaline and
salbutamol are preferred as bronchospasmolytic agents
as they reduce airway resistance with fewer side effects
than the less specific sympathomimetic amines e.g.
isoprenaline (Formgren, 1977; McFadden, 1981; Williams
and Shim, 1976).
At a cellular level, the activation of beta
receptors results in stimulation of the enzyme
adenylcyiase which causes increased production of cyclic
3', 5adenosine monophosphate (cyclic 3', 5'- AMP).
Cyclic 3', 5'- AMP stimulates calcium binding to cell
membranes and cytoplasmic reticulum thereby reducing the
myoplasmic calcium concentration which, in turn, gives
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rise to smooth muscle relaxation (Anderson and Nilsson,
1977) .
PARASYMPATHOLYTIC AGENTS
Parasympatholytic drugs e.g. atropine act by blocking
the effects of acetylcholine at postganglionic para¬
sympathetic nerve endings. In the airways, atropine
causes smooth muscle relaxation and reduces respiratory
secretions. Other effects of atropine include tachy¬
cardia, reduced gastrointestinal motility, mydriasis and
central nervous system stimulation. These side effects
preclude the widespread therapeutic use of atropine as a
bronchodilator in man.
XANTHINE DERIVATIVES
The xanthine derivatives have a number of pharma¬
cological actions including central nervous system
stimulation, myocardial stimulation, and smooth muscle
relaxation, notably in the airways (Ritchie, 1970).
Because the various xanthine derivatives differ markedly
in the intensity of their actions on various structures,
one particular xanthine derivative is usually more
suitable than another for any specific therapeutic effect.
Theophylline and its derivatives are potent broncho-
dilators and are widely used in the treatment of bronchial
asthma.
Biochemically, the xanthine derivatives, particularly
theophylline, act as competitive inhibitors of cyclic
nucleotide phosphodiesterase, an enzyme that catalyzes
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the conversion of cyclic 3', 5'-AMP to cyclic 5'- AMP
(Butcher and Sutherland, 1962). This results in
elevated cyclic 3', 3'-AMP concentrations in certain
tissues and consequently leads to relaxation of airway
smooth muscle similarly to that initiated by sympatho¬
mimetic stimulation of the beta receptors, as previously
described.
Bronchodilator drugs, including atropine, have
been found to induce temporary relief of clinical
dyspnoea in COPD affected horses (Raitsits, 1923; Obel
and Schmiterlow, 1948; Lowell, 1964; Muylle and
Oyaert, 1973; Sasse and Hajer, 1977). Marked clinical
improvement has also been reported in affected horses
with the use of sympathomimetic bronchodilators, in¬
cluding adrenaline, noradrenaline, scopolamine
If
hydrobromide and clenbuterol (Obel and Schmiterlow, 1948;
Schatzmann, Straub and Gerber, 1972; Corbella, 1978).
In more detailed studies on five COPD affected horses,
intravenous clenbuterol administration caused a signifi¬
cant but temporary decrease in the pulmonary viscous
resistance and clinical improvement lasting six hours
(Sasse and Hajer, 1977). However, values recorded at
the time of peak response were not compared with those
of normal horses, thus the authors provided no
quantitative indication of the efficacy of clenbuterol.
In contrast to the above-mentioned marked clinical
improvements following treatment of COPD affected horses
with bronchodilator drugs, Corbella (1978) reported only
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slight and transitory clinical improvement with the
sympathomimetic drugs, ephidrine, orciprenaline and
salbutamol. Many of these studies were carried out
on animals diagnosed as suffering from COPD on clinical
grounds only and the response to treatment assessed by
clinical observation alone. Such subjective assess¬
ments are possibly the cause of the disparity in results
obtained with bronchodilator therapy by different
authors .
Studies on the effects of five bronchodilator drugs,
namely atropine (a parasympatholytic drug), isoprenaline,
terbutaline and clenbuterol (all sympathomimetics) and
etamiphylline camsylate (a theophylline derivative) on
some pulmonary functions and clinical parameters in
normal and CQPD affected horses are described here.
MATERIALS AND METHODS.
The structural formulae of the bronchodilator drugs
used in these studies are shown in Figure 5.1.
DRUGS ADMINISTERED BY INHALATION
The following drugs were each administered by in¬
halation to 8 normal and 12 COPD affected horses;
isoprenaline sulphate (Thornton and Ross Ltd., Hudders-
field) (horses Nos. A21-28, Appendix 3.1 and Nos. B21-
32, Appendix 3.2), atropine sulphate (Macfarlane Smith
Ltd., Edinburgh) horses Nos. A29-36, Appendix 3.1 and
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Structural formulae of the bronchodilator drugs
used in these studies.
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respirator solution, Astra Chemicals Ltd., Watford)
(horses Nos. A37-44, Appendix 3.1 and Nos. B43-56
Appendix 3.2). Dosage levels which would provide
the maximum therapeutic effect without severe side
effects were established by previous pilot experiments
and for all drugs, a dose of 0.02 mg/kg was found
suitable. For inhalation administration, the drugs
were dissolved in physiological saline, to a total
volume of 4 ml, to standardise the time taken for
drug nebulisation. The drugs were aerosolised using
two Wright's nebuliser pumps and were administered via
plastic tubing to a face mask, Figure 3.6, page 58.
Nebulisation took 7 minutes.
DRUGS ADMINISTERED BY INTRAVENOUS INJECTION
The following drugs were each administered by slow
intravenous injection over 2 minutes to normal and
COPD affected horses; atropine sulphate (Bimeda U.K.
Ltd., Liverpool) (horses Nos. A45-52, Appendix 3.1 and
Nos.B57-68, Appendix 3.2) at a dose of 0.02 mg/kg,
clenbuterol (Ventipulmin, Boehringer, Sohn, Ingleheim,
BRD) (horses Nos. A33-60, Appendix 3.1 and B69-80,
Appendix 3.2) at a dose of 0.8 pq/kq and etamyphilline
camsylate (Millophyline, Dales Pharmaceuticals Ltd.,
Skipton)(horses Nos. A61-68, Appendix 3.1 and B81-92,




Prior to drug administration and during all
measurements, the animals were standing, untranquilised
and were handled quietly to prevent any excitement-
induced respiratory or cardiac*changes . Max. APpl,
measured using an intraoesophageal balloon, p. 49,
was monitored for 10 minutes, prior to treatment to
establish baseline values, for 30 minutes after drug
administration and, thereafter at hourly intervals
until the effects of the drug disappeared. Respiratory
rates were measured from the intrathoracic pressure
tracing .
Carotid arterial blood samples for Pa02 and
PaC02 estimations were collected and analysed as
previously described, p. 54. Samples were obtained
at rest and at 10, 20, 60, 120, 240 and 360 minutes
after treatment.
The heart rate was measured from a standard lead I
electrocardiogram recording (M19, Devices Ltd., London).
Other clinical parameters observed before and
after drug administration were the presence and degree
of double expiratory effort, dyspnoea, flaring of the
nostrils and wheezing.
STATISTICAL ANALYSIS OF RESULTS
In normal and C0PD affected horses, resting para¬
meters were compared with parameters obtained at
various intervals after drug administration by Student's
t—test as applied to paired observations. Values for
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respiratory rate, max.APpl, PaC^* PaC02 and heart rate
in normal and COPD affected horses were compared at




Horses affected with COPD showed a decrease in
respiratory rate after drug administration with
significant changes occurring 30 minutes after
isoprenaline inhalation, for up to 2 hours after atropine
and etamiphylline camsylate and for up to 4 hours after
terbutaline and clenbuterol administration (Figures 5.2
and 5.3). During these times, the mean respiratory
rates of the affected horses did not differ signifi¬
cantly from those of the normal horses (Appendices
5.2 to 5.7) .
There were slight transient increases in mean
respiratory rates in normal horses after bronchodilator
treatment (Figures 5.2 and 5.3) but they were not
statistically significant (P> 0.05).
INTRATHORACIC PRESSURE CHANGES
Max.APpl decreased significantly (P< 0.001) in
COPD affected horses after administration of all 5 drugs.
Examples of max.APpl changes occurring after
bronchodilator treatment are illustrated in Figure 5.4
where max.APpl in an affected horse (B28) dropped from
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Figure 5.2. Effects of inhaled bronchodilator drugs on
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Figure 5.3. Effects of intravenous bronchodilator drugs on
respiratory rate in normal and COPD affected
horses.
88.
26.4 mm Hg before treatment to 6.0 mm Hg 10 minutes
after isoprenaline inhalation and Figure 5.5 where,
in another affected horse (845), max.A.Ppl prior to
terbutaline treatment was 19.5 mm Hg and fell to 5.2
mm Hg 30 minutes after drug inhalation.
At peak response to inhaled isoprenaline, atropine
and terbutaline the mean max.APpl in COPD affected
horses was reduced by 70?o, 6 2°/a and 6 3% respectively
(Figure 5.6) and after intravenous atropine, clen-
buterol and etamiphylline camsylate, the mean max.A
Ppl values were decreased by 6 6 ?6, 6 2% and 5 7 % respect¬
ively (Figure 5.7). The intrathoracic pressure
decreases remained significant for 1 hour following
isoprenaline, 2 hours following atropine and
etamiphylline camsylate, 4 hours following clenbuterol
and 6 hours following terbutaline administration
(Appendices 5.2 to 5.7). Despite the large decreases
in max. 2A. Ppl after all drugs the values for COPD
affected horses at times of maximum response still
remained significantly higher (P< 0.01) than those of
the resting control horses.
No significant max.APpl changes were recorded in
the normal horses after bronchodilator treatment
(Figures 5.6 and 5.7).
ARTERIAL BLOOD GASES.
The effects of the bronchodilator drugs on Pa02
levels in COPD affected and normal horses are shown in
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Figure 5.4. Max.APpl recordings from a COPD affected horse (No.
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360 minutes after terbutaline: max.APpl = 12.5 mm Hg,
Figure 5.5. Max.APpl recordings from a COPD affected horse (No.
B45) at rest and at intervals after terbutaline inhalation.
91 .
| = Time of treatment
- = Mean value COPD horses
N = 12 for each drug





—«q— -■= z-==*b= -
—I 1 1 // 1 o 1
0 30 60 120 240
Time after treatment (minutes)
360
Figure 5.6. Effects of inhaled bronchodilator drugs on
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Figure 5.7. Effects of intravenous bronchodilator drugs on
max.APpl in normal and COPD affected horses.
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Figures 3.8 and 5.9. All drugs caused an initial
temporary drop in PaC^ levels in both COPD affected
and normal horses which was followed by increases in
Pa02 to above resting levels in COPD affected horses.
Significant increases in Pa02 levels were present up
to 2 hours after isoprenaline, 4 hours after atropine
and clenbuterol and for 6 hours after terbutaline
administration (Appendices 5.2 to 5.6). A non¬
significant (P> 0.05) increase in mean Pa02 levels
occurred from 2 to 6 hours after etamiphylline
camsylate treatment in the affected horses.
Despite the Pa02 increases in COPD horses after
treatment, their mean Pa02 levels remained significantly
lower (P< 0.001) than those of the control horses. The
only significant Pa02 increase recorded in the normal
horses after bronchodilator treatment occurred at 6
hours after etamiphylline camsylate administration.
The mean Pa02 rose from 88.06 mm Hg to 91.51 mm Hg
(P< 0.05) .
COPD affected horses showed a slight decrease
(1 to 3 mm Hg) in PaC02 levels from 1 to 6 hours after
treatment, corresponding to the times at which increased
Pa02 levels occurred. No significant PaC02 changes
were recorded in the control horses.
HEART RATE.
There was a significant (P <0.001) increase in
heart rate in both COPD and normal horses within 10 to
20 minutes of administration of all 5 drugs (Figures
94.
| = Time of treatment
— =Mean value COPD horses
N = 12 for each drug
=Mean value normal horses
N- 24
Time after treatment (minutes)
Figure 5.8. Effects of inhaled bronchodilator drugs on
PaO^ in normal and COPD affected horses.
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Figure 5.9. Effects of intravenous bronchodilator drugs
on PaO^ in normal and COPD affected horses.
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5.10 and 5.11). Tachycardia was most pronounced
after atropine injection and isoprenaline inhalation,
when the mean heart rates increased twofold over the
resting rates. The heart rates returned to resting
levels within 1 to 2 hours after all treatments.
CLINICAL OBSERVATIONS.
After drug administration, COPD affected horses
showed a temporary reduction in their expiratory effort,
dyspnoea and flaring of the nostrils. All drugs tempor¬
arily alleviated wheezing chest sounds in affected
animals. Clinical improvement persisted for 1 to 2
hours following isoprenaline and atropine and for 2 to
6 hours following terbutaline, clenbuterol and
etamiphylline camsylate treatment.
Atropine administration caused mydriasis in all
animals which persisted for 12 to 24 hours. Mild
sweating and muscle tremor occurred in 4 normal and 5
affected horses 10 to 20 minutes after isoprenaline in¬
halation and continued for approximately 30 minutes.
A similar phenomenon occurred in 2 normal and 2 affected
horses after terbutaline inhalation and in 4 normal
and 6 affected horses following clenbuterol treatment.
The sweating and tremor were more pronounced after
clenbuterol administration and persisted up to 3 hours
in some cases.
Individual values for respiratory rate, max. A Ppl,
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Figure 5.10. Effects of bronchodilator drugs on heart rate
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normal horses.
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horses before and after treatments as well as statistical
analysis of results are presented in Appendices 5.2 to
5.7.
DISCUSSION
The effects of isoprenaline were rapid in onset
and marked in effect but of short duration (i.e. % - 1
hour) (Figure 5.4). Although the decreases in max. A
Ppl with terbutaline and clenbuterol were not as great
as with isoprenaline, their actions were more prolonged
with max. A Ppl and respiratory rates significantly
decreased for 4 to 6 hours after treatment. Unlike
isoprenaline which is rapidly matabolised by catechol-
o-methyltransferase (COMT) (Hertting, 1964), terbutaline
and clenbuterol are not substrates for this enzyme
which accounts for their actions being more prolonged
than those of isoprenaline. The half life of
clenbuterol in the horse following intramuscular in¬
jection is 10 hours (Boehringer, 1980, technical
information) .
Atropine administration by either route produced
a similar degree and duration of max. A Ppl response
in affected horses (Figures 5.6 and 5.7) but the peak
response to inhalation occurred approximately 7
minutes later than after intravenous injection.
In the COPD affected horses, etamiphylline
camsylate caused a significant decrease in max. A Ppl
and respiratory rate for 2 hours after treatment. The
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period of efficacy was therefore considerably shorter
than those of terbutaline and clenbuterol but may be
explained by etamiphylline camsylate having a half
life of just 2 hours in the horse following parenteral
administration (Bogan, J.A., 1980, personal communi¬
cation). Although etamiphylline camsylate is
recommended by the manufacturers for the treatment of
a wide range of pulmonary disorders in the horse there
appear to be no reported studies on its efficacy.
Max. A. Ppl, which was one of the main parameters
used to assess pulmonary function in these experiments,
was found to decrease greatly after administration of
all drugs. While this max. A.Ppl decrease could most
obviously be attributed to a direct airway smooth
muscle dilating action, some other factors have also
to be considered, i.e. an increase in respiratory rate
and/or a decrease in tidal volume could also lead to
a decrease in max.A Ppl. However, in these studies,
the respiratory rate decreased significantly in COPD
affected horses as a result of treatment. Although
the effects of bronchodilator drugs on tidal volume
were not recorded in these experiments neither Muylle
and Oyaert (1973) nor Sasse and Hajer (1977) were able
to demonstrate any significant change in tidal volume
in CQPD affected horses after intravenous atropine or
clenbuterol administration. It is further possible
that atropine could have decreased airway resistance
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by decreasing airway secretions. Because the secretions
are not removed, but merely become more viscous in
nature and because of the similar max.APpl response in
COPD affected horses to other bronchodilator drugs
which do not have a drying effect on secretions, it is
unlikely that this phenomenon contributed significantly
to the observed decrease in max.APpl after atropine
administration.
After treatment with all drugs, the COPD affected
horses showed a marked clinical improvement corresponding
with the time that significant decreases in max. A Ppl
and respiratory rate occurred. It is probable that
this rapid improvement in pulmonary function which was
associated with a decrease in the work of respiration
was, in fact, due to a functional decrease in airway
resistance (i.e. airway dilation) induced by the drug
administration. In contrast, no such response was
observed in normal horses and so these results suggest
that airway smooth muscle spasm is involved in the
pathogenesis of equine COPD. Although the disease is
anatomically a predominantly small airways disease, the
site or sites of airway spasm in the tracheobronchial
tree is unknown. In bronchial asthma, functional
studies have shown that spasm occurs in both the bronchi
and bronchioles (Cade e_t al_. , 1971; Despas, Le Roux
and Macklem, 1972). In addition, there is some
suggestion that the response of the various size airways
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to antigen provocation may be different. The bronchi
tend to increase their resistance quickly when
stimulated and are, therefore, predominantly involved
in acute asthma, but the effect can be quickly reversed
through bronchodilator therapy. The reaction of
the bronchioles, however, tends to be slower but more
intense and persistent (McFadden, Kiser and de Groot,
1973; McFadden and Lyons, 1969). Until similar
studies are performed in horses with COPD, the sites
of airway spasm remain unknown.
Despite the marked decrease in max.A Ppl in COPD
horses after bronchodilator administration their
max. A Ppl and Pa02 values still remained significantly
different from those of normal horses indicating that
their airway obstruction was not fully alleviated.
This residual airway obstruction is undoubtedly due
to the previously noted anatomical changes in COPD
i.e. widespread exudative bronchiolitis (Nicholls ,
1978 ) .
The effects of bronchodilator therapy on arterial
blood gas tensions in horses affected with COPD do not
appear to have been reported previously. The initial
drop in Pa02 levels in both normal and COPD animals
occurred, without a simultaneous increase in PaC02
levels. De Moor (1968) also noted a transitory
hypoxaemia in normal horses after intravenous atropine
administration.
Reports on the effects of clenbuterol on arterial
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blood gas tensions in normal horses differ. Whereas
Shapland, Garner and Hatfield (1981) recorded no
significant changes in arterial blood gas levels in
4 normal horses following clenbuterol administration,
Lieske and Deegan (1980) reported PaC^ decreases of
between 4.6 mm Hg and 29.3 mm Hg in 15 normal horses,
15 minutes after clenbuterol treatment. In the 8
normal horses treated in this study the mean Pa02
levels decreased by 6 mm Hg for 2 hours following
clenbuterol administration.
Hypoxaemia has been found to temporarily (for
about 1 hour) intensify in human bronchial asthma
patients shortly after treatment with isoprenaline,
atropine, the xanthine derivatives and to a lesser ex¬
tent, the beta 2 sympathomimetic bronchodilators
(Knudson and Constantine, 1967; Field, 1967; Ingram
et al., 1970; Chick, Nicholson and Johnson, 1973;
Pain, 1973). This fall in Pa02 which occurs irres¬
pective of the route of drug administration (Svedmyr
and Simonsson, 1978), is generally thought to be
caused by an intensification of pre-existing ventil¬
ation - perfusion inequalities resulting from direct
pulmonary vasodilation induced by these drugs (Field,
1967; West, 1976).
McFadden (1981) recorded the effects of broncho-
dilator therapy on Pa02 in normal and asthmatic humans.
He found that the higher the pretreatment PaC^ levels,
the greater the fall in Pa02 following treatment and
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that asthmatics with initial low PaO^ tensions usually
show no further PaO^ decreases after bronchodilator
treatment. This author concluded therefore, that the
initial hypoxaemia-inducing effects of bronchodilators
are not of clinical importance in human bronchial
asthma. The situation in hypoxaemic COPD affected
horses appears different however, as they suffered
further transient Pa02 decreases following broncho-
dilator therapy which were similar in magnitude to
those Pa02 decreases recorded in normal horses. Bron¬
chodilator treatment of severely hypoxaemic horses
might therefore be contra-indicated unless oxygen
therapy can be given in addition.
The dual action of isoprenaline on both beta 1
and beta 2 receptors is disadvantageous in that broncho-
dilation is usually accompanied by marked tachycardia,
as was observed in both normal and COPD affected horses.
Although terbutaline and clenbuterol exhibit a useful
degree of selectivity for beta 2 receptors, the
increased heart rates noted in these experiments in¬
dicate that these agents, even in clinical doses may
exert significant beta 1 receptor activity in the
horse. Another possible way in which bronchodilator
drugs could cause tachycardia is indirectly through
causing a fall in peripheral vascular resistance there¬
by causing a reflex increase in heart rate to maintain
blood pressure (Sackner e_t a_l_. , 1 975 ). The decrease
in pulmonary artery pressure recorded in normal horses
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following clenbuterol administration by Shapland,
Garner and Hatfield (1981) and Lieske and Deegan (1980)
were ascribed by these authors to a fall in the
peripheral vascular resistance. A transient tachy¬
cardia was also recorded in these horses. A decrease
in pulmonary artery pressure can also result from the
relief of hypoxaemic pulmonary vasoconstriction (Dixon,
1979). However, this mechanism was not considered
by Shapland, Garner and Hatfield (1981) or Lieske and
Deegan (1980) probably because these authors were using
normal horses which were, therefore, not hypoxaemic at
the outset of the trials and consequently no increase
in PaO^ levels were recorded with the decreases in
pulmonary artery pressure.
Tachycardia and muscle tremor are common side effects
of the selective beta 2 stimulating drugs in man
(Bowman and Raper, 1976). Whereas the cardiac stimul¬
ating effect can be prevented by pretreatment with a
selective beta 1 blocking drug, skeletal muscle tremor
which was observed in horses following terbutaline and
clenbuterol is mediated by beta 2 receptors and is
therefore an unavoidable side-effect of this group of
drugs (Larsson and Svedmyr, 1974). Xanthine derivatives
cause tachycardia through their myocardial stimulating
effects (Nimmo, 1976). This would explain the transient
increase in heart rate recorded in normal and COPD
horses after etamiphylline camsylate treatment.
In addition to their airway dilating properties,
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the sympathomimetic amines have other actions which
could play a role in improving lung function but which
have not as yet been widely reported. In man, the
beta agonists have been shown to facilitate mucociliary
transport (Santa Cruz e_t al_. , 1974) and are thought to
inhibit mast cell degranulation in sensitised individuals
on bronchial provocation tests (McFadden, 1981).
The short duration of action and the previously
mentioned side effects of isoprenaline (i.e. cardiac
stimulation) and atropine (i.e. cardiac stimulation,
increased viscosity of bronchial secretions, reduced
bowel motility and mydriasis) preclude their widespread
use as therapeutic agents for equine COPD. The use of
the longer acting bronchodilator drugs for the treatment
of COPD remains subject to many limitations in that they
do not control the cause of the disease, they only
partially alleviate the physiological changes and
clinical signs and the resulting improvement is of short
duration. However, terbutaline, clenbuterol and
etamiphylline camsylate could be used for the treatment
of acute attacks of COPD. Orally administered pre¬
parations of the latter two drugs are commercially
available and may be found useful when continuing broncho-
dilator treatment in horses following the initial
parenteral dose. Further studies on the orally admini¬
stered compounds are described in Chapter 6.
CONCLUSIONS
Administration of bronchodilator drugs to horses
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affected with COPD brought about a temporary, marked
improvement in clinical dyspnoea, accompanied by
significant decreases in max.APpl and respiratory rate
and significant increases in Pa02 values. However,
bronchodilator treatment failed to restore normal pul¬
monary function in CGPD affected horses. None of the
above effects were observed in normal horses. This
suggests that airway spasm is involved in the patho¬
genesis of equine COPD.
Although the use of inhaled or intravenous
bronchodilator drugs in the treatment of equine COPD
is subject to many limitations, bronchodilator therapy
could be of value as a temporary measure in the treat¬
ment of acute and severe attacks.
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CHAPTER 6.
THE EFFECTS OF ORALLY ADMINISTERED
BRONCHODILATOR DRUGS AND ENVIRONMENTAL
CONTROL ON COPD AFFECTED HORSES.
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INTRODUCTION
Studies described in Chapter 5 and those of Obel
and Schmiterlow (1948), Muylle and Oyaert (1973) and
Sasse and Hajer (1977) have shown that a single
«
parenteral treatment or inhalation with a variety of
bronchodilator drugs brings about a marked improvement
in the clinical appearance and respiratory function
of COPD affected horses. These beneficial effects
are, however, temporary although some agents, for
example, the beta 2 sympathomimetic bronchodilators
are longer acting than their predecessors.
Repeated bronchodilator inhalation or injections
for COPD treatment would be impractical except as a
temporary measure in severely affected animals. However,
orally administered compounds are now commercially
available and the use of oral clenbuterol (Ventipulmin,
Boehringer, Ingleheim, BRD) twice daily for 14 days has
been reported to cause an improvement in COPD affected
horses (Sasse and Hajer,1977). However, the response
was assessed by the owners' observations only. Further
investigations including veterinary clinical examin¬
ations and pulmonary function testing are therefore re¬
quired to objectively examine the efficacy of these
orally administered bronchodilator drugs for equine
COPD treatment.
This chapter aims to examine the effects of two
bronchodilating agents, namely clenbuterol and
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etamiphylline camsylate on (1) the clinical signs and
respiratory function in COPD affected horses when
administered without environmental control measures
and (2) these same parameters in affected horses when




16 COPD affected horses were divided into 2 groups;
horses Nos. B93 - 100 (Appendix 3.2) were treated with
clenbuterol in trials 6.A. and B. Horses Nos. B101-
108 (Appendix 3.2) received etamiphylline camsylate in
trials 6.C. and D. Each horse acted as its own control.
All these COPD affected horses suffered respiratory
hypersensitivity to M_. faeni and all showed clinical
signs of COPD when exposed to the natural challenge en¬
vironment (p 55) .
CLENBUTEROL TRIALS.
The flow diagram (Figure 6.1) indicates the
sequence of management changes and drug administration.
6.A. Effects of oral clenbuterol treatment on
horses housed in the natural challenge en¬
vironment .
6.A.(i). Challenge environment, no treatment.
8 COPD affected horses, (Nos. B93 - 100,
Appendix 3.2) were exposed to the natural challenge
environment for 14 days without any treatment. The
horses were given daily clinical examinations and their
TRIAL6,A(i).
Horsesinaturalchallenge environmentfor14days. Nodrugtreatment. TRIAL6.B(i). Horsesincontrolled environmentfor14days Nodrugtreatment.
TRIAL6,A(ii).
Hprsesinaturalchallenge environmentfor14days. Treatedwithclenbuterol. Horsesinaturalchall nge environmentfor7days. Nodrugtreatment.
Horsesinaturalchall nge environmentfor7days. Nodrugtreatment. TRIAL6.B(ii). Horsesincontrollede ¬ vironmentfor14days. Treatedwithclenbuterol orallytwicedaily,
Figure6,1.lowd agramfthestudiesnalclenbut roladministrati ntre tm ntfq i e COPD.
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max.APpl, PaC^j PaCO^ and arterial blood pH values
were recorded, using techniques previously described
(pp.49,54), on days 0, 1, 2, 4, 7, 9, 11 and 14.
6.A(ii). Challenge environment plus clenbuterol
treatment.
For the following 14 days, the horses were
kept in a similar environment and were given clenbuterol.
Treatment was initiated with a single intravenous
injection of clenbuterol (Ventipulmin, Boehringer,
Sohn., Ingleheim, BRD) at a dosage of 0.8 pg/kg and
continued by twice daily oral administration in their
concentrate feed (0.8 pg/kg b.i.d.) for 14 days. In
this trial and all ensuing treatment trials, the feed
was made into a mash to ensure that the full dose was
taken and a deep heavy trough was used to prevent drug
spillage. Clinical examinations and respiratory
function parameters were recorded as described in trial
6 . A (i ) .
On completion of this trial, horses were maintained
untreated in the same environment for 7 days prior to
commencement of trial 6.B.
6.B. Effects of oral clenbuterol treatment
on COPD affected horses housed in the
controlled environment.
6.B(i). Controlled environment, no drug treat¬
ment .
The 8 COPD horses described in trial
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6.A were examined clinically on day 0 and max.APpl,
PaCO^ and arterial pH recorded. Thereafter horses
were housed in a controlled environment (p. 57) for
14 days during which time, they received no drug
treatment. The horses received daily clinical exam¬
inations and, as in the previous trial (6.A), the same
respiratory function parameters were recorded on days
1, 2, 4, 7, 9, 11 and 14.
Upon completion of the controlled environment
trial the horses were re-exposed to the natural challenge
environment for 7 days prior to commencement of trial
6.B(ii ) .
6.B(ii). Controlled environment plus clenbuterol
treatment.
As in the preceding trial, the 8 horses
were clinically examined and respiratory function para¬
meters recorded at the start of the trial (day 0).
Thereafter, the horses were treated with clenbuterol
(Ventipulmin, Boehringer Sohn., Ingleheim, BRD) at a
dosage of 0.8 pg/kg intravenously and were moved to the
controlled environment where they remained for 14 days.
Throughout that period, the horses received oral
clenbuterol treatment (0.8 }jg/kg) twice daily in the
feed. Clinical examinations and respiratory function
parameters were recorded during this trial, as described
in the previous trial.
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ETAMIPHYLLINE CAMSYLATE TRIALS.
The design of the etamiphylline camsylate trials
is similar to the clenbuterol trials and is demonstrated
in Figure 6.2.
6.C. Effects of oral etamiphylline camsylate
treatment on COPD affected horses housed
in the natural challenge environment.
This trial followed the same protocol as the
first clenbuterol trial (6.A).
6.C(i). Challenge environment, no treatment.
8 COPD affected horses, (Nos. B101 - 108,
Appendix 3.2) were housed, examined and their respiratory
function monitored, as previously described in trial
6.A(i).
6.C(ii). Challenge environment plus etami¬
phylline camsylate treatment.
The horses were maintained in the challenge
environment and received 3.0 mg/kg etamiphylline
camsylate (Millophyline - V, Dales Pharmaceuticals Ltd.,
Skipton) intravenously on day 0, followed by 2.25 mg/kg
orally in the concentrate feed three times daily for
14 days. Clinical examinations and respiratory
function parameters were recorded as described under
trial 6.A(i ) .
The affected horses were housed in the natural
challenge environment, free of treatment, for 7 days
after completion of this trial prior to commencement
TRIAL6C(i).
Horsesinaturalch llenge environmentfor14days. Nodrugtreatment.
TRIAL6.C(ii).




Horsesinaturalch llenge environmentfor7days. Nodrugtreatment.
TRIAL6.D(ii).
Horsesincontrolledenviron¬ mentfor14days.Treat d withetamiphyllinecamsylat orallythreeim sdaily.
Figure6.2.lowdiagramfthest diesno letamiphyllinecamsylatdmin str tionint treatmentofequi eCOPD.
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of trial 6.D (See Figure 6.2).
6 . D. Effects of oral etamiphylline camsylate
treatment on CQPD affected horses housed
in the controlled environment.
The protocol for this trial is similar to that
described in the corresponding clenbuterol trial (6.B(i),
(ii)).
6.D(i). Controlled environment, no drug treat¬
ment.
This controlled environment study was carried
out as previously described in trial 6.B(i) using COPD
affected horses Nos. B101 - 108 (Appendix 3.2).
At the end of this trial, the horses were re-exposed
to the natural challenge environment for 7 days prior
to commencing trial 6.D(ii).
6.D(ii). Controlled environment plus etami¬
phylline camsylate treatment.
In this trial, the horses were treated with
3.0 mg/kg etamiphylline camsylate intravenously prior
to being moved to the controlled environment. There¬
after, horses received' 2.23 mg/kg etamiphylline camsy¬
late orally three times daily for 14 days. Clinical
examinations and respiratory function parameters were
recorded as described under trial 6.B(ii).
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STATISTICAL ANALYSIS OF RESULTS.
In trials 6.A, B, C and D, values for respiratory
rate, max.APpl, PaO^, PaC02 and arterial blood pH in
the untreated horses (in trials 6.A(i), 6.B(i),
6.C(i) and 6.D(i)) on days 0, 2, 4, 7, 9, 11 and 14 were
compared to the corresponding values for the treated
horses (in trials 6.A(ii), 6.B(ii), 6.C(ii) and 6.D(ii))
by Student's t-test as applied to paired observations.
RESULTS
CLENBUTEROL TRIALS.
6.A. Effects oF oral clenbuterol treatment on
COPD affected horses housed in the
natural challenge environment.
At the start of both the control and treatment
trials, all horses were symptomatically affected with
COPD. The mean respiratory rate, max.APpl and Pa02
values are presented in Figures 6.3, 6.4, and 6.5 re¬
spectively. Each horse showed many of the clinical
signs of COPD although the severity of the disease
varied between horses. All horses coughed, had a
double expiratory effort with increased and harsh lung
sounds. Wheezing audible at the nostril, was present
in horses Nos. B96 and B98 at the start of both parts
of this trial, and in horse No. B94 at the commencement
of trial 6.A(ii) only.
6.A(i). Challenge environment, no treatment.
Throughout this trial, horses continued to be
118.
• = Mean values for clenbuterol
treated horses.
0
= Mean values for untreated horses.
= Horses in natural challenge
environment.
= Horses in controlled environment.
Figure 6.3. Effects of oral clenbuterol treatment
on respiratory rate in COPD affected
horses, (i) in the natural challenge
environment and (ii) in the controlled
environment.
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• = Mean values for clenbuterol treated horses,
o = Mean values for untreated horses.
= Horses in natural challenge environment.
_= Horses in controlled environment.
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Figure 6.4. Effects of oral clenbuterol treatment
on max.APpl in COPD affected horses,
(i) in the natural challenge environ¬
ment and (ii) in the controlled
environment.
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• = Mean values for clenbuterol treated horses.
0 = Mean values for untreated horses.
—
= Horses in natural challenge environment.
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Figure 6.5 Effects of oral clenbuterol treatment
on Pa02 in COPD affected hurses,
(i) in the natural challenge environ¬
ment and (ii) in the controlled
environment.
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symptomatically affected. The mean respiratory rate,
PaO„, PaC02 and arterial pH did not alter significantly
from values recorded on day 0, but the mean max.APpl
increased and was significantly higher (P< 0.05) than
the baseline value on days 7, 11 and 14 (Figure 6.4).
Horses Nos. B94, 97 and 98 showed an increasing
severity of clinical signs over the 14 days. Their
double expiratory efforts became very pronounced, horses
coughed more frequently and horse No. B94 began
wheezing on day 4 which continued until the end of the
trial. The wheezing in horses Nos. B96 and B98 became
more pronounced.
6.A(ii). Challenge environment plus clenbuterol
treatment.
The effects of clenbuterol treatment on res¬
piratory rate, max.A.Ppl and PaO^ in the COPD affected
horses are shown in Figures 6.3, 6.4 and 6.5 respectively.
During the first 4 days, the respiratory rate did
not differ significantly from the values recorded on
corresponding days in the challenge environment trial
(6.A(ii)), but during the latter 7 days, the mean
respiratory rates decreased and were significantly lower
(P<0.05) than those for the untreated horses on days 7
and 11. From day 4 onwards, the mean max.A.Ppl values
for the treated horses were lower than those for the un¬
treated horses but this decrease was only statistically
significant (P< 0.01) on day 11.
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The only significant difference in Pa02 values from
the challenge environment trial was recorded on day 4
when mean PaC^ values for the treated horses was 73.4
mm Hg as 'compared to 68.1 mm Hg for the untreated horses
(P< 0.01). All horses remained hypoxaemic throughout
the trial except for horse No. B93 whose PaO^ was in
the normal range from day 4 to day 9 (Appendix 6.1).
There were no significant changes in PaCC^ or arterial
pH as a result of treatment.
In general, the horses showed little improvement in
their clinical condition whilst on clenbuterol treatment
in the challenge environment. Horse No. B93 did, how¬
ever, improve markedly from day 4 to 10, during which
time she ceased coughing and by day 10 only a very slight
double expiratory effort was present but, during the
last 4 days of the trial, the clinical signs worsened.
Horses Nos. B96 and B98 continued wheezing throughout
the trial. Horse No. 394 continued to be severely
affected throughout the trial with just a slight clinical
improvement over the last 7 days.
6.B. Effects of oral clenbuterol treatment on
COPD affected horses housed in the con¬
trolled environment.
At the outset of both parts of this trial, all
horses were symptomatically affected with COPD. The
mean values for respiratory rate, max.APpl and PaO^
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recorded during this trial are shown in Figures 6.3,
6.4 and 6.5 respectively.
6 . B (i ) . Controlled environment, no drug treat¬
ment.
When horses were housed in the controlled
environment, there was a steady, highly significant
(P <0.001) decline in the mean max.A,Ppl and respiratory
rate and increase in the mean PaO^ over the 14 days.
At the start of this trial, the horses' clinical
conditions were similar to those described at the start
of the challenge environment plus clenbuterol treatment
trial (6.A(ii) ) . As this trial progressed, the horses
all showed a marked clinical improvement and became
asymptomatic in 6 to 14 days except for horse No. B96
which, although very much improved, was still showing
clinical signs of COPD on day 14. The mean S.D.)
time taken for horses to become asymptomatic was 9.25
- 4.40 days.
6.B(ii). Controlled environment plus clenbuterol
treatment.
At the commencement of this trial, horses were
clinically affected to a similar degree as at the be¬
ginning of the controlled environment trial (6.B(i)).
Once again, there was a marked decrease in the mean
max.A.Ppl and respiratory rate and increase in the mean
Pa02 value. Although the max.APpl and Pa02 changes
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occurred slightly faster in this trial (when horses
were receiving clenbuterol treatment) than in the
preceding trial, there were no significant differences
in the values for the above-named parameters recorded
on corresponding days, between the two trials.
Neither were there any significant differences in
PaC02 or arterial pH levels between treated and un¬
treated horses.
The horses became asymptomatic between days 4
to 12 (mean (- S.D.) 7.25 - 2.60 days) which is less,
but not significantly so (P> 0.05), than the time
taken for the untreated horses to become asymptomatic.
Horses Nos. B93 and 399 showed sweating, muscle
tremor and tachycardia (heart rate 45-55 beats per
minute) for 2 to 3 hours after clenbuterol admini¬
stration on several occasions during both clenbuterol
treatment trials (6.A(ii) and 6.B(ii)).
ETAMIPHYLLINE CAMSYLATE TRIALS.
6 . C. Effects of oral etamiphylline camsylate
treatment on COPD affected horses
housed in the natural challenge environ¬
ment .
At the beginning of both parts of this trial,
all horses were symptomatically affected with COPD.
The horses coughed, showed a double expiratory effort
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and increased harsh lung sounds. Wheezing, audible
at the nostril was present in horse No. B107. Mean
values for respiratory rate, max.APpl and PaC^ are
presented in Figures 6.6, 6.7 and 6.8 respectively.
6.C(i). Challenge environment, no treatment.
The horses continued to be symptomatically
affected throughout this trial. Values for respir¬
atory rate, max.APpl, PaC^, PaCO^ and arterial pH
recorded during the trial did not differ significantly
from those recorded on day 0. The horses' clinical
signs showed little change during the 14 days of this
trial except for horse No. B105 which became much
more severely affected from day 6 to day 13, with pro¬
nounced dyspnoea and wheezing audible at the nostril
during this time.
6.C(ii). Challenge environment plus etami-
phylline camsylate treatment.
Similarly to the previous trial (6.C(i)),
all horses remained symptomatically affected with COPD
when retained in the challenge environment despite
treatment with etamiphylline camsylate. The mean
values for respiratory rate, max.APpl and PaC^ during
this trial, which are shown in Figures 6.6, 6.7 and 6.8
respectively, did not differ significantly from the
corresponding values recorded in the untreated horses
1 26.
• = Mean values for etamiphylline
camsylate treated horses.
0
= Mean values for untreated
horses.
™~
= Horses in natural challenge
environment.
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Figure 6.6. Effects of oral etamiphylline camsylate
treatment on respiratory rate in COPD
affected horses, (i) in the natural
challenge environment and (ii) in the
controlled environment.
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• = Mean values for etamiphylline camsylate
treated horses.
0
= Mean values for untreated horses.
—. = Horses in natural challenge environment.
= Horses in controlled environment.
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Figure 6.7. Effects of oral etamiphylline camsylate
treatment on max.APpl in COPD
affected horses, (i) in the natural
challenge environment and (ii) in
the controlled environment.
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• = Mean values for etamiphylline
camsylate treated horses.
0 = Mean values for untreated
horses.
= Horses in natural challenge
environment.




Figure 6.8. Effects of oral etamiphylline camsy¬
late treatment on PaO^ in COPD
affected horses, (i) in the natural
challenge environment and (ii)
in the controlled environment.
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(trial 6.C(i)). Neither were there any significant
differences in the horses' PaCC^ or arterial pH
values between the two trials.
The clinical signs of COPD in horse No. B101
became less pronounced from the 6th day onwards. No
other horses showed any clinical improvement as a re¬
sult of etamiphylline camsylate treatment whilst
retained in the challenge environment.
6 . D . Effects of oral etamiphylline camsylate
treatment on COPD affected horses housed
in the controlled environment.
All horses were symptomatically affected with
COPD at the beginning of both parts of this trial. The
mean values for respiratory rate, max.A Ppl and Pa02
recorded during the trials are shown in Figures 6.6,
6.7 and 6.8 respectively.
6.D(i). Controlled environment, no drug
treatment.
When horses were moved from the natural
challenge environment and housed in the controlled en¬
vironment, there was a gradual, highly significant
(P < 0.001) decrease in the mean max . A. Pp 1 and respir¬
atory rate and increase in the mean PaO^ over the
course of the trial. Most horses showed more
advanced clinical signs at the beginning of this trial
than at that of the previous trial (6.C), but they im¬
proved markedly as this trial progressed and became
130.
asymptomatic in 4 to 14 days (mean (- S.D.) 8.13 -
3.23 days ) .
6.D(ii). Controlled environment plus etami-
phylline camsylate treatment.
At the commencement of this trial, thq
horses were affected to a similar degree as at the
beginning of the previous trial (6.D(i) ) . When moved
to the controlled environment and given etamiphylline
camsylate, changes in max.APpl, Pa02 and respiratory
rate occurred, similar to those for the untreated horses
(in trial 6.D(i)) and there were no significant
differences between these corresponding values or those
of PaC02 and arterial pH in the two trials.
Horses became asymptomatic in 4 to 10 days (mean
(- S.D) 6.50 - 1.93 days) which is not significantly
less (P > 0.05) than the time taken for horses to
become asymptomatic in the controlled environment trial
( 6 . D ( i ) ) .
No side effects were observed as a result of oral
etamiphylline camsylate treatment. There were no
problems associated with drug palatability, all horses
ingested both clenbuterol and etamiphylline camsylate
quite readily.
The individual values for respiratory rate, max.A
Ppl, Pa02> PaC02 and arterial pH recorded during trials
6.A, 3, C and D as well as the results of the
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statistical analyses are presented in Appendices 6.1,
6.2, 6.3 and 6.4 respectively.
DISCUSSION
Despite clenbuterol and etamiphylline camsylate
having different pharmacological modes of action,
these drugs were shown to have similar effects on the
respiratory parameters examined in COPD affected
horses. The results of the trials will, therefore,
be discussed together.
When COPD affected horses, housed in the natural
challenge environment, were treated with clenbuterol
(trial 6.A(ii)) and etamiphylline camsylate (trial
6.C(ii)), they'continued to be clinically affected
with COPD and there were very few significant changes
in their respiratory function values from those for
horses untreated and housed in similar conditions.
Despite the decrease in mean max.APpl and increase
in mean Pa02 values when horses were on clenbuterol
treatment, these values did not approach normal levels,
i.e.; max.APpl<6 mm Hg and Pa02 > 82 mm Hg (McPherson
et al . , 1978 ). Horse No. B95 alone had values
within these ranges on days 4, 7 and 9 of trial 6.A(ii)
(Appendix 6.1).
When symptomatically affected horses were housed
in the controlled environment, neither drug caused
significant changes in max.APpl or PaO^ from the
corresponding values in the preceding trials, when the
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horses were housed in this same environment but re¬
ceived no drug treatment. Neither was the remission
of clinical signs significantly hastened through
treatment with these agents in conjunction with the
c
controlled environment.
The apparent lack of response in CQPD affected
horses to these orally administered bronchodilator
drugs is difficult to explain in view of the marked
improvements recorded after their intravenous injection,
reported in chapter 3. In keeping with the drug
manufacturers' recommendations, the same clenbuterol
dose was used for intravenous and oral administration
(i.e. 0.8 pg/kg) and a lower dose of etamiphylline
camsylate was used for the oral administration trials
(i.e. 2.25 mg/kg) than for intravenous administration
(i.e. 3.0 mg/kg). Although both drugs are well
absorbed from the equine gastrointestinal tract, it
is possible that higher doses of orally administered
compounds are required to achieve a similar response
to that which has been demonstrated with intravenous
administration. Detailed dose response studies
would be required to elucidate this point. The half
lives of clenbuterol and etamiphylline camsylate after
oral administration in the horse vary considerably;
clenbuterol having a half life of 20 hours (Boehringer,
1980, technical information) whilst that of etami¬
phylline camsylate is 6 hours (Bogan, J.A., 1981,
personal communication). Following intravenous
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administration of clenbuterol and etamiphylline camsy-
late to COPD affected horses, significant pulmonary
function improvements were present up to 4 hours and
2 hours respectively (chapter 5). The monitoring
time in experiments described in this chapter was
constant, i.e. 3 to 3% hours after the morning treat¬
ment. Whilst it is possible that the response
occurred prior to monitoring and that the effects
were diminishing by 3 to 3% hours after treatment,
this seems unlikely as the response would be more de¬
layed after oral administration than after intravenous
injection. In addition, the monitoring time was
well within the half life of both drugs.
When the affected horses were treated with clen¬
buterol or etamiphylline camsylate whilst housed in
the challenge environment, it is possible that high
levels of aetiological antigens in the atmosphere
counteracted the effects of these bronchodilator drugs.
However, in the trials where antigen exposure was
minimised through use of a controlled environment
(trials 6.B(ii) and 6.D(ii)), bronchodilator therapy
appeared equally ineffective.
The poor response to oral bronchodilator therapy
in clenbuterol and etamiphylline camsylate treatment
trials when horses were housed in the challenge environ¬
ment (6.A(ii) and 6.C(ii)) might have been attributed
to the horses having permanent structural pulmonary
changes. However, the fact that all horses became
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asymptomatic in the controlled environment shortly
thereafter indicates that the pulmonary changes were
primarily functional (i.e.. reversible) rather than
structural (i.e. irreversible).
The side effects of oral clenbuterol administration
(sweating, muscle tremor and tachycardia) noted in two
horses were not recorded by Sasse and Hajer (1977) during
their oral clenbuterol trials. However, the response to
treatment was assessed by the owners and no details were
provided regarding the times of observation after
treatment. It is possible, therefore, that the
owners failed to notice any transient side effects
through infrequent observation. Nausea and gastro¬
intestinal discomfort commonly occur in man after
administration of oral etamiphylline preparations
(Flenley, 1981), however, no such side effects were
seen in the horse after oral etamiphylline camsylate
treatment.
CONCLUSIONS.
In these trials, neither oral clenbuterol nor
etamiphylline camsylate were effective in-treating symptomatic
COPD affected horses exposed to the natural challenge en¬
vironment. In addition, neither drug significantly hastened
the remission of COPD which normally occurred when sympto¬
matic horses were housed in the controlled environment.
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CHAPTER 7.
THE EFFECTS OF SODIUM CHRQMOGLYCATE ON




Ammi visnaqa is an umbelliferous plant (Figure
7.1) which grows wild in eastern Mediterranean regions.
Since ancient times, extracts from the seeds of this
plant have been used medicinally by the local popul¬
ation mainly as an antispasmodic in the treatment of
renal colic and ureteral spasm (Anrep et_ al_. , 1947 ).
Chemical analysis of extracts of this plant showed
the active principle to be a chromone named khellin
(di-methoxy-methyl-furano-chromone) (Figure 7.2).
In vitro studies showed that khellin causes marked
relaxation of visceral smooth muscle, including
bronchial muscle (Samaan, 1932). Later, khellin
was reported to be an efficient bronchodilator in
certain forms of human asthma (Kennedy and Stock,
1952).
Sodium cromoglycate was discovered in 1965 during
research to find a more effective agent for the treat¬
ment of human bronchial asthma. In an attempt to
improve the smooth muscle relaxant properties of
khellin while eliminating its systemic vasodilatory
side effects, a series of synthetic chromones were
produced. One of these compounds, a dimeric chromo-
necarboxylic acid (Figure 7.2) known as sodium
cromoglycate became the prototype of a new class
anti-allergic drugs (Cairns e_t al_. , 1 972 ).
In preliminary studies in man, prophylactic
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Figure 7.1. Ammi visnaqa, an Eastern
Mediterannean plant from





Figure 7.2. Structural formulae of khellin and sodium cromo-
glycate.
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inhalation treatment with sodium cromoglycate was
found to inhibit the bronchospasm which normally
occurred in sensitised bronchial asthma affected sub¬
jects, following inhalation of the appropriate antigen,
although it possessed no direct bronchodilator
properties (Altounyan, 1967). This finding led to
the widespread use of sodium cromoglycate in the
treatment of bronchial asthma and several other allergic
diseases including hay fever, gastro-intestinal
allergies, ulcerative colitis, chronic proctitis and
vernal kerato-conjunctivitis.
The mechanism of action of sodium cromoglycate in
bronchial asthma is not completely understood but it
is believed to stabilise sensitised pulmonary mast
cell membranes. This prevents degranulation of these
mast cells after antigen exposure, thus inhibiting the
release of pharmacologically active substances (Cox,
1976) (Figure 7.3). These substances including
histamine, slow releasing substance of anaphylaxis
(SRS-A), serotonin and 3-hydroxytryptamine (5-HT)
cause constriction of the airway smooth muscle, in¬
flammation, mucosal secretion and oedema of the airways.
The process by which sodium cromoglycate prevents
mediator release from the mast cells is incompletely
understood. Studies in animals, particularly the
rat, have shown that sodium cromoglycate does not appear
to affect either fixation of reagenic antibodies
to mast cells or the interaction between antigen and
140.
ANTIGEN CHALLENGE WITHOUT PRIOR SODIUM CROMOGLYCATE TREATMENT.












Figure 7.3. Schematic representation of a possible mode of
action for sodium cromoglycate (on pulmonary
mast cells).
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cell-bound antibody (Cox, 1970). However, the bio¬
chemical events which occur subsequent to the
combination of antigen with cell-bound antibody can
be inhibited by sodium cromoglycate. These include a
«
decrease in membrane associated cyclic 3',5'- AMP.
This cyclic 3',5'-AMP decrease causes increased mast
cell membrane permeability, an influx of calcium into
the cell, a decrease in the mast cell cyclic 3 ' ,51-AMP
levels followed by mediator release from the mast cell
(Church, 1978). Sodium cromoglycate is thought to
act by preventing the influx of calcium into the mast
cell and thereby halting the biochemical chain of
events leading to mediator release (Garland and Mongar,
•1974, 1976). Another possible mechanism of action of
sodium cromoglycate is that it may cause blockade of
airway irritant receptors and this has been demon¬
strated experimentally in dogs following sodium cromo¬
glycate inhalation (Jackson and Richards, 1977). It
has been postulated that these receptors might be
involved in the pathogenesis of exercise—induced
asthma where mast cell degranulation is not thought
to be primarily involved. Sodium cromoglycate is,
therefore, not a bronchodilator, a smooth muscle re¬
laxant or anti-inflammatory agent, nor does it
antagonise any specific pharmacologically active sub¬
stance, e.g. histamine.
In the treatment of bronchial asthma, sodium
cromoglycate is predominantly used to prevent Type I
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(reagin-mediated) allergic lung reactions, however,
clinical studies have shown that sodium cromoglycate
also protects against the late allergic pulmonary
reactions (some possibly of Type III, Arthus reactions)
which develop 4 to 6 hours after antigen exposure
(Pepys e_t al. , 1968; Laitinen e_t al_. , 1978; Booij-
Noord, Orie and De Vries, 1971). These late
allergic reactions are seen typically in farmer's
lung and bird fancier's lung diseases in which
extrinsic allergic alveolitis is the important patho¬
logical feature. However, late bronchial reactions
in man (which occur without many of the features of
alveolitis) caused by inhalation of house dust, are
also inhibited by sodium cromoglycate (Booij-Noord
et_ al . , 1972) .
Horses affected with COPD frequently show respir¬
atory hypersensitivity to mycological antigens in
stable dust and forage or to pollens. COPD signs may
be exacerbated as early as 30 minutes after antigen
exposure (Eyre, 1972) or more typically as a delayed
response, 4 to 8 hours after challenge (McPherson
et al., 1979b). The pathogenesis of equine COPD is
not completely understood but airway spasm is known to
be involved as well as a widespread exudative bronchio¬
litis, as was shown in chapter 3. The role of mast
cells in this equine disease has not been established,
but pulmonary mast cell hyperplasia has been noted in
COPD affected horses (Nicholls, 1978). If mast cell
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degranulation is involved in the pathogenesis of COPD,
it is possible that prophylactic treatment with sodium
cromoglycate prior to antigen challenge could prevent
the onset or exacerbation of the disease.
This chapter describes some preliminary studies
on the effects of prophylactic sodium cromoglycate
administration to COPD affected horses.
MATERIALS AND METHODS.
HORSES.
Two horses (horses Nos. B111 and B112, Appendix
3.2) were diagnosed as being affected with COPD
according to the criteria of McPherson e_t a_l_. , (1978 ).
Horse No. B111 showed respiratory hypersensitivity to
M_. f a eni and A^. f umigatus, whilst horse No. B1 12 was
hypersensitive to ML fa eni only. The horses were
housed in the controlled environment (p. 57) during
the trials.
SODIUM CROMOGLYCATE TREATMENT.
Sodium cromoglycate B.P. 1 % w/v solution (Intal,
Fisons Ltd., Loughborough) was aerosolised using a
Wright's nebuliser and administered via a mask which
covered the horse's mouth and nose (p.57 ). 80 mg
sodium cromoglycate was administered as a single dose.
ANTIGEN INHALATION CHALLENGE.
Prior to antigen challenge, the horses' max.A.Ppl,
Pa02 and clinical state were determined as previously
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described (pp.49,54). M_. faeni and A_. fumiqatus
antigens were prepared and administered as described
on p. 57. Clinical observations were made hourly
thereafter and the max. A Ppl and PaO^ were re-measured
five hours after antigen inhalation. The following
max. A Ppl values were taken as indicating a positive
response; where the pre-exposure max.APpl value was
less than 6 mm Hg and increased after antigen challenge
to greater than or equal to 6 mm Hg (the value de¬
lineating affected animals by McPherson £t_ £_1 . , 1978 )
or where the pre-exposure max.APpl was already greater
than 6 mm Hg, an increase of 15?o in this figure was
considered to indicate a positive reaction (McPherson
et_ al_. , 1979b) .
TRIALS.
7.A. Antigen challenge, no drug treatment.
To establish the mean response of each horse to
antigen inhalation, both horses were challenged with
M_. faeni on three occasions. Horse No. B1 11 was also
challenged with A_. fumiqatus on three occasions.
7.B. A single M. faeni challenge following sodium
cromoqlycate treatment.
80 mg sodium cromoglycate was administered 20 to
30 minutes prior to the M_. faeni challenge of both
horses on three occasions and the response monitored
at 5 hours after challenge as previously described.
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7.C. Repeated M. faeni challenge following sodium
cromoqlycate treatment.
The duration of protection provided by a single
sodium cromoglycate treatment in the affected horses
against repeated M_. faeni challenge was tested as
follows :
(i). The horses were treated with sodium cromo¬
glycate and challenged as in trial 7.B and thereafter
were challenged daily with M_. faeni until a positive
response was recorded.
(ii). Horses received sodium cromoglycate treat¬
ment on day 1 and were challenged with M_. faeni on days
2 and 4.
(iii). Antigen challenge was applied only at the
end of the protective period as established in (i),
on day 4 for horse No. B111 and days 4 and 5 for horse
No. B112.
7.D. Multiple antigen challenge following sodium
cromoqlycate treatment.
The effects of multiple antigen challenge on the
duration of protection provided by a single sodium
cromoglycate treatment was tested in horse No. B111,
using M_. fa eni and A_. f umigatus challenge on alternate
days .
(i). Sodium cromoglycate was administered on
day 1 and the horse challenged with M_. faeni. On day
2, the horse was challenged with _A. fumiqatus and on
day 3 with M. faeni.
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(ii). The trial took the same form as (i)
except that A_. fumiqatus was administered on days 1
and 3 and M_. faeni on day 2.
RESULTS
7.A. Antigen challenge, no drug treatment.
The effects of M_. faeni and _A. fumigatus inhalation
challenge (on max.APpl and PaC^) on horses Nos.
B111 and B112 are shown in Table 7.1. The horses were
not always in an identical disease state at the time of
antigen challenge and this accounts for the wide range
in max.APpl values for horse B111 before and after
A_. fumigatus challenge. There was a mean max.APpl
increase of 7 mm Hg in horse No. B111 five hours after
M_. fa eni challenge, 8 mm Hg in the same animal after
_A. fumigatus challenge and 8 mm Hg in horse No. B112
after M_. fa eni challenge. These increases all con¬
stituted positive responses, being well in excess of
the required 15?o increase. Examples of max.APpl
recordings from horse No. B111 before and after M_. fa eni
inhalation challenge are shown in Figure 7.4.
Changes in PaC^ values were less consistent.
Mean PaO^ levels decreased after antigen challenge, but a
wide variation occurred. Clinically, both animals
showed a double expiratory effort and increased, harsh
inspiratory chest sounds 5 hours after antigen challenge,
in contrast with the absence of these signs before
challenge.
TABLE7.1.
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7.B. A single M. faeni challenge folowinq sodium
cromoglycate treatment.
Sodium cromoglycate inhalation did not induce any
clinical, max.APpl or PaC^ changes in either animal
with 30 minutes of treatment. Table 7.2 shows the
mean max. A. Ppl and Pa02 values at rest (after sodium
cromoglycate treatment and prior to antigen challenge)
and 3 hours after antigen challenge, in the trials
where animals were asymptomatic prior to challenge.
In contrast to the findings in Table 7.1, little
change was recorded in max.APpl values in either horse,
with the mean values at 5 hours after challenge being
less than 6 mm Hg. Pa02 changes recorded after
challenge were very slight. The horses were not
dyspnoeic after challenge and there was no evidence of
double expiratory effort or increased breathing sounds.
Examples of max.APpl recordings from horse No. B111
which had been prophylactically treated with sodium
cromoglycate before _M. faeni inhalation challenge are
shown in Figure 7.4.
When symptomatic at the commencement of the trial,
horse No. B111 showed no further increase in max.A.Ppl
after antigen challenge and a PaC^ decrease of 4.2 mm Hg,
whilst in horse No. B112 max.APpl increased from 6 mm
Hg to 7 mm Hg with a PaC^ increase of 3.2 mm Hg.
7.C. Repeated M. faeni challenge following sodium
cromoglycate treatment.
(i). Horses Nos. B111 and B112 , challenged daily
TABLE7.2.
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with M_. faeni, did not show positive responses to
antigen challenge until days 4 and 5 respectively after
sodium cromoglycate treatment. Table 7.3 shows the
daily pre- and post-challenge max. A Ppl and PaC^ value§.
In horse No. B111 on day 5, the pre-exposure max.APpl
value was elevated, PaC^ depressed and the horse was
showing clinical signs of COPD. This was possibly as
a result of the positive response to challenge on day
4. This reaction was intensified by antigen challenge
on day 5.
(ii). When the frequency of M_. faeni inhalation
challenge was reduced to days 2 and 4 after sodium
cromoglycate treatment, both horses showed positive
responses to challenge on day 4.
(iii). A single antigen challenge on day 4 after
sodium cromoglycate treatment induced a positive res¬
ponse in horses No. B111 but not in horse No. B112. A
second challenge on day 5 produced a positive response
in horse No. B112 .
7.D. Multiple antigen challenge following sodium
cromoqlycate treatment.
The duration of protection after sodium cromoglycate
treatment in horse No. Bill was shorter in the face of
multiple antigen challenge. In parts (i) and (ii) this
animal showed an increase in max.APpl of 2 and 2.5 mm
Hg respectively on day 2. However, the post-challenge value on this
day was less than 6 mm Hg. On day 3, max.APpl
TABLE7.3.











































































increased by 5.5 and 7.5 mm Hg respectively and the
horse showed clinical signs of COPD.
DISCUSSION.
These antigen inhalation studies in two COPD
affected animals showed that the usual response to
challenge can be prevented by prior treatment with
sodium cromoglycate . This protection was most
efficient when horses were asymptomatic, but when horses
were symptomatic sodium cromoglycate prevented the
normally observed intensification of the disease after
challenge. A single sodium cromoglycate inhalation in
symptomatically affected animals did not produce any
apparent clinical improvement, this being similar to
the findings in bronchial asthma in man where sodium
cromoglycate is of no value in the symptomatic treat¬
ment of the disease (Cox, 1970).
The studies showed that the duration of protection
of COPD affected horses after a single sodium cromo¬
glycate dose was much longer than that for human
bronchial asthma patients where sodium cromoglycate in¬
hibits antigen-induced bronchoconstriction for less
than 24 hours (Kolotkin, Lee and Townley, 1973). The
reason for the prolonged protection in horse may be due
to differences in the pathogenesis of these two diseases
or to interspecies differences in, for instance, the
metabolism and excretion of the drug or mast cell
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longivity, between the horse and man. The half life
of sodium cromoglycate in the horse has not been
established, but in man, it varies from 45 to 90
minutes (Cox, 1970).
The duration of sodium cromoglycate protection in
the horse does, not appear to be related to the frequency
of challenge with a single antigen but multiple antigen
challenge does shorten the protective period. The
response is therefore similar to that in bronchial
asthma patients where protection occurs for up to 24
hours when the same antigen is used sequentially but
not when a dissimilar antigen is introduced 5 hours
after sodium cromoglycate treatment (Kolotkin, Lee and
Townley, 1973).
Although these trials were performed on only two
horses, they suggest that sodium cromoglycate is
effective in controlling COPD in horses. Consequently,
a clinical trial to evaluate the efficacy of sodium
cromoglycate on a larger number of affected horses is
described in the following chapter (chapter 8).
CONCLUSIONS.
These trials showed that prophylactic treatment
of COPD affected horses with sodium cromoglycate prevents
the exacerbation of respiratory disease, normally
observed at 4 to 8 hours after inhalation challenge
with an appropriate antigen. The duration of
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protection against antigen challenge after a single
sodium cromoglycate treatment is approximately 4 to 5
days and protection does not appear to be prolonged by
reducing the frequency of antigen challenge. However,
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In the preliminary studies (chapter 7) on 2 COPD
affected horses with respiratory hypersensitivity to
M_. faeni , sodium cromoglycate inhalation 20-30 minutes
prior to artificial antigen inhalation challenge, pre¬
vented the exacerbation of respiratory disease normally
observed 4 to 8 hours after challenge. Following a
single sodium cromoglycate treatment, this protection
lasted for 4 to 5 days. However, the horses, being
in a controlled environment, were only exposed to
daily artificial challenge with a single antigen and
a
not continuously exposed to/range of aetiological
allergens as they could be if housed in the natural
challenge environment.
This chapter describes a clinical trial to
evaluate the prophylactic effects of sodium cromoglycate
treatment on a greater number of COPD affected horses
continuously stabled in the natural challenge environ¬
ment. The effects of repeated sodium cromoglycate
administration on the duration of the protective period
in COPD affected horses was also examined.
MATERIALS AND METHODS.
HORSES .
56 confirmed COPD cases (horses Nos. B109-164,
Appendix 3.2), were divided into 4 groups, each group
receiving a different, number of sodium cromoglycate
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treatments. Their breed/type, age and duration of
illness prior to the trial are presented in Table 8.1.
TRIAL PROTOCOL.
8.A. Natural challenge environment, no drug treat¬
ment.
Initially, the COPD affected horses were housed in
the natural challenge environment (p. 55) for 4 days
to establish that this environment induced an exacer¬
bation of COPD signs. Respiratory function parameters
including respiratory rate, max.APpl, Pa02 and PaC02
were measured before and after 24 hours in this environ¬
ment and horses received daily clinical examinations
during this phase.
8.B . Controlled environment, no drug treatment.
The horses were then housed in the controlled envir¬
onment (p, 57) until clinical signs abated and their
max.APpl and Pa02 levels were within normal ranges.
8.C. Sodium cromoglycate treatment, (in controlled
environment).
As soon as the horse became asymptomatic in the
controlled environment, they were given 80 mg sodium
cromoglycate B.P. 1 % W/V solution (Cromovet, Fisons
Ltd., Loughborough) nebulised into a face mask. Two
types of nebulisation apparatus were used, namely, the
Wright's nebuliser and face mask previously described
for antigen inhalation challenge (p. 57) or a Pulmo-
Aide, series 561 Portable Compressor (Devilbiss,
TABLE8.1.
Thebreed/type,agenddurationofillnessCOPDaff ctedh rstr t d withsodiumcr moqlycate.
Group Number
Number of days treat¬ ment
Number and Identification ofhorses
BREED/TYPE
Age (mean-S.D.i years)






































Pennsylvania) along with a Cromovet nebuliser and
face mask (Fisons Ltd., Loughborough) (p. 59). Both
systems are alleged to produce a droplet size of less
than 8 microns. Sodium cromoglycate treatment of
COPD affected horses using both systems had been shown
by previous pilot experiments, to be equally effective.
Sodium cromoglycate was administered daily for 1,
2, 3, or 4 successive days to 9, 23, 16 and 8 horses
respectively (Groups 1, 2, 3 and 4; Table 8.1).
8.D. Natural challenge environment after sodium
cromoqlycate treatment.
On completion of the sodium cromoglycate admini¬
stration, horses were immediately returned to the
natural challenge environment and were subjected to
daily clinical examinations with particular attention
paid to the presence and degree of double expiratory
effort, coughing, respiratory rate and chest sounds.
Max.APpl, Pa02 and PaC02 levels were monitored as
previously described (pp.49, 54 ) at 2 and 3 day
intervals.
8.E. End of the trial.
The end of the protective period (induced by
sodium cromoglycate treatment) was established by both
clinical assessment and when values for max.APpl and
PaO^ became abnormal i.e. max. APpl>6 mm Hg and PaC^
82 < mm Hg.
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STATISTICAL ANALYSIS OF RESULTS.
Within each group of horses, values for respiratory
rate, max. A Ppl, PaO^ and PaCO^ recorded during the 4
phases of this trial (i.e. 8 . A. Chal1enge environment,
no drug treatment, 8.B. Controlled environment, no
drug treatment, 8.D. Challenge environment after sodium
cromoglycate treatment, 3.E. End of the trial) were
individually compared using the paired Student's t-
test.
The correlation between the number of sodium cromo¬
glycate treatments and the duration of the protective
period after treatment was calculated by regression
analysis (Snedecor and Cochran, 1967). The signifi¬
cance of the correlation between the duration of the
protective period after treatment and age, bodyweight,
duration of illness, max. APpl, PaO^ and PaCC^ values
for untreated symptomatic horses, was tested by regres¬
sion analysis. These correlations were tested within
each group and on the massed data from the four groups.
RESULTS .
8.A. Natural challenge environment, no drug treat¬
ment.
Exposure to the natural challenge environment
(without sodium cromoglycate treatment) induced clinical
signs of COPD in all horses after 24 hours. Mean
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values for max. A Ppl and blood gases also showed that
the horses became symptomatic (Table 8.2). Horses
remained symptomatic throughout the 4 days that they
remained in this environment.
8.B. Controlled environment, no drug treatment.
When placed in the controlled environment, COPD
affected horses became asymptomatic in 4 to 32 days
(mean (- S.D.) 9.1 - 4.9 days). Mean values for
respiratory rate, max.APpl and blood gases in asympto¬
matic horses are shown in Table 8.2.
Compared to the previous phase (8.A), the decreases
in respiratory rate and max.APpl and increase in PaO^
were highly significant (P< 0.001) in all groups. A
significant decrease (P <0.03) in PaC02 was recorded
in all groups.
8 . D . Natural challenge environment after sodium
cromoqlycate treatment.
Sodium cromoglycate treatment prior to natural
antigen challenge temporarily prevented an exacerbation
of COPD in the affected horses. The duration of this
protective period ranged from a mean of 3.6 days after
a single day's treatment to a mean of 24.3 days after
treatment on 4 successive days (Figure 8.1). The
correlation between the number of sodium cromoglycate
treatments and the duration of the protective period
was highly significant; correlation coefficient r (54)
= +0.709 (P< 0.001). The line of best fit was linear
(Figure 8.1).
TABLE8.2.
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164.
Number of treatments
Figure 8.1. The relationship between the number of sodium
cromoglycate treatments and the protective
period in COPD affected horses housed in the
natural challenge environment. (• = values
recorded for individual horses, *** = P< 0.001).
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The mean values for respiratory rate, max.APpl
and blood gases recorded during the protective period
are shown in Table 8.2. an average of 3 pulmonary
function examinations were made from each horse in
Group 1, 5 per horse in Group 2, 7 per horse in Group 3
and 12 per horse in Group 4. The values expressed
are a mean of these recordings for all horses.
The differences in the horses' respiratory rate,
max. A. Ppl and PaC^ values between when they were un¬
treated and symptomatically affected (8.A) and during
the protective period were highly significant (P< 0.001)
whereas the decrease in PaC02 was less significant
(P < 0.05) (Table 8.2).
Comparison of the values recorded for these para¬
meters when the horses were asymptomatic in the controlled
environment (8.3) and during the protective period
showed no significant differences (P> 0.05) in max.APpl,
respiratory rate or PaC02 between the two phases. In
groups 2 and 3, there were no significant Pa02 differ¬
ences (P > 0.05) between these same two phases but Pa02
values in Groups 1 and 4 were significantly lower
(P <0.01) during the protective period as compared to
the asymptomatic period in the controlled environment
( 8 . B ) .
There were no significant correlations between the
duration of the protective period after sodium cromo-
glycate treatment and the horses' age, bodyweight,
duration of illness, symptomatic max.APpl, Pa02 and
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PaCQ^ values or the time required to become asympto¬
matic in the controlled environment, either within each
group or on the massed data from the 4 groups. The
correlation coefficients from the massed data are
shown in Table 8.3.
8.E. End of the trial.
Towards the end of the protective period, faint,
harsh respiratory sounds were auscultated and these
became louder over the following 1 to 3 days. This
was accompanied by a slight double expiratory effort
which became increasingly more pronounced and, in some
cases, an increase in respiratory rate and coughing.
Mean values for respiratory rate, max.APpl and blood
gases when symptoms became re-established at the end of
the protective period are shown in Table 8.2. The in¬
crease in max. A Ppl and decrease in PaO^ were significant
(P< 0.001 and P<0.01 respectively) compared to values
recorded during the protective period (8.D) but there
were no significant changes in respiratory rate or
PaC02 values.
No untoward side effects were observed in any
of the horses following sodium cromoglycate treatment.
The individual values for respiratory rate, max.
A Ppl, Pa02 and PaC02 recorded from the COPD affected
horses during the trial as well as duration of the




Statistical correlation of the duration of protection in
CQPD affected horses after sodium cromoqlycate treatment,
with their age, bodyweiqht, symptomatic max.A.Ppl and
PaO^ values, duration of illness and remission time









Bodyweight r(54 ) =0 .004
NS
P> 0 .05
Symptomatic max.APpl r(54)=-0 .101 P> 0 ,05NS
Symptomatic Pa02 r(54) =0 .220
NS
P > 0.05
Duration of illness r(54) =0.010
NS
P> 0 .05 N°
Remission time r(54 ) =-Q . 183
NS
P> 0 .05
0 The correlation coefficients are from the massed
data, from Groups 1, 2, 3 and 4.
NS = not significant.
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DISCUSSION
From this study, it is apparent that sodium cromo-
glycate administration to asymptomatic COPD affected
horses is effective as a short-term prophylactic
measure against exposure to the natural challenge en¬
vironment. Each horse acted as its own control by
virtue of its previous positive response to the natural
antigen challenge.
The protective period afforded to COPD affected
horses by sodium cromoglycate depended most on the
number of successive days treatment with this drug prior
to antigen challenge. The protective period of 3.6 -
1.1 days (mean - S.D.) after a single sodium cromo¬
glycate inhalation is similar to the protective period
recorded in chapter 7 where 2 horses failed to respond
to M. faeni inhalation challenge for 4 and 3 days after
a single sodium cromoglycate treatment. With increas¬
ing daily sodium cromoglycate inhalations, the
protective period increased linearly. The protect¬
ive period was 8.0 - 3.4 days (mean - S.D.) after 2
days treatment, 11.9 - 2.9 days after 3 days treat¬
ment and 24.3 - 13.4 days after 4 days treatment.
There was a wide range in the duration of the
protective period from all 4 treatment schedules,
particularly after the 2 days treatment and 4 days
treatment when the respective protective periods ranged
from 2 to 19 days and 12 to 50 days (Figure 8.1,
Appendices 8.2 and 8.4). Statistical analysis showed
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no significant correlations between the duration of
the protective period and the parameters shown in
Table 8.3 i.e.: age, duration of illness, symptomatic
max.A.Ppl and PaC^. As the challenge conditions
were similar for all horses, these differences in the
duration of the protective period are difficult to
explain.
During the protective period (8.D), values for the
horses' respiratory function parameters did not differ
significantly from those when the horses were asympto¬
matic in the controlled environment (8.B) except for
Pa02 in Groups 1 and 4. In these groups several horses
became hypoxaemic 1 to 2 days before clinical signs of
COPD and max. A Ppl increases occurred. These reduced
PaC^ values account for the lower mean PaC^ values
during the protective period in Groups 1 and 4
(Appendices 8.1 and 8.4).
The prolonged periods of protection recorded in
many horses after sodium cromoglycate treatment (e.g.
24 days after 4 days treatment) is in contrast to
the usual situation in human bronchial asthma patients
where sodium cromoglycate inhalation is required 4
times daily in order to maintain adequate protection.
However, some workers have demonstrated prolonged
prophylactic effects of sodium cromoglycate in a small
percentage of bronchial asthma patients. Bernstein
et al., (1972), Kennedy (1969) and Silver (1971) all
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recorded remission of bronchial asthma in some patients
for up to 4 weeks following cessation of treatment.
In addition, it has been clinically noted that prolonged
sodium cromoglycate therapy in bronchial asthma
patients is often associated with periods of almost
total remission requiring no therapy or only occasional
therapy (Pain, 1973). However, the reason for this
prolonged efficiency has not been elucidated. In
this respect, Bernstein ejt sl1_. , (1972 ) suggested that
possible non-immunological effects of the drug may be
involved as they considered that its effects on immuno¬
logical reactions mediated by reaginic or Arthus-type
antibodies could hardly account for such long-term re¬
mission from clinical disease. Altounyan, Cox and
Orr (1971) postulated that desensitisation to specific
antigens under the protective cover of sodium cromo¬
glycate may also account for the long—term effects of
the drug, whilst Kerr, Govindaraj and Patel (197Q)
suggested that this effect might arise from sodium
cromoglycate exerting a specific protective effect
upon the bronchial smooth muscle membrane. As yet,
there is no experimental evidence to support any of
the above hypotheses.
A feature of sodium cromoglycate treatment in
bronchial asthma patients is the variability in response
to treatment, in both the proportion of patients that
respond to treatment and the quality of the observed
response. In a review of numerous therapeutic trials,
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Brogden, Speight and Avery (1974) calculated that the
proportion of asthma patients that responded to long-
term sodium cromoglycate treatment varied from 52 to
100?o. , These authors suggested that, in general, young
patients, extrinsic asthmatics and exercise-induced
asthmatics are most likely to respond. A possible
explanation for the disparity in response to sodium
cromoglycate in bronchial asthma patients is given by
Bryant, Burns and Lazarus (1973) who reported that
sodium cromoglycate is effective in the majority of
patients with IgE mediated reactions whereas it was
ineffective in patients with IgG mediated reactions.
As it is not yet possible to measure IgE levels in the
horse, the relationship between IgE mediated reactions
in equine COPD patients and their duration of pro¬
tection following sodium cromoglycate treatment has not
been tested.
COPD affected horses are usually capable of
working normally as long as they remain asymptomatic
and this can best be achieved by implementing environ¬
mental control measures as previously outlined (p. 57 ).
In some situations, this regime is impractical, for
instance, during transportation or when horses are
moved temporarily away from the home environment, e.g.
for competitive events. Even limited antigen exposure
may provoke clinical signs of COPD and render the horse
incapable of performing to its full potential. In
such cases, prophylactic sodium cromoglycate adminis¬
tration may prove beneficial to COPD affected horses
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during periods of unavoidable challenge. This drug
cannot, however, be used in race horses in Great
Britain and Ireland under the current rules of racing.
Ensuring strict environmental control for an
individual horse frequently proves difficult in large
stables, particularly when horses are kept at livery.
Such cases could benefit from long term prophylactic
treatment which would avoid having to make special
provision for the management of these horses (personal
observations). It was postulated that additional
courses of sodium cromoglycate treatment administered
to COPD affected horses prior to the end of their
sodium cromoglycate protective period, might prevent
the onset of clinical signs over a more prolonged
period than after a single course of treatment.
Studies to investigate this are described in the
following chapter.
CONCLUSIONS.
Prophylactic treatment of asymptomatic COPD
affected horses with inhaled sodium cromoglycate is
an effective method of controlling the onset of COPD.
A linear response exists between the number of succes¬
sive days treatment with this drug and the duration of
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In the previous two chapters (chapters 7 and 8),
prophylactic sodium cromoglycate administration to
asymptomatic COPD affected horses was shown to
temporarily prevent the onset of COPD after exposure
of susceptible horses to the aetiological antigens.
This chapter describes studies to assess whether
the protective period afforded to COPD affected horses
by sodium cromoglycate can be prolonged by repeating
treatment whilst horses are housed in the challenge




Prior to the commencement of the trial, 8 COPD
affected horses (horses Nos. B117, B121, B126, B130,
B140, B154, B162 and B163, Appendix 3.2) were housed
in the controlled environment (p. 37) for 14 days and
by the end of this period all horses were asymptomatic.
TRIAL PROTOCOL.
The sequence of the ensuing intermittent sodium
cromoglycate treatment trial is shown in Figure 9.1.
9.A. Challenge environment, no drug treatment.
Initially, the COPD affected horses were housed
in the natural challenge environment (p. 55) for 28



















16. Figure9.1.lowdiagramfthestudiesnintermittentdiucro oglycat inhalationfort eherapyfquineCOPD.
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horses received daily clinical examinations and values
for max.A.Ppl and arterial blood gases were recorded
as previously described (pp.49,54) three times weekly
throughout this phase of the trial.
On day 28, the horses were returned to the con¬
trolled environment for 14 days and by the end of this
period they were all asymptomatic. The horses
received no drug treatment during this time. On the
following 2 days (days 15 and 16) horses were treated
with 80 mg sodium cromoglycate by inhalation using
the Cromovet inhalation system, as previously de¬
scribed (p. 59). Following treatment on day 16,
the horses' max.APpl and arterial blood gas values
were monitored and thereafter, horses were returned
to the challenge environment.
9 . B. Challenge environment and intermittent sodium
cromoglycate treatment.
For the ensuing 28 days, the horses were maintained
in the challenge environment. 80 mg sodium cromo¬
glycate was administered using the Cromovet inhalation
system on days 6, 7, 13, 14, 20 and 21. As in 9.A,
the horses received daily clinical examinations and
their max. A Ppl and arterial blood gas values were
recorded three times weekly throughout the 28 days.
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STATISTICAL ANALYSIS OF RESULTS.
The Student's t-test as applied to paired obser¬
vations was used to compare:-
(a) Values for respiratory rate, max.APpl, Pa02>
PaC02 and arterial pH recorded immediately prior to
challenge (on day 0), with values recorded during
exposure to the challenge environment in trials 9.A
and 9.B.
(b) Values for respiratory rate, max.APpl, Pa02>
PaC02 and arterial pH recorded during 9. A when horses
were untreated,with the corresponding values recorded
during 9.B when horses were treated with sodium cromo-
glycate.
RESULTS.
9.A. Challenge environment, no drug treatment.
All horses were asymptomatic at the start of this
phase. The mean (- S.D.) values for max.APpl and
Pa02 were 3.74 - 0.53 mm Hg and 88.51 - 2.98 mm Hg
respectively. After being housed in the challenge
environment for 1 day, all horses became symptomatically
affected with COPD. The increase in mean max.APpl
and the decrease in mean Pa02 values were both highly
significant (P <0.001).
The mean max.APpl continued to increase steadily
up to 19.20 - 5.52 mm Hg (mean - S.D.) on day 16 and
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remained between 18.01 - 6.44 mm Hg and 19.6 - 6.22 mm
Hg until the end of the 28 day period (Figure 9.2).
The mean respiratory rate was very significantly
elevated (P <0.001) above the baseline value on day 2
and remained so throughout the 28 days (Figure 9.3).
The mean Pa02 decreased steadily to 68.40 - 3.30 mm Hg
(mean - S.D.) on day 16 and remained between 67.89 -
5.00 mm Hg and 70.54 - 5.26 mm Hg during the remainder
of this phase (Figure 9.4). PaC02 levels were in¬
creased (P< 0.05) from day 1 onwards (Figure 9.5) but
there was no significant alteration in the pH values.
Marked clinical signs of C0PD were present in all
horses throughout this period.
9.B. Challenge environment and intermittent sodium
cromoglycate treatment.
The horses were once again asymptomatic at the
start of this phase and mean values for max.APpl,
respiratory rate, Pa02> PaC02 and arterial pH were
similar to those recorded at the beginning of 9.A.
Upon exposure to the challenge environment, most horses
showed little clinical alteration in their respiratory
signs. Mean (- S.D.) values for max. A. Ppl, respiratory
rate, PaC^ and PaCC^ recorded during the trial are
shown in Figures 9.2, 9.3, 9.4 and 9.5 respectively.
During this period (9.B), no significant differ¬
ences (P> 0.05) were recorded in respiratory rate,
PaC02 or arterial pH from the immediate pre-chal1enge
179.
= Sodium cr'omoglycate inhalations.
= Exposure to challenge environment commences.
= Mean - S.D. values for sodium cromoglycate
treated horses.
= Mean - S.D. values for untreated horses.
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Figure 9.2. Effects of intermittent sodium cromoglycate
treatment on max.APpl in COPD affected horses.
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* = Sodium cromoglycate inhalation.
0 = Exposure to challenge environment commences.
I
i
= Mean - S.D. values for sodium cromoglycate
treated horses.
= Mean - S.D. values for untreated horses.
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Figure 9.5. Effects of intermittent sodium cromoglycate
treatment on PaCO^ in COPD affected horses.
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values (recorded on day 0). Max. A Ppl values were,
however, significantly elevated (P <0.03) above the
pre-chal1enge values on days 11, 25 and 28 while PaO^
values were significantly decreased (P< 0.05) on days
11, 18, 25 and 28 (Appendices 9.1 and 9.2). Despite
significant max.APpl increases on certain days, mean
max.APpl values did not exceed 6 mm Hg (Figure 9.2).
Throughout this trial, max.APpl and Pa02 values
were significantly (P <0.001) lower and higher respect¬
ively than the corresponding values for these horses
when untreated (in 9.A). The mean respiratory rate
and PaC02 levels were lower when horses were treated
as compared to when they were untreated. The decreases
in respiratory rate were significant (P< 0.05) in 7
out of 13 pulmonary function examinations. Similarly,
decreases in PaC02 were significant (P<0.05) in 5
out of 13 recordings (Appendices 9.1 and 9.2).
Horses Nos. B117, B126, B130, B154 and B163
remained asymptomatic throughout the 28 days while
horse No. B121 was asymptomatic up to day 27.
Horses Nos. B14Q and B162 showed varying degrees of
C0PD signs at intervals during this phase. Horse
No. B162 had a slight double expiratory effort,
slightly increased and harsh inspiratory lung sounds
and coughed occasionally on days 14 to 20 and 25 to 28
but was asymptomatic at other times. Horse No.
B140 was asymptomatic up to day 21 apart from an
occasional cough and slightly increased and harsh
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inspiratory lung sounds on isolated days. However,
from day 21 to 28, this horse showed a marked double
expiratory effort, frequent coughing and increased,
harsh inspiratory sounds were present on auscultation.
Individual values for respiratory rate, max.A.Ppl,
Pa02 and PaCC^ recorded from horses during 9.A. and
9.8 as well as the results of statistical analyses are
presented in Appendices 9.1 and 9.2.
DISCUSSION.
The results of this short—term trial indicate
that in the majority of cases, intermittent sodium
cromoglycate is effective in preventing the onset of
COPD in affected horses continuously exposed to the
challenge environment.
In chapter 8, the mean (- S.D.) protective period
after 2 consecutive days sodium cromoglycate treatment
was 8.0 - 3.4 days. In this trial, the 2 consecutive
days sodium cromoglycate treatment were repeated at 5
day intervals to fall within the previously recorded
mean protective period following the 2 days sodium
cromoglycate treatment. Increases in max.APpl and
decreases in Pa02 values tended to occur towards the end
of the interval between sodium cromoglycate inhalations,
i.e. days 11, 18, 25 and 28. This might indicate that
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COPD affected horses housed in the natural challenge
environment and intermittently treated with sodium
cromoglycate may reguire treatment at shorter intervals
than might be expected from the results of chapter 8,
i.e. the mean protective period recorded in chapter 8
following 4 consecutive days sodium cromoglycate treat¬
ment was 24.3 days. Intermittent 4 day sodium cromo¬
glycate treatment should therefore be administered at
shorter time intervals, e.g. 20 or 21 days.
The results of studies into the efficacy of long-
term sodium cromoglycate therapy for the control of
human bronchial asthma are inconsistent. Some authors
have found the efficacy of sodium cromoglycate to de¬
cline with prolonged use (Stewart, 1971; Vialatte and
Delayeun, 1971) although other reports do not support
this (Medical Research Council Collaborative Trial,
1972; Silverman et_ £l_. , 1972 ; Hermance and Brown,
1976). In the COPD affected horses, the overall
response to sodium cromoglycate treatment did not decline
with successive inhalations over the 28 days. However,
a more prolonged trial lasting several months would be
reguired to more accurately assess the efficacy of long-
term sodium cromoglycate treatment in COPD affected
horses.
The individual response to treatment was consis¬
tently good in 6 horses but unsatisfactory at times in
the remaining 2 (horses Nos. B140 and 162). Horse
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No. 8140 was a 23 year old mare which showed a very
marked response to the challenge environment when un¬
treated (in 9.A), with max.A Ppl varying between 30
to 35 mm Hg and PaC^ as low as 58.5 mm Hg (Appendix
9.1). It appears, therefore, that she was extremely
sensitive'to the natural challenge environment and the
protracted exposure to this environment in 9.B might
have accounted for the unsatisfactory response to
sodium cromoglycate treatment during the last week of
the trial. During the treatment of horse No. B162,
problems arose with the Cromovet nebuliser unit on days
13, 14 and 21. The nebuliser unit became partially
blocked with dust particles on several occasions which
necessitated repeated cleaning and re-assembly of the
unit. It is possible that there was a slight loss of
sodium cromoglycate during this process which resulted
in the horse having a lower dose and consequently in¬
complete protection. Alternatively, nebulisation
of the drug whilst the nebuliser unit was partially
blocked could have resulted in increased droplet size,
reduced drug distribution into the smaller airways and
hence lowered the efficacy of the treatment.
Intermittent sodium cromoglycate treatment may be
found useful for the management of COPD affected horses
in general practice. 4-day courses of sodium cromo¬
glycate treatment would result in a more prolonged
period of protection and hence reduce the frequency of
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treatment. However, this form of treatment is by its
nature very flexible and individual treatment schedules
could be designed according to each horse's response
to treatment and the owner's requirements.
CONCLUSIONS.
In a 28 day trial, twice weekly sodium cromoglycate
inhalation was effective in preventing the onset of
COPD in 6 out of 8 affected horses which were contin¬
uously housed in the natural challenge environment.
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CHAPTER 10.
GENERAL DISCUSSION AND CONCLUSIONS.
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The studies described in this thesis provide more
information both on the therapy of equine COPD and on
the pathophysiology of the disease itself.
Minimising exposure to the aetiological antigens
through use of a controlled environment allowed COPD
affected horses to become asymptomatic within 4 to 32
days (mean - S.D. = 9.0 - 4.8 days). The time taken
to become asymptomatic correlated significantly with
the severity and the duration of the disease.
Whep the horses were asymptomatic, their pulmonary
function values (i.e.: respiratory rate, max.APpl,
tidal volume, inspiratory and expiratory flow rates,
PaO^) and PaC02 and arterial pH) did not differ
significantly from those of normal horses. It is,
therefore, apparent that the pathophysiological changes
occurring in equine COPD are largely reversible and
that most affected horses are capable of regaining
normal pulmonary function when contact with the
aetiological antigens is minimised. These findings
are in agreement with the observations of several
authors who reported clinical improvement in COPD
affected horses kept permanently outdoors or housed in
minimal dust environments (Thurlbeck and Lowell, 1964;
Eyre, 1972; Cook, 1976) and are also in accordance
with the findings of Meister, Gerber and Tschudi (1976)
and Dixon (1979) who additionally recorded reversal of
hypoxaemia in COPD affected horses when housed in
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controlled environments.
Two avenues of chemotherapy were investigated
i.e. bronchodilator therapy of symptomatic COPD
affected horses and prophylactic sodium cromoglycate
treatment of asymptomatic horses.
Intravenous administration of atropine, clenbuterol
or etamiphyHine camsylate and inhalation of atropine,
isoprenaline or terbutaline to symptomatic COPD
affected horses brought about a temporary, marked im¬
provement in clinical signs, accompanied by signi¬
ficant decreases in max. A Ppl (by 60 to 70?o of the
pre-treatment value) and respiratory rate and
significant increases in Pa02 values. These findings
indicate that airway spasm does play a role in the
pathogenesis of equine COPD. Despite the marked
improvement at the peak response to treatment, the
horses failed to regain normal pulmonary function.
This is undoubtedly due to the widespread bronchio¬
litis which occurs in symptomatically affected horses
which would not be compensated for by bronchodilator
treatment.
Whereas the beneficial effects of isoprenaline,
atropine and etamiphylline camsylate did not last
more than 2 hours in affected horses, the actions of
terbutaline and clenbuterol were more prolonged with
significant improvement in pulmonary function for 4
to 6 hours after treatment. Although terbutaline,
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clenbuterol and etamiphylline camsylate could be
useful for the treatment of acute attacks of CQPD,
parenteral bronchodilator treatment remains subject
to many limitations in that it only partially alleviates
the clinical signs and the resulting improvement is of
short duration. In addition, side effects are
frequently observed following parenteral bronchodilator
administration although these are minimal with the use
of the more specific beta 2 sympathomimetic broncho-
dilators (i.e. terbutaline and clenbuterol) and with
etamiphylline camsylate.
The clinical improvement in COPD affected horses
recorded in these trials following atropine, iso-
prenaline and clenbuterol treatment is similar to that
previously reported by other authors (Obel and
ft
Schmiterlow, 1948; Muylle and Oyaert, 1973; Sasse
and Hajer, 1977). The effects of terbutaline and
etamiphylline camsylate on respiratory function in
COPD affected horses do not appear to have been
described previously.
Studies, into the efficacy of orally administered
bronchodilator drugs in the treatment of equine COPD
proved disappointing. When horses were housed in the
challenge environment and treated with oral clenbuterol
or etamiphylline camsylate, they continued to be
symptomatically affected with COPD. Apart from the
significant decreases in respiratory rate and max.A Ppl
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on days 7 and 11 of the clenbuterol trial, there were
no significant changes in their respiratory function
values from those recorded when horses were untreated
and housed in similar conditions. In addition,
neither drug significantly hastened the remission of
clinical signs of COPD which normally occurred when
symptomatic horses were housed in the controlled en¬
vironment .
The reason for this apparent lack of response of
the COPD affected horses to oral bronchodilator treat¬
ment is difficult to explain, especially after the
marked response shown by affected horses to these
same agents administered intravenously. In keeping
with the drug manufacturer's recommendations, the same
clenbuterol dose was used for intravenous and oral
administration (i.e. 0.8 pg/kg) and a lower dose of
etamiphyHine camsylate was used for oral administration
(i.e. 2.25 mg/kg) than for intravenous administration
(i.e. 3.0 mg/kg). Although both drugs are well
absorbed from the equine gastrointestinal tract, it is
possible that higher doses of orally administered
compounds are required to achieve a similar response to
that which has been demonstrated with intravenous admini¬
stration. Detailed dose-response studies on orally
administered bronchodilator drugs in COPD affected
horses would be required to elucidate this point.
To date, there appears to be only one published
report on the oral administration of bronchodilator drugs
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to COPD affected horses (Sasse and Hajer, 1977). In
contrast to the findings in this thesis, Sasse and
Hajer (1977) reported a good response in horses
treated with clenbuterol at a dosage rate of 0.8 jug/kg
for 14 days. However, as the response to treatment
was only subjectively assessed by the owners' obser¬
vations it is impossible to critically compare the
results of the two studies.
Should higher doses of the orally administered
bronchodilator drugs prove more successful in treating
COPD, it still seems unlikely that this form of
therapy would be useful as a long-term measure as it
does not control the cause of this disease. Unless
contact with the aetiological antigens is minimised,
COPD signs would recur on cessation of treatment.
Although it is alleged that long-term clenbuterol
administration also aids in the treatment of bronchio¬
litis in COPD through its mucolytic effect which
prevents "pooling" of the mucus in the airways
(Boehringer, technical information, 1980), there have
been no published studies to support this claim.
In contrast to the results of bronchodilator
treatment, studies on the prophylactic treatment of
asymptomatic COPD affected horses with sodium cromo-
glycate proved hopeful. In the initial studies
(chapter 7), prophylactic sodium cromoglycate inhalation
in 2 affected horses prevented the exacerbation of
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respiratory disease, normally observed in COPD affected
horses 4 to 8 hours after M_. faeni inhalation challenge.
These studies were followed by a clinical trial using
56 horses (chapter 8) in which it was shown that a
linear response exists between the number of successive
days treatment with this drug and the duration of the
protective period while horses are exposed to the
natural challenge environment. The protective period
was 3.6 - 1.1 days (mean - S.D.) after a single sodium
cromoglycate treatment, 8.0 - 3.4 days after 2 days
treatment, 11.9 - 2.9 days after 3 days treatment and
24.3 - 13.4 days after 4 days treatment. In a 28
day trial (chapter 9), two successive days sodium
cromoglycate inhalation administered at weekly intervals
was effective in preventing the onset of COPD in 6 out
of 8 affected horses which were continuously housed
in the natural challenge environment.
These experiments show that prophylactic inhalation
treatment of asymptomatic COPD affected horses with
sodium cromoglycate is an effective method of control¬
ling the disease in the short term. As sodium cromo¬
glycate is believed to act by stabilising the mast
cell membranes, these results suggest that pulmonary
mast cell degranulation is involved in the pathogenesis
of equine COPD.
Whilst environmental control is a preferable form
of therapy for COPD, sodium cromoglycate treatment may
be found useful when unavoidable exposure to the
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aetiological antigens is anticipated. This could
occur, for instance, during transportation or when
horses are moved temporarily away from the home
environment. Alternatively long-term intermittent
sodium cromoglycate treatment could facilitate the
management of a horse kept at livery or in large stables
where the provision of special environmental control
measures may prove difficult to institute.
There is, however, one main disadvantage to sodium
cromoglycate treatment of COPD affected horses, i.e.
the method of drug inhalation is labour intensive (20
to 30 minutes per dose) and can be prolonged by faulty
equipment, which may, in addition, reduce the efficacy
of treatment. It would, therefore, be preferable if
an orally administered compound with similar activity
to inhaled sodium cromoglycate could be developed for
equine COPD treatment.
Since the introduction of sodium cromoglycate,
numerous related compounds have been synthesised as
potential anti-al1ergic drugs. These include benzo-
pyrans, xanthones, quinolines, azapurinones and
oxanilic acid (Church, 1978 ) . Many of these compounds
can be administered either by inhalation or orally and
in experimental animals, have been found to possess
even greater anti-allergic activity than sodium cromo¬
glycate. However, clinical tests in bronchial asthma
patients have shown that none of these cromoglycate
analogues are more effective than sodium cromoglycate.
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The orally administered cromoglycate-like compounds
are still undergoing investigation for the treatment
of asthma. If successful, the use of these orally
administered drugs for the treatment of equine COPD
merits investigation.
There are a number of other drugs with anti¬
allergic properties which might be beneficial for the
treatment of equine COPD but which have not as yet
been investigated for this purpose. These include
the non-steroidal anti-inflammatory drugs (NSAIDS),
diethycarbamazine, ketotifen and oxatomide (Eyre and
Hanna, 1980; Hawking, 1979; Daniel and Schromm, 1980).
In addition to investigation into the efficacy
of newer anti-allergic drugs in COPD affected horses,
more fundamental research into the disease is required
in order to gain a better understanding of the immuno¬
logical and biochemical processes occurring in the
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Normal Horses: Case details, resting respiratory function measure¬



































A 1 Hunter 9 Mn
A 2 H.Hunter 13 Mn
A 3 Hunter 9 F
A 1+ Hunter 1+ Mn
A 5 TB 5 F
A 6 Hunter 8 Mn
A 7 TB 1+ Mn
A 8 Hunter 9 Mn
A 9 Hunter 20 Mn
A 10 Hunter 9 Mn
A 11 TB 7 Mn
A 12 Hunter 10 F
A 13 Hunter 3 Mn
A Hi TB 2 Mn
A 15 Hunter 10 F
A 16 H.Hunter 8 Mn
A 17 Norwegan 10 M
FJoord
A 18 Hunter 12 F
A 19 TB 6 Mn
A 20 TB 10 Mn
A 21 Welsh ft>ny k Mn
A 22 Pony 1+ Mn
A 23 Pony 5 F
A 2k Hunter 22 Mn
A 25 Hunter 17 Mn
A 26 Hunter 9 Mn
A 27 TB 12 Mn
A 28 TB 5 F
A 29 Pony 6 F
A 30 Pony 7 F
A 31 TB 3 Mn
A 32 Hunter 16 Mn
A 33 TB 8 Mn
A 3k Hunter 7 Mn
A 35 TB 10 F
A 36 Arab 5 Mn
A 37 Pony 6 Mn
A 38 Pony 1+ F
A 39 Welsh 7 F
A ko Fell X 13 Mn
A 111 TB 1+ Mn
A k2 Hunter 6 Mn
A k3 TB 12 Mn
A UU Trotter 1+ F
A 1+5 Arab 7 Mn
A 1+6 Pony 7 Mn
A 1+7 Hunter 9 Mn
A I4.8 TB 10 F
A 1+9 TB 5 F
A 50 Pony 3 Mn
A 51 TB 8 Mn
A 52 Hunter 21+ Mn
A 53 Pony 6 F
A 51+ Pony 10 Mn
A 55 TB k Mn
A 56 Hunter § Mn
A 57 TB 6 Mn
A 58 Pony 20 F
A 59 TB 1+ F
A 60 TB 6 Mn
A 61 Pony 6 F
A 62 TB 1+ Mn
A 63 TB 8 Mn
A 61+ TB 3 Mn
A 65 TB 10 Mn
A 66 Pony 10 F
A 67 TB 6 Mn


























































































































































































































































































































































































































































































































Symptomatic COPD affected horses; Case details, resting respiratory
function measurements, arterial blood gas and pH values.









Horse Breed (kg) Rate/ APpl Volume litres/ litres/
No. Type Age Sex Weight Minute (mm H«) (litres) min. min.
B 1 TB 10 Mn 1*80.0 14 9-0 6.1* 89.0 297.0
B 2 Hunter 8 Mn 452.3 21 9.6 4-4 96-4 280.6B 3 Hunter 15 F 511 .8 14 19.7 6.0 81*.8 360.7B 1* Pony 6 Mn 383.6 16 12-3 4-0 69.9 291*. 5B 5 Hunter 10 Mn 584-1 26 7-0 6-3 169.8 260.8
B 6 Hunter 12 Mn 509.1 13 12.1* 8.2 72.8 233.5
B 7 Hunter 12 Mn 519.1 26 19.5 5.8 140.8 31*6.1
B 8 Hunter 23 F 458.2 10 33-0 8.1* 64.0 31*0.9B 9 H.Hunter 13 Mn 636.7 9 8.2 9-9 89.4 296.3
B 10 H.Hunter 10 Mn 659.1 20 10.1 9.2 186.6 237.2
B 11 Hunter 16 Mn 409.1 16 24-5 k.l* 73-4 195.5
B 12 Hunter 10 Mn 521 .8 8 17.5 3.5 67.0 173-1
B 13 TB 11 M 525-5 12 15.5 7.6 94-2 227-1
B 11* TB 7 Mn 469-3 1i* 12.4 6.3 87.2 219.1*B 15 Hunter 5 F 492.6 18 8.5 5.2 95-3 337.9
B 16 TB 11* Mn 515-7 1 1 14.3 6.9 75-0 191* .o
B 17 TB 12 Mn 529.0 12 19.6 6.0 74-1 302.1*
B 18 TB 8 F 488.2 12 10.5 6.6 78.0 237.1
B 19 Hunter 7 F 526-4 9 12.0 7-2 64-5 177.1*
B 20 Hunter 10 Mn 559.7 12 13.2 5-8 70.6 215.2
B 21 Pony 5 F 354-5 18 10.5 - - -
B 22 TB 9 Mn 509.1 20 23.2 - - -
B 23 Hunter 7 Mn 518.2 18 14.5 - - -
B 21* Hunter 9 Mn 467-7 16 17.0 - - -
B 25 Draught 1£ Mn 636.4 18 13.5 - - -B 26 TB 8 Mn 499.1 9 16.5 - - -
B 27 TB 9 Mn 515.9 9 18.0 - - -
B 28 TB 6 F 462.7 12 26.4 - - -
B 29 TB 9 Mn 500.8 12 15.6 - - -
B 30 Hunter 12 F 486.1* 20 13.5 - - -
B 31 H.Hunter 12 F 520.6 33 33-2 - - -
B 3 2. H.Hunter 7 Mn 608.1 20 26.0 - - -
B 33 TB 11 F 457.3 28 18-4 - - -
B 31* Hunter 7 Mn 534.0 18 20.1 - - -
b 35 TB 8 F 451 -9 12 23-5 - - -
B 36 TB 3 F 459.1 24 11*.0 - - -
B 37 Pony 6 F 1*00.0 20 12.5 - - -
B 38 TB 9 Mn 525.9 19 15.5 - - -
B 39 TB 7 Mn 520-5 28 21 -5 - - -
B 1*0 Hunter 9 Mn 512.2 20 19.0 - - -
B 1*1 Pony 8 Mn 376.9 12 13.5 - - -
B 1*2 Pony 10 Mn 350.9 14 15.0 - - -
B 1*3 Hunter 12 Mn 1*49.8 12 17.4 - - -
B 1*1* Hunter 10 Mn 422.6 16 14.5 - - -
B 1*5 TB 12 Mn 534-0 12 19.5 - - -
B 1*6 Hunter 7 Mn 515.9 14 12.6 - - -
B 1*7 Hunter 9 F 495-5 16 14-S - - -
B 1*8 TB 7 Mn 528.2 18 18.0 - - -
B 1*9 TB 12 Mn 565.6 12 14.s - - -
B 50 TB 7 F 522.7 10 26.1 - - -
B 51 Hunter U F 459.1 24 30.0 - - -
B 52 Hunter 8 Mn 527.3 23 27.0 - - -
B 53 TB 9 F 555- 5 24 20.3 - - -
B 51* Draugh t 7 Mn 620.5 16 12.7 - - -
B 55 Draugh t 8 Mn 650.0 23 10.5 - - -
B 56 Pony 8 F 396.2 18 12.0 - - -
b 57 Hunter 11* Mn 372-7 21 19.5 - - -
B 58 TB 7 Mn 617-2 21 12.2 - - -
B 59 TB 9 Mn 518.2 17 18.4 - - -
B 60 Hunter 7 Mn 536.8 18 14.5 - - -
B 61 Hunter 9 Mn 545-0 20 22.0 - - -
B 62 Hunter 9 F 1*82.1 18 15-3 - - -
B 63 Anglo A*ab 6 M 494-0 24 13.0 - - -
B 61* TB 8 F 532.6 19 26.6 - - -
B 65 TB 7 Mn 534-5 30 22.2 - - -
B 66 H.Hunter 8 Mn 601*.9 20 19.0 - - -
B 67 Hunter 11 Mn 472.3 18 23.6 - - -
B 68 H.Hunter 13 Mn 592.8 24 12.5 - - -
B 69 Hunter 15 F 531 -4 16 1§"1 - - -B 70 Hunter 22 F 1*08.9 16 28.0 - - -
B 71 Pony 5 F 368.2 16 11.1* - - -
B 72 Hunter 9 Mn 1*80.1* 14 18.3 - - -
B 73 TB 7 Mn 580.5 13 8-5 - - -
B 71* TB 7 Mn 485-5 12 12.0 - - -
B 75 HeavyHurter 10 Mn 592.7 22 23.1 - - -
B 76 Hunter 10 Mn 529.1 16 16.6 - - -
B 77 TB 7 Mn 541 .8 14 14.5 - - -
B 78 TB 10 F 420.5 13 13.7 - - -
B 79 Hunter 15 Mn 592-7 18 21 .0 - - -
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B 94 Hunter 11
B 95 Hunter 16
B 96 Hunter 24
B 97 TB 9
B 98 H.Hunter 13









































B131 Fell Pony 13
B132 Pony 25









































































































































































































































































































































































































- - - 72.9 34-5
- - - 69.3 36.2
- - - 74-6 40.7
- - - 77-8 33.0
- - - 67.2 39.2
- - - 73-0 35.1
- - - 76.1 35.9
- - - 65-5 37.2
- - - 70.9 36.0
- - - 70.2 39-9
- - - 72.5 42.1
- - - 68.0 34-3
- - - 68.5 39.7
- - - 65-7 42.4
- - - 73.9 38.4
- - - 64.0 44-8
- - - 73.9 39-5
- - - 62.1 43-9
- - - 7! .6 36.2
- - - 80.7 33-2
- - - 69.7 39-9
- - - 72.5 40.9
- - - 69-3 37-4
- - - 76.9 36.9
- - - 63.O 43.9
- - - 71.2 38.4
- - - 59.7 43-4
- - - 76.3 39.6
- - - 63.1* 40.2
- - - 76.1 37-6
- - - 72.4 39.0
- - - 75.9 38.2
- - - P'2 38.5
- - - 82.9 39.9
- - - 74.1 41.0
- - - 64-4 42.0
- - - 71.0 43.5
- - - 73.° 38.3
- - - 78.6 44-7
- . - 60.9 39.2
- - - 68.5 39.1
- - 78.1 38.5
- - - 82.3 39.0
- - - 62.5 40.5
- - - 61.9 40.0
_ - _ 65.6 41.2
- - - 59.7 41*-5
- - - 61 .0 45-9
- - - 74-6 39.2
- - - 63.8 36.4
_ - - 72.3 37-6
- - - 67-5 42.6
- - - 83.6 30.0
- - - 71 .9 36.1
_ _ - 58.0 35.0
- - - 75.0 34.1
- - - 59.4 44.6
- - - 72.6 37.4
- - - 83.0 34.9
- - - 73.4 38.O
- - - 69.5 43.2
- - - 64-4 47.0
- - - 63.9 44-3
- - . 69.4 38.2
- - - 62.0 41.9
- _ - 72.0 36.3
- _ _ 58.4 42.1
_ _ _ 66.1 34.8
_ _ _ 81 .9 36.1
- _ _ 74.1 38.2
_ _ _ 63-1 46.0
- _ - 62.5 44.6
_ _ _ 82.3 29.7
_ _ _ 76.5 37.8
_ _ _ 76.2 39.0
_ _ _ 79.4 30.3
_ «. _ 70.6 39.0
_ _ _ 68.1 39.2
_ _ _ 73-9 38.4
_ _ _ 64-4 39.2
_ _ _ 74.3 37.5
_ _ _ 60.2 36.1
_ _ _ 77-0 38.2
- - _ 63.0 40.7
20 20 20 20 164 164
6.65 93.11* 261.34 201.90 70.55 39-28

























































































Asymptomatic COPD affected Horses: Resting respiratory function
measurements, arterial blood gas and pH values and time taken to become
asymptomatic in the controlled environment.
* HesDiratorvplr 't ry
X Inspiratory
0 Expiratory
*Resp. Max. Tidal Minute
Horse Rate/ ^Ppl Volume Volume





























































































































































































































































































































































































































































































































































































































































































































































































Pilot in vitro hypersensitivity studies using pulmonary
tissues from normal and COPD affected horses.
INTRODUCTION.
As these ijn vitro studies do not follow the general
pattern of this thesis (i.e. the therapy of equine COPD),
they are presented as an appendix.
In vitro studies on isolated equine pulmonary
tissues have been performed by several workers. Chand
and Eyre (1978) showed that strips of equine tracheal
and bronchial muscle contracted i_n vitro in the presence
of histamine, 5-HT, prostaglandin F^oi, SRS-A, brady-
kinin and carbachol and relaxed in the presence of
isoprenaline, prostaglandin E^ and They also
demonstrated that mepyramine selectively antagonised
contractions to histamine. Earlier, Eyre (1972) had
examined the responses of pulmonary venous strips from
3 COPD affected horses which had positive intradermal
reactions to A_. fumiqatus in vivo. Tissues from 2
of these horses contracted i_n vitro when challenged
with A_. fumiqatus indicating pulmonary vascular hyper¬
sensitivity to this antigen in these animals (a
Schultz-Dale reaction) (Schultz, 1910; Dale, 1913).
Burka e_t a^. , (1976) sensitised 4 normal ponies to
bovine plasma by an initial intravenous injection of
whole bovine plasma followed by a second injection of
bovine plasma in Freund's complete adjuvant, given
224 .
subcutaneously. Subsequently, pulmonary venous
strips from 3 of these same animals contracted in
vitro to bovine plasma, thus these authors also demon¬
strated Schultz-Dale reactions in horses.
The aim of the following pilot studies was to
determine whether a similar phenomenon could be demon¬
strated in the pulmonary tissues of COPD affected
horses upon antigen challenge. Such information could




Pulmonary tissues of 10 confirmed COPD affected
horses were used in these studies (Table 1). All
horses responded positively to M_. faeni inhalation
challenge i_n vivo and were symptomatically affected
with COPD at the time of death.
11 horses which (except for horse No. E8) had no
recent history of respiratory illness, which had no
clinical abnormality of the respiratory system and
which were normal on pulmonary function testing, were
used as controls (Table 2). Horse No. E8 had an
ethmoid haematoma, horses Nos. E1, 3, 7, 9, 10 and 11
suffered various chronic, mainly musculo-skeletal
conditions and animals Nos. E2, 3, 4 and 6 were normal
experimental ponies.
PREPARATION OF TISSUES.
Each horse was killed by an overdose of pentobarbitone
TABLE1.
































































































































sodium given intravenously. The animals were
exanguinated and the lungs were removed within 5 to
10 minutes of death (except for COPD affected horse
No. D5, where there was a delay of 20 to 30 minutes
between death and the excision of pulmonary tissues).
Blocks of pulmonary tissue were rapidly exised and
immediately placed in ice-cold Krebs-Henseleit solution.
Segments of fourth generation bronchi, pulmonary veins
and pulmonary arteries were then cut into spiral strips
approximately 30 x 3 mm. Lung parenchymal strips of
approximately 30 x 3 x 3 mm were taken from the
ventral border of the diaphragmatic lobe using the
technique of Lulich, Mitchell and Sparrow (1976).
Each preparation was mounted in a 50 ml organ bath
(Figure A) and aerated with a mixture of 95?o oxygen
and 5?£ carbon dioxide. The organ baths were maintained
at 37°C. The strips were allowed to equilibrate under
a tension of 3 grams for at least 1 hour. During this
time the Krebs-Henseleit solution in the organ baths
was changed at 15 minute intervals.
Changes in active tone of the tissues were
measured using isometric force transducers (serial no.
4151, Ormed Engineering Ltd., Welwyn Garden City) and
recorded using a hot wire pen system (MX4, Devices Ltd.,
London) (Figure B). Three preparations were run
simultaneously. After each test and washing of the
bath, a 15 minute rest was allowed. Good responses
could usually be obtained for about 8 hours with these
228 .
Figure A. Equine bronchial strips mounted
in 50 ml organ baths.
Figure B. The organ baths and recording





DRUGS, ANTIGEN AND CONTROL SOLUTIONS.
The tissues' responses were tested to: histamine,
5-HT, acetylcholine, carbachol, adrenaline, isopren-
aline, mepyramine, M_. faeni antigen and a control which
consisted of nutrient broth (Oxoid CMI) with 1 %
dextrose. The M_. faeni antigen and the control were
prepared by the Department of Veterinary Pathology,
University of Edinburgh, as described by Lawson, e_t al. r
(1979). The antigen was diluted in saline to a
final concentration of 2.4 mg/ml.
RESULTS.
Histamine, 5-HT, acetylcholine and carbachol
caused contraction in all four tissue types from both
normal and COPD affected horses. Isoprenaline and
adrenaline caused relaxation of all tissues when
partially contracted in response to carbachol.
Typical responses of the horses' bronchial strips to
the above agents are shown in Figure C. In all
tissues, mepyramine (10-^ to 5 x 10"^ M) selectively
antagonised histamine in a dose-dependant fashion.
The nutrient broth control (at doses ranging
from 0.2 to 1.0 ml) failed to cause contraction in any
of the tissues. Doses of nutrient broth control
solution ranging from 1.0 to 2.0 ml caused very slight
Figure C. Responses of bronchial strips from
COPD affected horses in Krebs-Henseleit
solution mixed with 5?o CC^ in at 37°C,
under a resting tension of 3 grams.
Contractions are taken from resting
state. Time markers indicate minutes.
Panel (i) shows contractile responses
of a bronchial strip to histamine
(H), 5-hydroxytryptamine (5-HT),
acetylcholine (ACH) and carbachol
(CARB) and relaxation to isoprenaline
(ISO). Doses are expressed in molar
bath concentration.
Panel (ii). A bronchial strip from a
COPD affected horse showed no response
to increasing concentrations of
nutrient broth control (C) but con¬
tracted on initial exposure to M.
faeni (MF). Repeated IM. faeni
challenge at increased concentrations
produced no further response from
the tissue.
Panel (iii). A bronchial strip from
a COPD affected horse showing re¬






contractions in the bronchial strips and lung paren¬
chymal strips of normal horse No. E6 and COPD affected
horse No. D4 and in the lung parenchymal strip only
of COPD affected horse No. D9. No other tissues from
any other horses contracted to this concentration of
nutrient broth control. All 4 tissues from 8 out
of the 10 COPD affected horses contracted in the
presence of M_. faeni antigen at concentrations of
0.01 to 0.03 mg M_. faeni extract/ml tissue bath
fluid. Increasing the M_. faeni concentration did
not further enhance the strength of contractions in
these tissues. Some tissues only responded to a
single challenge dose whilst other tissues contracted
more than once but rapidly showed tachyphylaxis.
The pulmonary vein and bronchial strips from COPD
affected horse No. D2 showed very weak contractions
to M_. faeni whilst the other two tissues from the
same animal failed to respond at all to antigen
challenge. Tissues from COPD affected horse No. D5
failed to respond to antigen challenge and only
showed weak contractions in the presence of histamine,
5-HT and acetylcholine. In this animal, there was
a delay of 20 to 30 minutes between death and the
excision of the pulmonary tissues which could
possibly have reduced the viability of the tissues,
resulting in poorer i_n vitro responses. Tissues from
2 normal horses, Nos. E6 and E9 showed slight con¬
tractions to M. faeni at concentrations of 0.01 to
232.
Q.03 mg/ml. Increasing the M_. faeni concentration
did not cause contraction in any of the tissues from
the control horses. The contractions to M_. faeni
in tissues from normal horse No. E6 were only
slightly larger in magnitude than those recorded from
the same tissues when tested to the nutrient broth
control.
CONCLUSIONS.
The isolated tissues from the majority of CQPD
affected horses with in_ vivo respiratory hyper¬
sensitivity to M_. faeni contracted i_n vitro when
challenged with that antigen. This indicated in
vitro hypersensitivity of pulmonary vascular and air¬
way tissues in these horses.
APPENDIX5.2.
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notsignificant. P<0.05 P<0.01 P<0.001
notsienifieant P^0.05 P<0.01 P<0.001
APPENDIX5.3.
Effectsofatropineinhalatioons merespiratoryfu ctipa ametersinorm la dCOPD affectedhorses. Respiratoryate(/»ln .) Tineaft rtre tm nt(ml .) 20601202436 16820 18684
AJ4 *35 A36
Statiaticnl differenceafpost treatmentvalues fromrestingvalues. COTO AmXTKD HORSES
3.0 3.0 3.1 4.5
Hex.APpl(ang)
Timeaft rtreat ent(mln.)
10ajoJ20 3.2 3.1 3.0 3.0 4.5 3.0 3.* 3.63.0 2.9 3.5U.1 3.93.5 3.0 3.6 3.0 4.1 2.8 3.6 3.4
3.0 3.0 3.1 3.4 3.5 3.0 3.5

































































































































































































































































































































































































































































































































































































37.1 38.8 39.8 35.0 36.9 38.0 38.5 38.1 37.6 38.5 40.3 38.0






























































































































































































































































Statistical differenceofpoet treatmentv lues fromrentingvalues. copd affected horses Statistical differencefrom comparativevalues innormalhorses.


































































































































































































































































8U.0 90.6 89.7 92.0 91.3 96.0 97.9 94.4
83.0 85.6 86.4 92.8 87.7 95-3 92.1 90.4
7*».S 8u.7 89.7 85.W 85.«» 90.1. 94.4 83.1
86.7 92.1 90.4 90.5 95.0 96.8 96.0 80.1
260 84.9 92.6 95.3 88.0 87.9 90.2 94.9 93-6
Tlaeaftertrsata nt(aln .) -S555T3 ~
33.8 3^.5 33.5 33.4 33.0 32.1 30.2 39.3
35.6.5 35.06. 30.6 33.8 31.3 <•0.5
34.2 33.0 35.2 35.0
35.21.0
34.0 33-5 35-5 34.3
34.2 33.1 54.0 32.9
37.940.5i.o4 .3
260 36.8 35.1 32.7 36.3 35.4 30.7 34.0 37.6





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3*.o5.06 37.66 0 35.05.5
35.5 36> 35.9
6.3.629 2.7*511.68 38.* 36.5 38.5 38.5 3,».2 *1.6 *•1.5 *2.* 1.3.0 1*2.5 36.1. 36.V38.5 36.1. 3«.6 38.6 38.5 1.0.8 1.1.1. 10.2 1.1.9
>8.2 36.0 38.0 35.0 38.3 38.* 39.8 39.0 1.1.0 38.8 37.0 35«*
39.1*968 2.5*.251 53
35.2 35.6 36.5 3*.8 37.0 37.0 *3.2 3*.0 36.66 2.35 35.1 J6.1 37.* 37.9 37.1* 38.5 >8.2 >8.5 *0.0 >8.5 36.5 35.9
3*.1 36.0 36.3 35.0 37.0 36.5 1.1.1. 3*.6 36.36 2.27 38.6 35.9 37.9 37.0 37.5 39.8 *0.8 i*>.1 >8.3 *1.0 36.9 >6.0
37.7838.32 1.177
HeartIfcte(y^lin.) Tineaftertreatm nt(nln.) XL 58






































































































































notsignificant P40.05HS-notaignlfleant P<0.01•-. .05 P<0.001••-P< .01
-P<0.001
APPENDIX5.6.
EffectsofClenbuterol(byintravenousi j cti n)osomrespirato yfunctiparameters inormalandCOPDffectedhors s. BeeplrmtoryIfcte(/nin .)agtAjajg\).
Horae




























































































































































































































































































































































































































































































































































































































































































































































Statistical differencefrom comparatIt*value* innormalhor*ea.




























































































































































































































































































































































EffectsofEtamiphyllinecams ate(bintr venousi je ti n)oso er sp ratoryfu cti n parametersinor alandCOPDaffect dhors s. Reaplrmtoryl^t.Qlia )
Statistical differenceofpost treatmentvalues Bg1 B&* B87
m































































































































































































































notsignificant r<o.05 F<0.01 P<0.001
10.1 17.6 13.8 9.0 23.6 16.0 10.0 12.9 18.3 1*.0 *.J7
Ifc*.APpl(■Hit)






















































































































Tinsaftartrastn nt(al .) 60
6.* 12.1 8.5 7.5 12.2 10.9 7.3 5.2 13.3 8.59 2.9*
5.2 6.0 3.2 5.0 10.1 6.* 3.5 9.5 8.7 *.0 3.0 10.7 6.28
1202*36 86.592 *0.7 82.17.99*.3
































































































































































































Tin.aftartr. tn.nt(s s.) 1020
32.1 3*.3 36.1 36.* *3.0 38.6 3*.1 32.* 3*.5 36.2 *0.7 33.0 39.2 35.1 35-9 37.2 36.0 39.9 *2.1 3*.3
35.7 37.6 3*.2 38.2 *0.* *0.6 36.7.. 31.*3.5
37.0 33.2 3*.1 39.5 *1.3
3.1002 36.0 35.3 38.2 35.0 *0.7 36.9 37.* 35.0 3*.2 *2.* 38.0 36.5











































































































































32.1 37.6 *1.9 3*.7 38.3 36.2 *0.7 3*.1 38.* 36.* 38.2 3*.7
3*.9 38.* *2.0 37.5 *2.5 35.1 36.2 37.6 36.1 39.0 39.9 36.9
35.* 3*.9 37.6 35.0 37.9
37.98.3 36.72.5 37.5*1.7 **.70.6 33-22.0 37.*66 65 2.923.0
33.83 I.flo












































































































































































































































































































































































































































































































































































































































































































38.*»9.64o7 43.62 1.51 8
7.4377 240.4 8. 0126 7.3907. 6287.4006





EffectsofralClenbuteroltreatmentonsor spiratoryfunctiparametersiCOPD affectedhorseshou dint controlledenvironment.
HORSES UNTREATED. HORSES TREATED WITH CLENBUTEROL.
B9J B9* B97 B9* B99 B100
Statistical differencefroa correspondingvalues inuntreatedhomes.
BaspirmtoryRata(/ilns.) to i121
16 16














































































































































































































































































































82.1 89.7 88.1 75.7 88.7 82.3 9*.1 90.2 86.36 5.89
87.1 90.7 72.3 88.9 84.6 90.5 78.4 84.9 6.**
NS
80.9 85.* 86.0 77.7 81.6 78.6 93.6 86.0 83.73 5.15
NS
87.6 92.* 80.5 83.1 90.7 86.* 87.7 83.9 86.5* 3.95
37.5 39.9 38.* **.8 39.5 *3.9 37.9 >^-5 39.55 3.39
39.8 37.5 37.6 *3.0 36.3 39.9 36.3 35.7




37.2 37.6 37.9 39.7 38.* 38.2 35.* 36.5 37.61 1.29 38.3 37.6 37.9 37.5 38.2 39.1 38.2 35.7 37.81 0.99
NS
2


































37.* 36.* 38.* 39.3 35.* 38.5 37.0 38.3
38.5 35.* 39.1 *0.* 36.* *0.1 38.1 36.2
37.598 03 1.2886
36.6 38.O *0.7 38.0 38.9 38.2 37.1 33.0 37.56 2.22
NS
7.*19 7.382 7.*15 7.370 7.*06 7.378 7.*20 7.*30 7.*03 0.023 NS
7.*15 7.*20 7.*12 7.390 7.*38 7.*00 7.*23 7.*30 7.*16 0.016
2112.
7.*28 7.*16 7.*28 7.*01 7.*20 7.*10 7.*35 7.**2 7.*23 0.013
7.*30 7.*26
ArterialpH ^s 2*2.
7.*12. 6.*0927 7.396*08. 20.*2'*/.<»«> 7.*2530216.**5 7.396*01.385* 817 7.*163*.*198*0 7.396*10228 7.*1823*.*39*0 7.**2397 21. 78 7.*13.*21563 0.016*10 7.*20. 3* 7.*2*36 7.*15 7.*12 7.**2 7.*12 7.*20 7.*30 7.*229 0.010.0 97.*22 7.*16 7.*38 7.*19 7.434 7.*35
7.*32 7.*15 7.*30 7.*30 7.*35 7.*22 7.*32 7.*20 7.*27 0.007
7.*270 7.*26.*35 7.*20 7.*087.*39 7.*15 7.*207. 3* 7.*159 7.L38 7.445 7.*25 0.012



















































































































































































7*»«5 78.1 77.1 76.2 68.9 72.1 66.2 72.9
70.2 79.2 71.9 77.3 67.0 7<*.9 68.* 75.6
*Z-
75.* 79.0 70.0 7J.* 72.1 73.2 66.2 81.0





































































































37.6 36.* 36.6 37.2 *0.* 38.9 **.0 39.0
ArterialpH








































































































































































































































































































































37.9 36.7 36.5 38.5 *3.9 39.9 *1.7 38.6
36.5 37.5 37.0 39.7 *1.8 38.2 *2.6 *0.*
37.0 35.8 *0.7 38.0 *0.9 37.5 39.9 39.3
36.3 37.6 38.* 36.* *3.5 39.0 38.5 37.*
2.53.271 85!
7.*22 7.*25 7.*16 7.*12 7.396 7.*2* 7.385 7.*09 7.*11 0.01*
7.*28 7.*31 7.*28 7.*16 7.390 7.*25 7.390 7.*19 7.*16 0.017
7.*39 7.*25
7.*20 7.**6
7.*205 7.*1228 7.388 7.*0' 7.*12
7.385 7.*10 7.390
7.*2819 7.*3228 7.*180 7.*20. 36 7.*01 7.*15 7.398 7.*08
7.392 7.*27 7.*01 7.*1*
7.*135 0.01620
7.*15.*16 0.01215






























































































































































































18.1 11.5 15.5 14.4 25.2 17.5 20.5 10.V 16.64 4.82 16.4 11.0 13.1 17.6 26.5 19.0 18.2 13.6 16.93 4.77





































































5.2 3.3 7.5 9.5 9.4 12.5 10.9 7.5 8.23 3.00
MS
3.1 3.5 4.5 5.5 4.0 5.5 6.5 5.5 4.67 1.17
3.4 3.2 3.5 5.6 3.5 5.5 5.8 3.1 4.20 1.20
3.7 3.5 3.1 5.2 4.5 5.5 5.5 5.0 4.50 0.95
3.5 4.1 3.5 4.9 4.8 4.1 4.0 5.5 4.30 0.71
0
69.7 72.5 69.3 76.9 63.0 71.2 59.7 76.3
72.6 79.3 75.7 79.8 69.7 79.0 68.5 80.6
69.8375.6579 31 5.984.812.86
80.4 84.5 80.9 79.5 74.6 78.6 77.6 78.4
72.6 78.9 72.0 69.0 62.9 64.9 61.2 74.5 69.50 6.13
80.3 84.0 75.1 70.1 72.6 70.9 70.9 74.0
85.1 87.6 78.2 75.4 79.9 72.6 74.6 79.3
fc^s
2
85.4 86.0 81.2 87.0 76.0 76.5 70.4 90.4 81.5 6.7 89.381.5 82.0 82.3 88.0 82.9 80.2 87.3 84.19 3.45
2
82.7 93.2 86.9 90.1 80.9 84.5 75.9 88.2 85.3 5.50
86.2 85.9 85.9 84.6 95.3 77.3 94.1 87.43 5.74
14
96.3 79.5 88.2 92.7 87.8 89.2 86.0 90.7 88.66 5.00
90.1 90.7 87.5 84.5 94.5 84.9 75.3 92.1 87.45 6.00
94.5 82.6 93.6 86.0 90.7 76.4 81.9 84.0 86.21 6.28
92.7 92.8 85.9 85.3 87.1 85.9 87.93 3.04
39-9 40.9 37.4 36.9 43.9 38.4 43.4 39.6 40.05 2.58 38.3 38.0 36.2 39.5 38.6 40.6 40.2 39.0






































































































36.3 39.2 37.1 38.6 37.2 39.9 37.3 <♦1.5
34.3 40.4 36.4 39.9 36.4 40.7 38.6 37.5
36.4 37.3 39.7 38.9 37.2 38.7 40.1 36.4
36.1 36.9 37.0 40.9 37.5 40.4 39.2 42.0
35.5 37.4 38.4 39.5 38.9 38.7 40.2 38.6
38.840.01390754 1.38742 2.451 3
7.410 7.415 7.405 7.401 7.381 7.402 7.400 7.420 7.404 0.012
7.412 7.443 7.425 7.398 7.398 7.392 7.396 7.420 7.411 0.018
7 7.441 7.426 7.435 7.418 7.410 7.436 7.400 7.419 7.423 0.014
7.43440 7.421. 09 7.420 7.405 7.410 7.402
921ill 7.446420 7.4307. 4 6 7.43082 7.425227 38 7.425287 36 7.440638 7.41707. 06 7.4223930 7.4293332 0.010. 20 1
7.434 7.416
7.4086 7.404. 09 7.410 7.425 7.4139 0.010. 13
7.432 7.426 7.413 7.420 7.415 7.412 7.408 7.436 7.420 0.010
7.445 7.445 7.428 7.418 7.434 7.415 7.420 7.400





Respiratoryfunctionparametersrecord droCOPDaffecthors sb rnft1 sodiumcr moqlycatetreat ent(G p1). ChallengeenvironmentControlledenvironmentChallengeenviro mentafter NodrugtreatmentNodrugtreatmentsodiumcr moglycatetreat ent.
Endof
trial
































































































































































































































Challengeenviro m nt,ndrutreatment-M nvaluescord daft r2*+hou sinch lle genvironment. Controlledenvironment,ndrugtreatment-M anvaluesreco d dwheho s sclinicallyasymptoma ic. Challengeenvironmentaftersodiucromoglycattreat ent-Mev lu sre rd donc mpositefday1nd2yintervalsthrough uteachho se'sp riodfpro ecti n Endoftrial-Me nvaluesrecordtthenofsodiumcromogly atepr t ctivepe i .
APPENDIX8.2.
















































































































































































































































































































































































































































































































Challengeenvironment,ndrugtre tme t-M aval esrecord dft r2khourichallen ment. Controlledenvironment,drugtrea me t-M avalu sr c dewh nh sereclinicallyasymptom tic. Challengeenviro mentaftersodiumcromoglycatetre t n-Meaval sr c rd dc mposifd y23yint valt r ughoutachho se'pe odfp ecti n. Endoftrial-Me nvaluesr cordedthndft so iumcr moglycateprotectiveriod.
APPENDIX8.3.
Respiratoryfunctionparametersr cordedfroCOPDaffe edhors sbef rea dftsodiumcr moqlyc tetreat¬ mento3successiveday(Gr up). ChallengeenvironmentControlledenvironmentChallengeenviro mentfter NodrugtreatmentNodrugtreatmentsodiumcromoglycatetreat ent
Endof
trial






































































































































































































































































































































































Challengeenvironment,ndrutreatm t-M nv lu sr cordedaf e2bhou sinchallengenvironme t. Controlledenvironment,drugtreatme t-M anv luesr cord dwhho s seclinical yasymptoma ic. Challengeenviro mentftersodiucromoglycatetreat t-Me nv lu sr c r doc mp sitefdayt2nd3yinte sthroughoue chhors 'p i dfprot c ion. Endoftrial-Meanvaluesrec rdedttheenoft s diumcromoglycatepr ectiveperi d.
APPENDIX8.4.



























































































































































































































Challengeenvironment,ndrutreatme t-M av u srecordedaft r2khoursich llengenvironm nt. Controlledenvironment,drugtrea me t-Meav luesr co d dwhenhorscli ica lyasymptoma i . Challengeenvironmentaftersodiumcr moglycatetreat-Meav lu srecord doc mpositeday2n3interthroughoute chhors 'sp ri dfr t cti n. Endoftrial-Me nvaluesrecordedattheeofsodiumcr moglycateprotect vepe i d.
APPENDIX9.1.






















































































































































































































































































































































































































































































































































































































































Statisticaldifference ofvaluesrecorded duringtherialf om baselinevalues(Ehy0). Statisticaldifference fromcorrespondingvaluesNS inuntreatedhorses.
=notsignificant =P<0.05 nP<0.01 P<0.001
APPENDIX9.2.
Prophylacticeffe sfintermittentsodiumcro oq ycatetreat nnP ?ndC02iCOPDaff ct dho es housedinthaturalch llengeenvironment.
HORSES UNTREATED.
Horse Number B117 B121 B126 B130 B140 B154* B162 B163
PaO^(mmHg).
88.9 84.9 92.1 87.0 84.6 89.5 88.if 92.7
80.7 77.0 80.9 80.6 72.9 82.1 82.1 84.6
80.9 74.3 76.5 78.2 68.0 72.5 78.2 83.0
78.1+ 70.6 72.4 72.5 65.4 78.9 74.0 77.2
7 76.7 73.1 70.9 70.6 62.0 68.4 78.1 74.1
2 80.5 75.5 72.1 74.1 66.3 73.5 75.5 78.5
II 72.1 71.9 67.5 72.0 65.4 70.6 76.2 79.0
14. 73.0 66.0 68.3 66.4 59.7 76.1 75.0 79.0
16 75.4 61.3 64.1 69.7 62.3 70.9 69.4 74.1
18 79.5 60.7 66.6 67.3 64.5 68.4 73.0 70.7
21 72.5 64.5 62.5 75.0 66.1 74.3 74.1 75.3
22 68.1 64.0 63.O 70.8 60.8 69.5 76.0 70.9
22 70.7 68.1 68.5 73.1 61.9 66.1 71.9 72.1
Statisticaldifference ofvaluesrecorded duringtherialfrom baselinevalues(Eay0). Statisticaldifference fromcorrespondingvaluesNS inuntreatedhorses.










































































































































































































36.1 37.6 33.5 35.3 36.3 38.4 37.6 33.1
Pa002(mmHg) Cays
37.5 37.8 35.7 37.5 37.0 37.3 38.2 35.7





































































































































1.930. 276 38.97.69 06 4O. 2514 3 36.77.1O8.524 6035 7 39.3 38.7 37.0 35.4 44.0 38.6 38.58 2.5739.2 37.6 37.6 37.8 37.9 37.539.0 39.3 35.7 36.0 37.6 35.337.3 37.5 37.8 38.4 37.9 37.038.4 36.6 40.0 35.2 39.8 36.536.1 37.4 37.5 36.9 38.4 38.1 37.79.3660 0.621. 1737.5905 1.69.2138.5 36.3 39.9 34.5 38.4 39.0 37.48 1.8038.9 35.5 40.7 32.7 37.2 39.1 37.55 2.4837.3 37.6 38.6 36.9 27.1 27.6 34.44 4.5539.6 36.1 36.5 35.4 30.9 33.3 35.61 2.61
37.8 37.8 40.7 39.7 36.7 32.2
38.0 36.8 43.4 36.3 33.5 33.4
38.7 37.7 36.4 37.6 31.9 30.1
38.856.801 2.783 1229
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Short Communication
THE EFFECTS OF SODIUM CROMOGLYCATE OK ANTIGEN INHALATION CHALLENGE IN TWO HORSES
AFFECTED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
JILL R. MUREHY, E.A. McPHERSON and G.H.K. LAWSON
Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh
(Great Britain)
(Accepted 9 August 1979)
ABSTRACT
Murphy, J.R., McPherson, E.A. and Lawson, G.H.K., 1979. The effects of sodium
cromoglycate on antigen inhalation challenge in two horses affected with chronic
obstructive pulmonary disease (COPD). Vet. Immunol. Immunopathol., 1: 89-95.
80 mg sodium cromoglycate (SCG) was administered by inhalation to two COPD-
affected animals known to have respiratory hypersensitivity to Micropolyspora faeni.
SCG treatment 20-30 minutes prior to inhalation challenge with M. faeni prevented
exacerbation of respiratory disease, usually seen 1+-8 hours after challenge. The
duration of protection against antigen challenge after a single SCG treatment was
h-% days. The duration of protection was not prolonged by reducing the frequency
of antigen challenge. Multiple antigen challenge, using M. faeni and Aspergillus
fumigatus, shortened the protective period of SCG to 3 days.
INTRODUCTION
Horses affected with COPD (heaves) show respiratory hypersensitivity to inhaled
antigens, e.g. Micropolyspora faeni and Aspergillus fumigatus, in the form of a
delayed response at I4—8 hours after challenge (McPherson et al., 1979)- Inhaled
sodium cromoglycate (SCG) is widely used in the prophylaxis of human bronchial
asthma and it inhibits both immediate and delayed asthmatic reactions to inhaled
allergens in allergic subjects (Altounyan, 1967; Pepys, 1968). It is believed
to act by maintaining membrane stability, so inhibiting degranulation of sensitised
pulmonary mast cells after exposure to the antigen and thus preventing release of
the pharmacological mediators which cause constriction of smooth muscle in the
airways.
The pathogenesis of COPD in the horse is not completely understood but airway
spasm is known to be involved (Murphy et al., 1979)- The role of mast cells in
this disease has not been established, but mast cell hyperplasia has been noted
in COPD-affected animals (Nicholls, 1978).





Two animals, horse A, an 8-year-old hunter gelding, and horse B, a lL|.-year-old
hunter mare, were diagnosed as being affected with COPD according to the criteria
of McPherson et al. (1978). Horse A showed respiratory hypex'sensitivity to M. faeni
and A. fumigatus, whilst horse B was hypersensitive to M. faeni only. To minimise
exposure to organic dust antigens, the horses were bedded on peat moss and fed only
on proprietary Horse and Pony Cubes (Spillers Ltd., Liverpool, U.K.).
Techniques
Treatment. Nebulised Sodium Cromoglycate B.P. 1% w/v solution (Pisons Ltd.,
Loughborough, U.K.) was administered via a mask which covered the horse's mouth and
nose. 80 mg SCG was administered as a single dose.
Antigen inhalation challenge. M. faeni and A. fumigatus antigens were prepared
according to the technique of Lawson et al. (1979)- The challenge dose of both
antigens was 12 mg suspended in $ ml normal saline. Nebulised antigens were
administered over a period of 20 minutes.
The horses' maximum change in intrathoracic pressure (max. A Ppl), arterial
oxygen partial pressure (PaO^) and clinical state were determined prior to
antigen inhalation. Clinical observations were made hourly thereafter and
monitoring of the max. A Ppl and PaO^ were repeated $ hours after inhalation.
The following max. A Ppl values were taken as indicating a positive response;
where pre-exposure value was <6 mmHg and increased after antigen challenge to
>6 mmHg (the value delineating affected animals) or where pre-exposure max. A Ppl
was already >6 mmHg, an increase of 1%% in this figure was considered to indicate
a positive reaction (McPherson et al., 1979)- Max. A Ppl was measured using an
intra-oesophageal balloon (McPherson et al., 1978) and PaOg was determined on a
Coming pH/blood gas 161 analyser (Corning Medical, Halstead, Essex) from
carotid samples.
To establish the mean response of each horse to antigen inhalation, horses
A and B were challenged with M. faeni on three occasions and horse A was also
challenged with A. fumigatus on three occasions prior to commencing trials.
Trials
The horses were in the remission stage of this disease (showing no signs of
COPD, max. A Ppl <6 mmHg and PaO^ >82 mmHg) at the start of all trials unless
otherwise stated.
Trial 1: 80 mg SCG was administered 20-30 minutes prior to the M. faeni
challenge of both horses on four occasions and the response monitored as previously
described. Both horses were in the remission stage at the start of three
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treatments and were symptomatic on the remaining occasion.
Trial 2: The duration of protection provided by a single SCG treatment in
horses A and B against repeated M. faeni challenge was tested as follows:
a) The horses were treated and challenged as in Trial 1 and thereafter were subject
to daily antigen challenge until a positive response was recorded.
b) Horses received SCG treatment on day 1 and were challenged on days 2 and 1|.
c) Antigen challenge was applied only at the end of the protective period as
established in (a), on day 1). for horse A and days U and 3 for horse B.
Trial J: The effects of multiple antigen challenge on the duration of protection
provided by a single SCG treatment was tested in horse A, using M. faeni and
A. fumigatus challenges on alternate days.
a) SCG was administered on day 1 and the horse challenged with M. faeni. On day 2,
the horse was challenged with A. fumigatus and on day 3 with M. faeni.
b) The trial took the same form as (a) except that A. fumigatus was administered
on days 1 and 3 and M. faeni on day 2.
RESULTS
The effect on the max. A Ppl and PaOj in horses A and B challenged by M.faeni
inhalation and in horse A challenged by A. fumigatus is shown in Table I. The
horses were not always in an identical disease state at the time of antigen
challenge and this accounts for the wide range of max. A Ppl values for horse A
before and after A. fumigatus challenge. There was a mean increase of 7 mmHg in
max. A Ppl after antigen challenge, which constituted a good positive response
being well in excess of the required 13% increase.
Changes in PaOg values were less consistent. Mean PaOg levels decreased after
antigen challenge, but wide variation occurred. Both animals showed a double
expiratory effort and increased harsh, inspiratory chest sounds at $ hours after
antigen challenge, in contrast with the absence of these signs before challenge.
Trial 1: SCG inhalation did not induce any clinical max. A Ppl or PaOj changes
in either animal within 30 minutes of treatment, whether animals were symptomatic
or in remission. Table II shows the mean max. A Ppl and PaOg values at rest (after
SCG treatment and prior to antigen challenge) and 3 hours after antigen challenge,
in the trials where animals were asymptomatic prior to challenge. In contrast to
the findings in Table I, little change was recorded in max. A Ppl values in either
horse, with the mean values at $ hours after challenge being <6 mmHg. PaOg changes
recorded after challenge were very slight. The horses were not dyspnoeic after
challenge and there was no evidence of double expiratory effort or increased
breathing sounds.
When symptomatic at the commencement of the trial, horse A showed no increase
in max. A Ppl after antigen challenge and a PaOg decrease of 1+.2 mmHg, whilst in
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TABLE I
Maximum change in intrathoracic pressures (max. A Ppl) and arterial oxygen partial
pressures (PaC^)- Mean values and standard deviation before and $ hours after







M. faeni A. fumigatus M. faeni
3 3 3










































d = mean difference between pre- and post-challenge values
TABLE II
Maximum change in intrathoracic pressures (max. A Ppl) and arterial oxygen partial
pressures (PaOp). Mean values and standard deviation before and $ hours after





































d = mean difference between pre- and post-challenge values
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horse B max. A Ppl increased from 6 mmHg to 7 mmHg with a PaO^ increase of 3-2 mmHg.
Trial 2: Horses A and B, challenged daily with M. faeni antigen inhalation did
not show a positive response until days 1; and 3 respectively after SCG treatment.
Table III shows the daily pre- and post-challenge max. A Ppl and PaOj values. In
horse A on day 5> the pre-exposure max. A Ppl value was elevated, PaOg depressed
and the horse showing clinical signs of COPD. This was possibly a result of the
positive response to challenge on day if. This reaction was intensified by antigen
challenge on day 5-
TABLE III
Maximum change in intrathoracic pressures (max. A Ppl) and arterial oxygen partial
pressures (PaOg) in two COPD-affected horses treated with sodium cromoglycate (SCG)
followed by daily M. faeni inhalation challenge. Mean values and standard deviation
before and $ hours after M. faeni inhalation on days 1-3
Horse
No. of exposures 5 5
max. A Ppl (mmHg)
Days 1-3 3.67 - 1-55 3.50 - 0.5
Day i| 3-5 3-5
Day 5 9.0 k-0
Rest
Days 1-3 85-50 ± 1.55 87.37 ± 1.07
Pa02 (mmHg) Day k 86.7 88.9
- Day 5 72.if 8b-9
r- Days 1-3 3.83 t 0.58 3.16 ± 0.29
5 hours
max. A Ppl (mmHg) Day k 10.0 U-5
Day 5 1lt-5 9-5
post-challenge
Days 1-3 85.77 - 3-93 89.27 - 3.89
Pa02 (mmHg) Day If 80.it 90.itL Day 5 70.6 80.6
When the frequency of M. faeni inhalation challenge was reduced to days 2 and it
after SCG treatment, both horses showed a positive response to challenge on day ij..
A single antigen challenge on day it after SCG treatment induced a positive
response in horse A, but not in horse B. A second challenge on day 5 produced a
positive response in horse B.
Trial 3' The duration of protection after SCG treatment in horse A was shorter
in the face of multiple antigen challenge. In trials 3 (a) and (b) this animal showed
an increase in max. & Ppl of 2 and 2.5 mmHg respectively on day 2; the post-
challenge value, however, was <6 mmHg. On day 3> max. A Ppl increased by 5-5
and 7-5 mmHg respectively and showed clinical signs of COPD.
DISCTJSSIOH
These antigen inhalation studies in two COPD-affected animals showed that the
usual response to challenge can be prevented by prior treatment with SCG. This
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protection was most efficient when horses were in the remission stage of the disease,
but when horses were symptomatic SCG prevented the intensification of the disease
after challenge. SCG inhalation in symptomatic animals did not produce any apparent
clinical improvement, this being similar to the findings in man (Cox, 1969)-
The findings showed that the duration of protection after a single SCG dose was
much longer than in human asthmatics where SCG inhibits antigen-induced broncho-
constriction at 3 hours but not at 21+ hours after treatment (Kolotkin et al., 1973)-
The reason for the prolonged protection in horses may be due to differences in the
pathogenesis of these diseases or to differences in the cellular physiology in the
horse.
The duration of SCG protection in the horse does not appear to be related to the
frequency of challenge with a single antigen but multiple antigen challenge does
shorten the protective period. The response is different in man, where protection
occurs when the same antigen is used sequentially and not when a dissimilar antigen
is introduced 9 hours after SCG treatment (Kolotkin et al., 1973)-
Although these trials were performed on only two horses, they suggest that SCG
may prove effective in controlling COPD in horses. A clinical trial to evaluate
the efficacy of SCG on a larger number of affected horses is currently in progress.
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Chronic obstructive pulmonary disease (COPD):
Effects of bronchodilator drugs on normal
and affected horses
JILL R. MURPHY, E. A. McPHERSON and P. M. DIXON
University of Edinburgh Veterinary Field Station, Easter Bush, Roslin, Midlothian EH25 9RG
Summary
The effects of the bronchodilator drugs, atropine, isoprenaline
and terbutaline, on normal horses and on horses affected with
chronic obstructive pulmonary disease (COPD), were assessed
by pulmonary function tests and clinical examination. Normal
horses were not affected but COPD horses responded by a
marked decrease in intrathoracic pressure, a decrease in
respiratory rate, an initial decrease followed by an increase
in arterial oxygen partial pressure and clinical improvement
after treatment with all 3 drugs. These changes were temporary.
Introduction
CHRONIC obstructive pulmonary disease (COPD) in horses
is associated with exposure to hay and straw containing
moulds, including Micropolysporct faeni and Aspergillus
fumigatus (McPherson et a/ 1979). The condition is usually
reversed when affected horses are kept at grass or in a dust-
free environment (Thurlbeck and Lowell 1964; Eyre 1972;
Cook 1976; McPherson et aI 1979). In the past, the disease
was widely believed to be irreversible and was erroneously
likened to alveolar emphysema in man, but recent studies
have shown that, in fact, bronchiolitis is the major patho¬
logical feature of the disease, with emphysema being absent
or confined to small areas of the lung (Nicholls 1978).
Additionally, a number of authors have postulated that
bronchospasm also plays a role in the pathogenesis of
COPD (Alegren and Carlstrom 1940; Obel and Schmitterlow
1948; Cook and Rossdale 1963; Lowell 1964; Eyre 1972;
Gerber 1973; McPherson and Lawson 1974; Cook 1976).
Bronchodilator drugs, including the parasympatholytic drug,
atropine, have been found to induce temporary relief of
clinical dyspnoea (Obel and Schmitterlow 1948; Lowell
1964; Muylle and Oyaert 1973; Sasse and Hajer 1977).
Clinical improvement has also been reported in COPD
affected horses with the use of sympathomimetic broncho-
dilators, including adrenaline, noradrenaline, scopolamine
hydrobromide and NAB 365 (Boehringer Sohn, Ingleheim,
BRD) (Obel and Schmitterlow 1948; Schatzmann, Straub
and Gerber 1972; Sasse and Hajer 1977; Corbella 1978).
However, Corbella (1978) reported only slight and tran¬
sitory clinical improvement following treatment of COPD
affected animals with the sympathomimetic drugs, ephedrine,
orciprenaline and salbutamol.
Many of these studies have been carried out on animals
diagnosed as suffering from COPD on clinical grounds only
and the response to treatment assessed by clinical obser¬
vation alone. This paper describes some studies on the effect
of 3 bronchodilator drugs, namely atropine (a parasym¬
patholytic drug), isoprenaline and terbutaline (both sympa¬
thomimetics) on some pulmonary functions and clinical
parameters in normal and COPD affected horses.
Materials and methods
Animals
COPD affected horses often coughed, were dyspnoeic,
manifested a double expiratory effect and had harsh chest
sounds, including wheezing and crepitant sounds in some
cases (McPherson et aI 1978). Additionally, all horses showed
maximum intrathoracic pressure changes (max a Ppl) of
Tss 6 mm Hg and resting arterial oxygen partial pressures
(Pa02) of 82 mm Hg. Most of the 37 COPD affected
horses were adult hunters and Thoroughbreds; a few were
ponies and draught horses. The controls consisted of 20
horses of similar breeds which had no history of chronic
respiratory illness and were normal on clinical and pulmonary
function examinations.
Monitoring techniques
During all measurements the animals were standing, un-
tranquillised and were handled quietly to prevent any excite¬
ment-induced respiratory or cardiac changes. Intrathoracic
pressures including maximum expiratory, minimum in¬
spiratory and maximum intrathoracic pressure changes (max
a Ppl) were measured using an intra-oesophageal balloon
(McPherson et aI 1978). These values were estimated from
the mean of 10 consecutive and representative respiratory
tracings. Intrathoracic pressures were monitored at rest for
10 min to establish baseline values, for 30 min after drug
administration and, thereafter at hourly intervals until the
effects of the drug disappeared. Respiratory rates were
measured from the intrathoracic pressure tracing.
Carotid arterial blood samples, for PaC>2 and carbon dio¬
xide partial pressure (PaCC>2) respectively estimations, were
collected using a previously described technique (McPherson
et al 1978). Samples were obtained at rest and at 10, 20, 30
60, 120 and 240 min after treatment and stored in iced water
until analysed, within 1 hour after sampling. Blood gas
estimations were carried out using a Corning pH/blood gas
161 analyser (Corning Medical, Halstead, Essex). The equip¬
ment was standardised according to manufacturer's specifi¬
cations and the error for both PaCG and PaC02 estimations
using this technique is reported to be less than 2 per cent.
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Fig 2. Effect of bronchodilator drugs on intrathoracic pressure
COPD affected and normaI horses.
Drugs and administration
Atropine sulphate (Macfarlane Smith Ltd, Edinburgh),
isoprenaline sulphate (Thornton & Ross Ltd, Huddersfield)
and terbutaline (Bricanyl respira tor solution, Astra Chemicals
Ltd, Watford) were administered by inhalation. Dosage levels
which would provide the maximum therapeutic effect without
severe side effects were established by previous pilot experi¬
ments. For all drugs, a dose of 0.02 mg/kg was found suit¬
able. For inhalation administration, drugs were dissolved
with saline to a total volume of 4 ml, to standardise the time
taken for drug nebulisation. The drugs were nebulised using
2 Wright's nebuliser pumps and were administered via plastic
tubing to a face mask (Fig 1). Nebulisation took 7 min.
Atropine sulphate (Birneda UK Ltd, Liverpool) was also
administered by intravenous injection over a 2 min period.
Statistical analysis of results
In normal and COPD affected horses, resting parameters
were compared with parameters obtained at various intervals
after drug administration by Student's t test as applied to
paired observations. Max a Ppl and Pa02 values of normal
and COPD affected animals were compared at rest and at
the time of peak response in COPD affected horses by
Student's t test.
Results
Atropine by inhalation and intravenous injection was
found to cause identical changes in all parameters except
heart rate.
Intrathoracic pressure changes
Max a Ppl decreased significantly (P <0.001) in COPD
affected horses after administration of all 3 drugs. Max a
Ppl was reduced by a mean of 72 per cent, 63 per cent and
68 per cent at the time of peak response to isoprenaline,
terbutaline and atropine respectively, (Fig 2). The intra¬
thoracic pressure decreases remained significant for 30 min
following isoprenaline, 1 to 2 hours following atropine, and
for 4 hours following terbutaline administration. Despite the
large decreases in max a Ppl after all drugs, max a Ppl of
COPD affected horses at times of maximum response still
remained significantly different (P<0.01) from that of the
resting control horses. No significant max a Ppl changes
were recorded in the normal animals.
Respiratory rate
Horses affected with COPD showed a decrease in respira¬
tory rate after drug administration with the maximum
response occurring 20 to 30 min after treatment (Fig 3). No
significant changes in respiratory rate occurred in control
animals.
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Fig 3. Effect of bronchodilator drugs on respiratory rate in COPD
affected and normal horses.
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Fig 4. Effect of bronchodilator drugs on PaO„in normal and COPD
affected horses.
Blood gases
The effects of the bronchodilator drugs on PaC>2 levels in
COPD affected and normal horses are shown in Fig 4. All
drugs caused a temporary drop in Pa02 levels in both
COPD affected and normal horses which was followed by
a significant increase in Pa02 to above resting levels in
COPD affected horses (5, 9.5 and 6.5 mm Hg after iso¬
prenaline, terbutaline, atropine by inhalation and atropine
by intravenous injection, respectively). However, Pa02 levels
of COPD affected horses remained significantly lower than
those of resting control horses, at all times after drug
administration (PcO.Ol). COPD affected horses showed a
slight decrease (2-3 mm Hg) in PaC02 levels from 1 to 4
hours after treatment, corresponding to the times at which
increased Pa02 levels occurred. No significant PaC02
changes were recorded in the control animals.
Heart rate
Within 10 to 20 minutes of intravenous atropine and
isoprenaline inhalation, the heart rate increased twofold in
both COPD and normal horses. A slight transient increase
in heart rate (~ 48/min) was recorded at 10 to 20 min after
inhalation of atropine and terbutaline.
Clinical observations
After drug administration, COPD affected horses showed
a temporary reduction in their expiratory effort, dyspnoea
and flaring of the nostrils. All drugs alleviated wheezing
chest sounds in affected animals. Clinical improvement
persisted for 1 to 2 hours following isoprenaline and atropine
and for 2 to 6 hours following terbutaline treatment. Atropine
administration caused mydriasis in all animals which persisted
for 12 to 24 hours. The control animals showed no other
clinical changes.
Discussion
Isoprenaline is a sympathomimetic drug which stimulates
both 13 j (or cardiac receptors) and 62 (or smooth muscle
receptors) causing cardiac stimulation and bronchial muscle
relaxation. Terbutaline is a sympathomimetic drug which
exhibits selectivity for B2 receptors, thereby causing broncho-
dilation with little or no cardiac stimulation. Isoprenaline
has been used for many years for the treatment of human
bronchial asthma, but recently its use has been superseded
by the more selective (32 stimulating agents (Formgren 1977).
The effects of isoprenaline were rapid in onset and marked
but of short duration (ie, 1-2 hours) (Fig 2), because iso¬
prenaline is rapidly metabolised by catechol-o-methyltrans-
ferase (COMT) (Hertting 1964). Terbutaline, in which the
catechol nucleus of isoprenaline has been replaced by a
resorcinol nucleus, is not a substrate for COMT and con¬
sequently, is longer acting. Although the decrease in max
a Ppl with terbutaline was not as great as with isoprenaline,
terbutaline's action was more prolonged with max a Ppl
significantly decreased for 6 hours.
Atropine administration by either route produced a similar
degree and duration of response but the peak response to
inhalation occurred approximately 7 min later than after
intravenous injection.
Intrathoracic pressure measurement was one of the main
parameters used to assess pulmonary function in these
experiments. Max a Ppl measurements have been shown to
be increased in COPD affected horses (Gillespie, Tyler and
Eberly 1966; Sasse 1971; Muylle and Oyaert 1973; McPherson
et al 1978) indicating the presence of airway obstruction in
this disease.
In these experiments max a Ppl was found to decrease
greatly after all drugs. While this max a Ppl decrease could
most obviously be attributed to a direct bronchodilating
action, some other factors have also to be considered (ie,
a marked decrease in respiratory rate was also recorded)
which could have contributed to this max a Ppl decrease;
it is also possible that a decrease in tidal volume could have
caused a decrease in max a Ppl. However, Muylle and
Oyaert (1973) failed to demonstrate any significant changes
in tidal volume in COPD affected horses after intravenous
atropine administration. Additionally, atropine could have
decreased airway resistance by decreasing excess airway
secretions. Because the secretions are not removed, but
merely become more viscous in nature and because of the
similar max a Ppl response in COPD affected animals to
isoprenaline and terbutaline which do not have a drying
effect on secretions, it is unlikely that this phenomenon
contributed significantly to the decrease in max a Ppl after
atropine administration.
After treatment with all drugs, the COPD affected horses
showed a significant increase in Pa02 levels and marked
clinical improvement, corresponding with the time that the
decrease in max a Ppl and respiratory rate occurred. It
appears probable that this rapid improvement in pulmonary
efficiency which was associated with a decrease in the work
of respiration was, in fact, due to a functional decrease in
airway resistance (ie, bronchodilation) induced by the drug
administration. In contrast, no such response was observed
in control horses and so these results suggest that broncho-
spasm is involved in the pathogenesis of equine COPD.
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Furthermore, an increase in max a Pp] has been recorded
in asymptomatic COPD affected animals within 2 hours of
inhalation antigen challenge (Murphy and McPherson,
personal observation) which suggests the involvement of a
type I hypersensitivity reaction (bronchospasm) in this
disease.
Despite the marked decrease in max a Ppl in COPD horses
after bronchodilator administration, their max a Ppl and
Pa02 values still remained significantly different from those
of the control horses indicating that their airway obstruction
was not fully alleviated. This residual airway obstruction is
undoubtedly due to the previously noted anatomical changes
of COPD (ie, exudative bronchiolitis) (Nicholls 1978).
The effects of bronchodilator therapy on arterial blood gas
tensions in horses affected with COPD have not been
previously reported. The initial drop in Pa02 levels in both
normal and COPD animals occurred, without a simultaneous
increase in PaC02 levels. De Moor (1968) also noted a
transitory hypoxaemia in normal horses after intravenous
atropine and hypoxaemia had been found to increase in
human bronchial asthma patients after treatment with
isoprenaline or atropine (Knudson and Constantine 1967;
Field 1967; Ingram, Krumpe, Duffell and Maniscalco 1970;
Chick, Nicholson and Johnson 1973). This fall in Pa02 is
generally thought to be caused by an intensification of the
pre-existing ventilation-perfusion inequality, induced by these
drugs (Field 1967; West 1976).
The dual action of isoprenaline on both 131 and 62 recep¬
tors is disadvantageous in that bronchodilation is usually
accompanied by tachycardia as was observed by us in both
normal and COPD affected horses. Although terbutaline
exhibits a useful degree of selectivity for B2 adrenoreceptors,
the increased heart rates noted in our horses indicates that
terbutaline even in clinical doses exerts significant 13, receptor
activity in the horse. During pilot experiments using terbut¬
aline at doses of 0.04 mg/kg and above, increases in heart
rate to 60/min occurred, accompanied by sweating and
muscular tremor in many cases. Similar results were observed
following administration of isoprenaline at higher dosage
rates. The short duration of action of isoprenaline and its
undesirable cardiac effects preclude its use as a therapeutic
agent in the horse. Atropine, also, produces a tachycardia
and causes increased viscosity of bronchial secretions,
reduced bowel motility and mydriasis and so it is unsuitable
as a long-term therapeutic agent. Terbutaline and other B2
sympathomimetic drugs with their prolonged selective activity
may prove to be of value in the symptomatic treatment of
COPD in the horse, particularly if oral preparations prove
effective.
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Resume
Les effets d'agents bronchodilateurs tels que l'atropine,
l'isoprenaline et la terbutaline sur des chevaux normaux et
sur des chevaux atteints de maiadie pulmonaire chronique
obstructive, ont ete apprecies par des examens cliniques et
par des tests. Les chevaux normaux n'en parurent point
affectes, mais les malades temoignerent d'une pression intra-
thoracique diminuee, d'un ralentissement du rythme
respiratoire et d'une variation en moins, d'abord, ensuite
augmentee de la pression arterielle d'oxygene. II en resulta
pour une amelioration clinique suivant Temploi des trois
medicaments.
Zusammenfassung
Die Wirkung verschiedener Bronchodilatatoren (Atropin,
Isoprenalin und Terbutalin) auf normale Pferde und auf
Tiere mit chronisch-obstruktiven Lungenleiden (COPD)
wurde mit Lungenfunktionsprufungen und durch klinische
Untersuchungen beurteilt. Gesunde Pferde zeigten keine
Veranderungen, aber COPD-Tiere beantworteten die Medi-
kation mit einer Herabsetzung des intrathorakalen Drucks,
der Atemfrequenz und des arteriellen Sauerstoffpartialdrucks,
wobei der letztgenannte Wert nachher anstieg. Klinisch
zeigten die Tiere eine Besserung. Alle beobachteten Wir-
kungen waren temporarer Natur.
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ABSTRACTS
Metabolism and nutrition
Utilisation of a corn oil supplemented diet by the pony
Kane, E., Baker, J. P. and Bull, L. S. (1979). J. Anint. Sci.
48, 1379-1384.
The utilisation by 6 mature Shetland pony geldings of a
maize oil supplemented diet was studied to determine the
apparent digestibility of fat and the digestible energy (DE),
metabolisable energy (ME) and net energy (NE) for weight
gain using an open circuit calorimeter. The maize oil pro¬
vided 0.15 and 30 per cent of the digestible energy of a
maintenance diet of oats, vitamins and limestone. The oil
did not depress dry matter or acid detergent fibre digest¬
ibility and ether extract of the corn oil had a digestibility
coefficient of 0.93. The DE, ME and NE for gain of the
corn oil were 36.8, 35.1 and 29.7 kJ/g.
The DE requirement for energy maintenance expressed as
kJ/kg °'75 daily was calculated to be 397 for the ponies
receiving the oat-maize oil diet. Similarly the ME for energy
maintenance was 345 kj/kg°'57 daily. The ME of the oil was
used for body fat synthesis with an efficiency of 0.85.
D. L. Frape
Energy and protein under-nutrition in the weanling filly foal
Ellis, R. N. W. and Lawrence, T. L. J. (1979). Br. vet. J.
135, 331-337.
Six Welsh weanling filly foals were allocated to each of 4
treatments for a winter period of 112 days. Three iso-energetic
diets were individually fed. In 2 treatments the diet contained
14.8 per cent crude protein and 0.70 per cent total lysine and
was fed either to maintain constant weight (LP) or to induce
a weight gain of 0.45 kg/day (HP). In 2 other treatments
the diets contained 6.0 per cent crude protein and either
0.28 per cent (LPP) or 0.70 per cent (LPPL) total lysine,
achieved by including L-lysine HC1 in the latter diet. These
2 diets were fed to maintain constant bodyweight. After this
all animals grazed together for 126 days (May to September).
During winter and (summer) periods the daily weight
changes were +0.30 (+0.41), + 0.03 (+0.57), -0.12 (+0.53)
and -0.09 (+0.50) kg for the HP, LP, LPP and LPPL treat¬
ments respectively.
In spite of being maintained at or near constant weight
the ponies on the 3 low-plane treatments made small gains
in height and length of skeletal parts while soft tissue was
lost. Compensatory growth in the latter during the summer
was the greater as measured by width of chest, heart girth,
body girth, hocks to pins, width of hocks and circumference
of legs. The decreases in liveweight during winter amongst
the LPP and LPPL groups largely reflected the method of
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Prophylactic effects of sodium cromoglycate on
chronic obstructive pulmonary disease in
the horse
JILL R. THOMSON and E. A. McPHERSON
University of Edinburgh Veterinary Field Station, Easter Bush, Ftoslin, Midlothian EH259RG
Summary
When stabled in a controlled environment, horses affected with
chronic obstructive pulmonary disease (COPD) became
clinically asymptomatic in 4 to 32 days (mean [± sd] 9.1 ± 4.9
days), the time being influenced most by the severity of the
disease judged on maximum intrathoracic pressure change (Max
A Ppl) and the age of the animal.
Sodium cromoglycate, a drug widely used for prophylaxis of
allergic respiratory disease in man, was administered by
inhalation to 56 COPD-affected horses. The results showed that
a linear response existed between the number of successive days
treatment with this drug and the duration of remission of
clinical signs of COPD while horses were exposed to natural
antigen challenge (poor quality straw bedding). Sodium cromo¬
glycate given as a single daily dose (80 mg) on one day and on 4
successive days prevented clinical signs for mean 3.6 days and
mean 24.3 days, respectively. These results indicate that
prophylactic treatment with inhaled sodium cromoglycate is an
effective method of controlling the clinical signs of COPD.
Introduction
CHRONIC obstructive pulmonary disease (COPD) ("heaves")
is usually associated with exposure of susceptible animals to
poor quality (dusty, mould-contaminated) hay and straw
bedding and inadequate stable ventilation. Most horses affected
with COPD show respiratory hypersensitivity to inhaled
antigens, eg, Micropolyspora faeni and Aspergillus fumigatus,
mainly as a delayed response at 4 to 8 h after challenge
(McPherson et al 1979).
Usually, the condition can be controlled by removal of the
affected horses from contact with the aetiological agents
(Thurlbeck and Lowell 1964; Cook 1976). However, strict
environmental control is not always possible and additional
means of prophylaxis are therefore required. Atropine,
sympathomimetic bronchodilators and corticosteroids cause a
temporary clinical improvement, but these compounds are
short-acting and some have side effects (Obel and Schmitterlow
1948; Muylle and Oyaert 1973; Gerber 1973; Sasse and Hajer
1977; Murphy, McPherson and Dixon 1980).
Inhaled sodium cromoglycate is widely used in the prophy¬
laxis of human bronchial asthma because it inhibits immediate
and delayed hypersensitivity reactions to inhaled allergens in
affected individuals (Altounyan 1967; Pepys, Hargreave,
Chan and McCarthy 1968). It is believed to act by maintaining
membrane stability of sensitised pulmonary mast cells, so
inhibiting cellular degranulation after exposure to the allergen
and thus preventing release of the pharmacological mediators
which cause constriction of smooth muscle in the airways.
The role of mast cells in the pathogenesis of equine COPD
has not been established but pulmonary mast cell hyperplasia
has been noted in COPD-affected horses (Nicholls 1978). In
preliminary studies on 2 COPD-affected horses hypersensitive
to M faeni, inhalation of sodium cromoglycate 20 to 30 mins
before antigen inhalation challenge prevented the exacerbation
of respiratory disease normally observed 4 to 8 h after challenge.
After a single sodium cromoglycate treatment, horses failed to
respond to antigen challenge for 4 to 5 days (Murphy,
McPherson and Lawson 1979).
A clinical trial to evaluate the efficacy of sodium cromo¬




Fifty-six horses, referred for respiratory disease investigation,
were divided into 4 groups according to duration of sodium
cromoglycate treatment. Their breed type, age and duration of
illness before the trial are shown in Table 1.
Diagnosis andprotocol ofantigenic challenge
The criteria of McPherson et al (1978) were used to diagnose
COPD. Affected animals showed many of the following signs:
coughing, dyspnoea, double expiratory effort, increased harsh
chest sounds with wheezing or crepitant sounds. All horses
showed a maximum intrathoracic pressure change (Max A Ppl)
of 6 mmHg or more and a resting arterial oxygen partial
pressure (Pa02) of 82 mmHg or less.
Horses were housed in loose-boxes (dimensions 5 x 4 x 3 m)
and fed a diet of hay ad libitum and oats. A natural antigenic
challenge was achieved by bedding the horses on wheat straw,
visibly contaminated with moulds.
Horses affected with COPD were exposed to this environ¬
ment for 4 to 5 days to establish that an exacerbation of COPD
signs occurred.
The horses were then bedded on peat moss and fed a complete
cubed diet (Spillers Agriculture Ltd, London) to minimise
exposure to aetiological antigens, until clinical signs abated and
their Max A Ppl and Pa02 levels were within normal ranges
(Max A Ppl < 5 mmHg, PaQ2 > 86 mmHg).
244 EQUINE VETERINARY JOURNAL




























The horses were then given sodium cromoglycate 1 per cent
w/v solution (Cromovet; Fisons Ltd, Loughborough) nebulised
into a face mask applied over the horse's mouth and nose. The
solution was converted into an aerosol using a Wright's
nebuliser or a Pulmo-Aide series 561 Portable Compressor
(Devilbiss, Pennsylvania) and a Cromovet nebuliser (Fisons Ltd,
Loughborough). Eighty milligrams of sodium cromoglycate was
administered as a single daily dose for one, 2, 3 or 4 successive
days to 9, 23, 16 and 8 horses respectively (Groups 1, 2, 3 and 4
— Table 1).
Parameters used to assess response
On completion of the treatment schedule, horses were
returned to the challenge environment and were subjected to
daily clinical examination. Particular attention was paid to the
presence and degree of double expiratory effort, coughing,
respiratory rate and chest sounds. Max A Ppl, Pa02 and carbon
dioxide partial pressures (PaC02) were monitored at 2 to 3 day
intervals and all measurements and observations were made at
rest. Maximum expiratory, minimum inspiratory and Max A
Ppl were measured using an intra-oesophageal balloon
(McPherson and Lawson 1974). These values were estimated
from the mean of 10 consecutive and representative respiratory
cycles (Sasse 1971). Samples for blood gas determinations
were collected and analysed using a previously described tech¬
nique (Murphy et al 1980).
Endpoint of trial
The end point of the post treatment asymptomatic period was
established by clinical assessment and when values for Max A
Ppl and PaC>2 became abnormal (ie, Max A Ppl > 6 mmHg,
PaC>2 < 82 mmHg).
Statistical analysis ofresults
The correlation between the number of sodium cromoglycate
treatments and the time horses remained asymptomatic after
treatment was calculated by regression analysis using all the
horses (Snedecor and Cochran 1967).
Max A Ppl, Pac>2 and PaCCh values for untreated sympto¬
matic horses and for symptomatic horses at the end point
of the trial were compared to values for clinically normal horses
in a controlled environment and sodium cromoglycate treated
horses exposed to antigen challenge by Student's t test.
The significance of the correlation between age, breed type,
body weight (bwt), duration of illness, Max A Ppl, PaC>2 and
PaCC>2 values for untreated symptomatic horses, and the time
taken for horses to become asymptomatic in the controlled
environment and the time horses remained asymptomatic after
sodium cromoglycate treatment, was tested.
Results
Diagnostic phase
On admission, exposure to antigen challenge (without sodium
cromoglycate treatment) induced clinical signs of COPD in all
horses after 24 h. Mean values for Max A Ppl and blood gases
(Table 2) also indicate that the horses became symptomatic.
Horses remained symptomatic throughout the 4 to 5 days that
they were maintained in this environment.
Pre-treatment (asymptomatic) phase
When placed in a controlled environment, COPD-affected
horses became asymptomatic in 4 to 32 days (mean [± sd] 9.1 ±
4.9 days). Mean values for Max A Ppl and blood gases in
asymptomatic horses are shown in Table 2.
The decrease in Max A Ppl and increase in PaQ2 was highly
TABLE 2: Efficacy of sodium cromoglycate as a prophylactic treatment for equine COPD. Maximum change in intrathoracic pressure


















Post treatment Endpoint of trial§
(asymptomatic) phased Horses in challenge
Horses exposed to antigen environment at end of
challenge protected by sodium cromoglycate
preceding sodium protective period
cromoglycate treatment
Max A Ppl Pac>2 PaC02 Max A Ppl PaC>2 PaCC>2
1 9
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* Means recorded on one day
j- Means recorded on one day
4: Means recorded on a composite of days, at 2 and 3 day intervals throughout period of remission
§ Means recorded on one day
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significant in all groups (P < 0.001). A significant decrease in
PaCC>2 (P < 0.05) was recorded in all groups. Significant linear
and positive correlations existed between the time taken for
horses to become asymptomatic and 2 variables, namely age (r
[54] = 0.375; P < 0.01) and symptomatic Max A Ppl (r [54] =
0.583; P < 0.01). There was no correlation with breed, bwt,
duration of illness or symptomatic PaC>2 and PaCC>2 values.
Post treatment (asymptomatic) phase
The duration of the asymptomatic period after various treat¬
ment schedules ranged from a mean of 3.6 days for a single
day's treatment to a mean of 24.3 days for treatments on 4
successive days (Fig 1). The correlation between the number of
treatments and the asymptomatic time was highly significant
(correlation coefficient r [54] = +0.709; P < 0.001). The line of
best fit was linear (Fig 1). The mean values for Max A Ppl and
blood gases after completion of the sodium cromoglycate
treatment and during the period of remission are shown in Table
2. During the asymptomatic period, an average of 3 recordings/
horse were made in Group 1, 5/horse in Group 2, 7/horse in
Group 3 and 12/horse in Group 4. The values expressed are a
mean of these recordings for all horses.
The differences in Max A Ppl and PaQ2 between the
diagnostic and post treatment phases (Table 2) were highly
significant (P < 0.001), whereas the decrease in PacC>2 was only
just significant (P < 0.05). There was no correlation between the
time horses remained asymptomatic after sodium cromoglycate
treatment and age, breed type, bwt, duration of illness,
symptomatic Max A Ppl, PaC>2 and PaCC>2 values, or the time
y=6»29x -4.37
Number of treatments
Fig 1. Relationship between the number of sodium cromoglycate treat¬
ments and the time horses remained asymptomatic after treatment, in
the face ofcontinuous antigen challenge (*** P< 0.001)
taken for horses to become asymptomatic in the controlled
environment.
Endpoint of trial
Towards the end of the post treatment asymptomatic period,
faint harsh vesicular respiratory sounds became audible on
auscultation and these rapidly increased in intensity over one to
3 days. This was accompanied by a slight double expiratory
effort which became increasingly more pronounced and, in
some cases, an increase in respiratory rate and coughing. Mean
values for Max A Ppl and blood gases when symptoms became
re-established at the end of the period of efficacy are shown in
Table 2. The increase in Max A Ppl and decrease in PaCh were
significant (P < 0.001 and P < 0.01, respectively) compared with
values for the previous phase but there was no significant change
in PaCC>2-
No untoward side effects were observed in any of the horses
as a result of sodium cromoglycate treatment.
Discussion
For many years, authors have recognised that removing
COPD-affected horses from dusty, mould-contaminated hay
and straw will usually alleviate clinical signs of the disease. The
use of a controlled environment enabled us to render affected
horses clinically asymptomatic with values for Max A Ppl and
Pac>2 within our range for normal horses. The time taken for
horses to show remission of COPD signs varied greatly and was
most affected by Max A Ppl when symptomatic (ie, the severity
of the horse's condition) and by the age of the animal.
From this study, it is apparent that sodium cromoglycate
administration to asymptomatic COPD-affected horses is
effective as a short-term prophylactic measure, the protective
period varying according to the number of daily treatments
before antigen challenge. Each horse acted as its own control by
virtue of its response to changes of environment. Normal horses
kept in a similar environment have shown no changes in their
respiratory pattern.
Intrathoracic pressure measurement was one of the main
parameters used to assess the response to change of environment
and treatment in these experiments. Max A Ppl measurements
have been shown to be increased in COPD-affected horses
(Gillespie, Tyler and Eberly 1966; Sasse 1971; McPherson et al
1978), indicating the presence of airway obstruction in this
disease.
Like Muylle and Oyaert (1973), we have found no significant
difference in tidal volume between COPD-affected and normal
horses. These authors showed that the ratio of tidal
volume:Max A Ppl was significantly lower in COPD-affected
horses than in normal horses and we can conclude that Max A
Ppl is the important basic measurement. Sasse (1971) attached
great importance to determination of Max A Ppl in COPD-
affected horses. He regarded "minute viscous work" values as
being the most important data. Sasse could not demonstrate any
significant difference in the minute respiratory volume between
COPD-affected and normal horses and it is apparent that
differences in Max A Ppl accounted for the highly significant
differences in "minute viscous work" between normal and
affected horses.
COPD-affected animals which are asymptomatic usually
show signs of COPD within 4 to 8 h of antigen challenge
(McPherson et al 1979) but increased Max A Ppl values have
been recorded within 2 h of antigen challenge (J. R. Murphy
and E. A. McPherson, unpublished data). Although the patho¬
genesis of COPD is not completely known, it is thought to
consist of a dual response, including a Type I reaction,
producing bronchospasm, and a Type Ill-like reaction with the
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main pathological findings being an exudative bronchiolitis
(Nicholls 1978). In human bronchial asthma, sodium cromo-
glycate is essentially used in the prophylaxis of Type I hyper¬
sensitivities, but it has also been found effective in the control of
Type III reactions.
In man and other species, the half-life of sodium cromo-
glycate is very short (45 to 90 mins) (Cox 1976) and, in the treat¬
ment of asthma, repeated administration (3 to 4 times daily) is
necessary to obtain adequate protection. The duration of
protection in the horse after treatment is surprisingly prolonged
compared to that in man.
COPD-affected horses are usually capable of working
normally as long as they remain asymptomatic and this can be
achieved by ensuring strict environmental control. In some
situations, this regime is impractical, eg, during transportation
or when horses are moved temporarily away from the home
environment. Minimal antigen exposure may provoke clinical
signs of COPD and render the horse incapable of performing to
its full potential. In such cases, prophylactic sodium cromo-
glycate administration may prove beneficial to COPD-affected
horses during periods of unavoidable challenge.
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Resume
Lorsqu'ils sont places dans des conditions hygieniques favor-
ables, les chevaux atteints d'affection pulmonaires obstructive
chronique, deviennent cliniquement asymptomatiques dans un
delai de 4 a 32 jours (moy. 9,1 ± 4,9 jours), ce delai depend
surtout de la severite de l'affection (appreciee par la variation
maximale de la pression intrathoracique) et de 1'age de 1'animal.
Le cromoglycate de sodium utilise frequemment dans la
prophylaxie des allergies respiratoires chez l'homme fut utilise
en inhalation chez 52 chevaux atteints de maladie pulmonaire
obstructive chronique (MPOC). Les resultats montrerent qu'il
existe une reponse lineaire entre le nombre de jours consecutifs
d'administration de ce traitement et la duree de remission des
signes cliniques de la MPOC, quand les chevaux sont exposes a
des antigenes naturels (litiere de mauvaise qualite). Le
cromoglycate de sodium donne chaque jour a dose unique (80
mg) durant 4 jours, prevenait les signes cliniques pour environ
24,3 jours, mais donne une seule journee a la meme dose, il
prevenait les signes cliniques pour 3,6 jours seulement. Ces
resultats indiquent que le traitement prophylactique avec le
cromoglycate de sodium par inhalation est une methode efficace
de controle des formes cliniques de la MPOC.
Zusammenfassung
In einer kontrollierten Umgebung wurden Pferde, die an
chronisch obstruktiven Lungenkrankheiten (COPD) litten,
innert 4 bis 32 Tagen (Durchschnitt 9.1 ± 4.9 Tage) symptomen-
frei; diese Zeit hangt vor allem vom Grad der Erkrankung —
beurteilt nach der maximalen intrathorakalen Druckver-
anderung max. A Ppl — ab und auch vom Alter des Tieres.
Natrium-Chromoglykat, ein in der Prophylaxe allergischer
Atemwegserkrankungen des Menschen haufig verwendetes
Medikament, wurde per inhalationem 56 COPD-Patienten
verabreicht. Die Resultate zeigen, dass zwischen der Anzahl sich
folgender Behandlungstage und der Remissionsdauer wahrend
natiirlicher Antigenexposition (Strohstreu schlechter Qualitat)
eine lineare Beziehung besteht. Na-Chromoglykat verabreicht
als eine einzige Tagesdosis von 80 mg, beziehungsweise wahrend
vier aufeinanderfolgenden Behandlungstagen, vermochte die
klinischen Symptome 3,6 Tage, beziehungsweise 24.3 Tage lang
zu unterdriicken. Diese Resultate deuten daraufhin, dass eine
prophylaktische Behandlung mit inhaliertem Na-Chromoglykat
eine wirksame Methode zur Beherrschung der klinischen
Manifestation von COPD darstellt.
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